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Editorial 
Crossing Borders - Innovation in the U.S. Health Care System 
Simone Singh and Andreas Schmid 
This publication of student essays resulted from a study tour of the U.S. health care 
system by University of Bayreuth students and faculty. The basis of this tour is an ex-
change program between the Health Economics and Management Program of the Uni-
versity of Bayreuth and the University of Michigan Department of Health Management 
and Policy. Since 2004, this collaboration has encouraged the exchange of thoughts and 
ideas between students and faculty from both sides of the Atlantic. During their most 
recent visit in the U.S. the group from Bayreuth encountered a health care system at a 
crucial crossroad.  
The Affordable Care Act (ACA), the sweeping health care law passed in 2010, has had 
a tremendous impact on the delivery and financing of health care in the U.S. First and 
foremost, the ACA has expanded health insurance coverage to millions of previously 
uninsured Americans. A second important goal of the ACA has been to test and imple-
ment innovative ideas for improving care coordination and reducing the high cost of 
health care in the United States. These efforts have fostered the development of new and 
innovative payment systems, including bundled payments for episodes of care and 
value-based payment components, by both public and private health insurers. Health 
care providers are responding to this changing environment by designing innovative 
models for delivering care to their patients that simultaneously address the need to im-
prove the quality of care while containing costs, such as Accountable Care Organiza-
tions (ACOs) and Patient-Center Medical Homes (PCMHs). The med-tech industry are 
adapting by developing new business models. At the same time, the future of the ACA 
is more uncertain than ever. The Trump administration has begun to take steps to repeal 
and replace the law but the details of a replacement bill have yet to be negotiated. Given 
the tremendous changes that U.S. health care system has been undergoing there is much 
to learn – for Americans and international visitors alike. In March 2017, 21 health eco-
nomics and management students and faculty from the University of Bayreuth embarked 
on a 10-day academic research excursion to the United States to do just that. Organized 
jointly by faculty and staff at the University of Bayreuth and the University of Michigan 
(UM), this excursion aimed to provide participants with a wide variety of opportunities 
to learn about health, health care, and health policymaking in the U.S. The tour started 
in Ann Arbor, where Bayreuth students and faculty had a chance to meet and interact 
with students and faculty in the Department of Health Management and Policy (HMP) 
at UM. During the first several days, HMP faculty took the time to provide the Bayreuth 
visitors with introductory overviews of the U.S. health care system to set the stage for 
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the many site visits, expert presentations, and group discussions that the group partici-
pated in during their time in the U.S. The tour then extended from Ann Arbor to Pitts-
burgh and Washington, DC.  
During their time in the U.S. the Bayreuth group had a chance to meet and engage in 
discussions with many inspiring people including: 
Bethany Lee-
Lehner 
 
Director of Patient Education and the Mardigian Wellness Center of 
the Frankel Cardiovascular Center, University of Michigan Health 
System 
John Popovich President and Chief Executive Officer, Henry Ford Hospital Detroit 
Dave Fisher Government Affairs and Policy, Siemens Healthineers 
Denise Pike Development Director, Community Health and Social Services 
(CHASS) Health Center 
Elanor Kerr Government Affairs and Policy, Siemens Healthineers 
Elliott Attisha Associate Medical Director, School-Based and Community Health 
Program, Henry Ford Health System 
James Pitcavage Strategic Program Director, Geisinger Health System 
Jersey Liang Professor of Health Management and Policy, Department of Health 
Management and Policy, University of Michigan 
Jim Jordan President & CEO of Pittsburgh Life Sciences Greenhouse, Distin-
guished Service Professor of Healthcare & Biotechnology Manage-
ment and Sr. Director of Healthcare & Biotechnology Programs at 
Carnegie Mellon University 
Joe Marks Executive Director of the Center for Machine Learning and Health 
at CMU, Pittsburgh Health Data Alliance 
Joneigh Khaldun Executive Director and Health Officer, City of Detroit Health De-
partment 
Kimberlydawn 
Wisdom 
Senior Vice President, Chief Wellness and Diversity Officer, Henry 
Ford Health System 
Louisa Laidlaw Administrative Fellow, Henry Ford Hospital and Health Network 
Mark Esherick Government Affairs and Policy, Siemens Healthineers 
Mohsin Hashmi  Kaiser Permanente Center for Total Health 
Noam Kimelman Co-Owner, Fresh Corner Cafe 
Pauline Do Administrative Fellow, Henry Ford Hospital and Health Network 
Peter Jacobson Professor of Health Management and Policy, Department of Health 
Management and Policy, University of Michigan 
Robert E.  
Moffit 
Senior Fellow in The Heritage Foundation’s Center for Health Pol-
icy Studies 
Steve Phillips Government Affairs, Johnson & Johnson 
Terrisca Des 
Jardin 
Administrative Director Physician Organization of Michigan ACO 
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The 16 student essays in this edited volume provide insights into the topics covered and 
trends discussed during the group’s visit to the U.S. While they cannot provide a com-
prehensive overview of the U.S. health care system of the early 21st century, they de-
scribe innovative ideas and trends in the delivery and financing of health care in the U.S.  
 
Simone Singh       Andreas Schmid 
(University of Michigan at Ann Arbor)   (University of Bayreuth) 
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Introduction to the U.S. Health Care System 
Meltem Sezer and Franziska Bauer 
One of the key topics of political discussion in the U.S. these days is its healthcare 
system. Most recently, “repeal and replace” has been the pivotal issue of political 
debate. The urge to reform the Affordable Care Act comes not from its many 
accomplishments, such as reducing the uninsured rate, but from what still needs 
improving: healthcare costs and spending. In this context, the “Triple Aim” ap-
proach is the center of focus within the healthcare system and will be portrayed in 
this essay after giving a short overview of the U.S. healthcare system itself. The 
framework of the “Triple Aim” consists of goals aiming to improve the experience 
of care and health of the population at a lower per capita cost. Providers of the U.S. 
healthcare organizations are being paid by a hybrid structure with different insur-
ance forms existing parallel to each other, resulting in an inefficient and extremely 
fragmented healthcare system. Like most other countries, there are both private 
and public insurers in the U.S., with payments coming from two main sources 
which will be explained in this essay. Political efforts play a big role in the Amer-
ican healthcare system. Health insurance marketplaces initiated by the Affordable 
Care Act come short of achieving managed competition where choice drives effi-
ciency. High administrative costs also contribute to the current inefficiency of the 
American healthcare system, making it difficult to reach the Triple Aim. The goal 
of the Trump Administration to change regulations of the Affordable Care Act 
could not be reached either, letting the final structure and outcome of the U.S. 
healthcare system be unknown. 
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1 Introduction 
Political debate over the U.S. healthcare system is a constant throughout the public space, 
media commentary, and the legislative bodies themselves. Most recently, “repeal and 
replace” has been the major topic of discussion, reignited by the transfer of governmen-
tal power from one party to another. The urge to reform the Affordable Care Act (ACA) 
comes not from its many accomplishments, such as reducing the uninsured rate, but from 
what still needs improving: healthcare cost and spending. The U.S. spent 17% of its gross 
domestic product (GDP) on healthcare in 2013, which correlates to twice the average 
of all Organization for Economic Cooperation and Development (OECD) countries 
(OECD, 2015). From 2015 to 2025, healthcare spending growth is projected to be 
an average of 5.8% or 1.3% faster than the growth in GDP, suggesting that by 2025 
the U.S. will spend 20.1% of its GDP on healthcare (Keehan et al., 2016, p. 1,522). 
Despite the rising costs, the U.S. population faces poorer health outcomes than other high-income 
countries such as Germany or the UK. When it comes to infant mortality, the U.S. leads the rank-
ing with 6 deaths per 1,000 live births, whereas in Germany (or the UK) 3.2 (or 3.9) infant deaths 
occur per 1,000 live births. In terms of life expectancy at age 60, the U.S. ranks last with 23.6 
years compared to 24.1 years in the UK (Schneider et al., 2017, pp. 4-24). The aim of this essay 
is to give a short overview of the U.S. healthcare system, especially recent developments 
and new health insurance markets, to understand the reasons for the exorbitant cost 
Americans pay for inefficient healthcare and to argue whether the Triple Aim approach 
is observed in action. 
2 Overview of the U.S. health care system 
Compared to many of the other OECD countries, U.S. healthcare has no uniform, na-
tionwide system. The U.S. hosts a hybrid payment structure with different insurance 
forms existing parallel to each other, resulting in an inefficient and extremely frag-
mented healthcare system (Schmid and Himmler, 2015, p.11). Additionally, no univer-
sal healthcare coverage is given in the U.S. As with most other countries, there are both 
private and public insurers in the U.S. healthcare system, with payments coming from 
two main sources: 
- Public: Centers for Medicare and Medicaid Services (CMS) 
- Private:  State-Specific Nonprofit Blue Cross Blue Shield and Private  
 Commercial Insurers 
Insurance choice is influenced by a number of factors, including age, income, geog-
raphy, employment status, and disability (Doonan and Katz, 2015, p. 747). Both private 
and public health insurance programs differ in regard to the benefits covered, financial 
sources, and payments to healthcare providers (De Lew et al., 1992, p. 151). Persons 
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without any health insurance can seek care from safety-net health systems that deliver 
essential services through inpatient, emergency, and ambulatory care. Core safety-net 
providers offer access to care regardless of a patient’s ability to pay and have a patient 
population consisting mostly of uninsured or Medicaid patients in addition to patients 
who are ineligible for coverage under public programs. These individuals depend on 
subsidies and charity to bear the rising healthcare costs, which results in low operating 
margins at safety-net facilities (Chokshi et al., 2016, p. 1,790). 
With the implementation of the ACA, the U.S. population was introduced to a new op-
tion for getting access to health insurance. However, this system is currently targeted to 
be repealed and replaced under the Trump Administration (Graves and Nikpay, 2017, 
pp. 297-304).  The ACA health insurance marketplaces in place are accessible via web-
sites and toll-free numbers enable insurance coverage independent of pre-existing con-
ditions. The system provides consumers with choices, increasing competition between 
insurers which theoretically reduces cost, maximizes quality, and increases the number 
of insured persons (Doonan and Katz, 2015, pp. 749-752). Insurers can combine the 
small individual insurance market with the also small group insurance market into one 
risk pool, reducing payer risk and increasing the number of consumer choices (Doonan 
and Katz, 2015, pp. 749). For further analyzing of these marketplaces, see section 5 in 
this essay. 
A new healthcare delivery concept initiated by the ACA is an Accountable Care Organ-
ization (ACO), a clinical care enterprise that influences provider financial risk by incen-
tivizing improvements (Rosenbaum, 2011, pp. 875-876). An ACO can be defined as a 
healthcare delivery system with either a Medicare or private payer payment model as 
well as a network of providers responsible for the cost and quality of care for a defined 
groups of patients (Rosenbaum, 2011, p. 875). Inspired by private-sector examples of 
integrated health delivery system, such as Kaiser Permanente and Geisinger Health Sys-
tem, the goal of an ACO is to provide financial incentives for coordinated, deliberate 
use of adequate high quality care (Frakt and Mayes, 2012, p. 1,954). Section 4 in this 
volume provides a more detailed insight into this health care delivery form. 
3 Triple Aim 
When talking about goals in the healthcare system, a widespread term in the U.S. is the 
Triple Aim. The Triple Aim is a term originated by the Institute for Health Improvement 
(IHI) that it defines as, “A framework for optimizing health system performance,” aim-
ing to (1) improve the experience of care, (2) enhance the health of the population, and 
(3) reduce the per capita costs of healthcare. As independent goals, movement towards 
achieving one goal can affect the other two positively or negatively, making it essential 
that all three components are balanced in order to optimize the healthcare system. Pre-
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conditions for reaching the three goals include the enrollment of an identified popula-
tion, a commitment to universality for its members, and the existence of an organization 
(an integrator) that assumes responsibility for all three aims for that population. 
In the U.S., the pursuit of the Triple Aim is facing a variety of obstacles which need to 
be overcome: supply-driven demand, physician-centric care, many new technologies 
that show limited impact on outcomes, little or no foreign competition to spur domestic 
change, and little appreciation of system knowledge among clinicians and organizations 
(leading them to sub-optimize the components of the system with which they are most 
familiar at the expense of the whole) (Berwick et al., 2008, p. 760). Similarly, the pursuit 
of the Triple Aim is also a question of political barriers since the effects of its vision 
includes disruption of the status quo in institutions, forms, habits, and income streams 
(Berwick et al., 2008, p. 768). Also absent, but necessary, is a focus on primary care and 
public health which must be developed (as a building block for high quality care) (Rice 
et al., 2014, p. 894). 
One of the founders of the Triple Aim is Dr. Donald Berwick, who was recruited by 
former President Barack Obama in July 2010 to serve as the Administrator of the CMS. 
Berwick and his colleagues derived the Triple Aim strategy from IHI’s leadership in 
measuring and improving the quality of care after having worked at IHI for decades. 
After Berwick left the Agency in 2011 (because of Senate Republicans refusing to con-
firm his nomination), the Triple Aim still remained a priority for CMS and the U.S. 
healthcare system (Fox and Grogan, 2017, pp. 32-33). 
4 Providers in the U.S. Health Care System 
4.1 Hospitals 
Regarding providers of healthcare in the U.S., one can distinguish between primary pro-
viders (organizations providing health services) and secondary providers (organizations 
providing financial, educational or technological resources) (Janus, 2003, p. 120). This 
section will focus on the primary providers of the American healthcare system. 
In 2017, more than 5,500 hospitals with about 900,000 beds were registered throughout 
the country (AHA, 2017a). Most of these are non-profit hospitals (Phelps, 2013, p. 214). 
With a total of 4,862, the majority of the hospitals are community hospitals, followed 
by 401 registered nonfederal psychiatric hospitals, 212 federal government hospitals, 79 
nonfederal long-term care hospitals, and about 10 hospital units within institutions (such 
as prison hospitals) (AHA, 2017a). The community hospitals are nonfederal and provide 
mainly acute, short-term care. Often, they also function as academic medical centers 
where medical staff is trained (Folland et al., 2007, p. 294). Currently, 59% of the com-
munity hospitals are owned by non-government, non-profit institutions, 21% are owned 
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by profit seeking companies, and 20% are owned by state and local governments (AHA, 
2017b).  
Two classifications of medical treatment in hospitals can be distinguished: (1) inpatient 
care and (2) outpatient care. The first represents the more traditional case where patients 
stay in the hospital for more than one day, whereas the second represents a patient’s 
intra-day treatment with no overnight stay included (Phelps, 2013, p. 233). In the past 
30 years, the core function of hospitals has changed dramatically. Hospital utilization, 
lengths of stay, and surgeries have decreased considerably. Instead of the traditional 
inpatient treatment path, the number of outpatient medical procedures has increased (in-
cluding outpatient clinics, emergency departments, outpatient surgeries, and other ex-
amples). Since 1975 outpatient visits have risen from 254,814 to 637,689 in 2005, which 
amounts to an inflation of about 165% (Phelps, 2013, p. 233).  
4.2 Physicians 
Several decades ago, the vast majority of physicians were in private practice and paid 
on a fee-for-service (FFS) basis. They could provide care to their patients in their offices 
and admit them to hospitals where they could personally serve them further (De Lew et 
al., 1992, p. 151). Nowadays, most physicians have negotiated third-party contracts with 
insurers and hospitals (Getzen, 2010, pp. 135-136). In 2010, the number of new doctors 
who started to work in hospitals exceeded the number of those who chose the work in a 
physician-firm for the first time in U.S. history (Ärztezeitung, 2012). In 2015, an AMA 
study found that nearly 57% of physicians worked in physician-firms (descending trend) 
and, in contrast, about 33% of the physicians worked directly for a hospital (ascending 
trend) (AMA, 2015). 
In the U.S. healthcare system, a doctor in a hospital is not an employee, nor the owner 
of the hospital, since physicians function as independent economic entities (Janus, 2003, 
p. 123). Nevertheless, physicians in the U.S. often apply to the institutions in order to 
get access to hospital staff privileges and receive assignments for special procedures 
being practiced almost exclusively within hospitals. Yet physicians do not pay hospitals 
for the privilege of working there, rather the hospital functions as the doctor’s “rent-free 
workshop” where the physicians get access to important resources (Folland et al., 2007, 
p. 296). It is another type of competition compared to other countries such as in Great 
Britain or Germany because in the U.S. the hospital does not hire physician, rather, it 
has to attract them. Evidently, without the service of a doctor, no hospital can provide 
medical treatment. However, because the two players do not directly exchange money, 
hospitals have to offer doctors other advantages to attract them, for example, by provid-
ing a high-tech environment, excellent nursing staff, and particular operating rooms and 
equipment. Hospitals aim to make themselves more attractive and ease the strain of 
medical practice while increasing profit (Phelps, 2013, pp. 239-240).  
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5 Health Insurance in the U.S. 
In America, 28.5 million people remain uninsured, representing nearly 9% of the total 
population. For comparison, two thirds of the insured population is covered by private 
health insurance with the remainder covered under public insurance (Table 1) (Kaiser 
Commission on Medicaid and the Uninsured, 2016, p. 1). 
 
Table 1: Percentage of People by Type of Health Insurance Coverage: 2015 
 
Source: United States Census Bureau, 2016a. 
A citizen has private coverage either through employment or direct purchase of coverage 
from a private company. Public insurance uses Tricare to cover those in military service 
and the Department of Veterans Affairs to cover military veterans1. The two pillars of 
public insurance are Medicare (primarily serving the elderly) and Medicaid (primarily 
serving poor persons). Medicare and Medicaid were both developed with the Social Se-
curity Act of 1965 and represent more than a third of national health spending today 
(Béland et al., 2016a, p. 92).  
5.1 Public Health Insurance 
Medicare is the predominant public insurance of the U.S. This national insurance pro-
gram provides health insurance for people 65 years of age or older as well as for persons 
                                              
1 The medical supply of the veterans, the military and their relatives is beyond the scope of this study. 
For more information look at Barnett and Vornovitsky, 2015, p. 1. 
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with disabilities, end-stage renal disease, and amyotrophic lateral sclerosis (CMS, 
2014). With the original Social Security Act in 1965, Medicare consisted of two parts: 
Hospital Insurance (HI, which covers inpatient care, hospice care, and home health 
care) and supplementary medical insurance (SMI, which covers physician services, hos-
pital outpatient care, and other services) (Jonas, 1998, p. 93). 
2015 marked the 50th anniversary of signing the Medicare program into law. After 50 
years of growth and development, 52 million Americans are covered by Medicare under 
one or many parts, most predominantly Parts A through D. All Medicare recipients have 
access to HI, also known as Part A, with all other parts coming at additional cost. Part B 
is for SMI, Part C is for Medicare Advantage plans, and Part D is for drug coverage. On 
average, Medicare Part A covers half of all expectant costs, forcing patients to cover 
remaining costs with supplemental Medicare insurance, separate insurance, or out-of-
pocket spending (Cohzven et al., 2015, p. 15). 
Medicaid is a welfare-based program that provides coverage for some health services to 
qualifying low-income people and those with disabilities (Cohen et al., 2015, p. 12). In 
2014, 66 million people were covered by Medicaid, with applicants judged and placed 
in categories. Compared to Medicare, Medicaid covers a range of services that other 
government programs do not, including dental and long-term care coverage, but the 
program reimburses provider at a lower rate, thereby incentivizing providers to avoid 
Medicaid patients (Cohen et al., 2015, p. 14).  
Medicaid functions as both federal and state-run initiative. The federal government cre-
ates general guidelines and mandates, while each state defines its own precise policy 
rules. The program is financed through federal, state, and municipal taxes with the fed-
eral government paying 50-80% of the total expenses for every state based on an agreed-
upon-federal-state matching system. As a result, the financial health and stability of the 
program differs between states since Medicaid investments depend on the amount of 
federal funding received (Cohen et al., 2015, p. 14). 
5.2 Private Health Insurance 
In 2015, 67.2% of the American population had some kind of private health insurance 
coverage, with 55.7% of the population insured through employer-sponsored plans and 
the other 16.3% insured through direct purchase exchanges (Barnett and Vornovitsky, 
2015, p. 1). The two biggest players in this sector are the 36 regional non-profit Blue 
Cross/Blue Shield organizations and large commercial for-profit companies (Blue Cross 
Blue Shield, 2017).  
Private insurance coverage models have shifted over the last 30 years starting with the 
traditional FFS system chronologically trending towards the managed care or health 
maintenance organization (HMO) system, the preferred provider organization (PPO) 
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system, the points of service (POS) system, and the high deductible health plans 
(HDHPs, which are currently generating the most interest) (Table 2).  
 
Table 1: Distribution of Health Plan Enrollment for Covered Workers, by Plan Type, 1988-2016 
 
Source: Kaiser Family Foundation, 2016. 
FFS is the easiest system to implement as it reimburses providers for every unit of care 
they offer, ensuring that they are fully compensated for their efforts. However, the sys-
tem incentivizes providers to carry out the maximum volume of care without regard to 
its value, leading to high costs for the entire system while presenting limited value to its 
consumers. 
In response, progressive provider organizations began the “Managed Care Movement” 
represented by the HMOs which became increasingly prevalent, even into today. The 
Managed Care Movement started in 1973 with the primary purpose of managing cost, 
quality, and access to health care. Additionally, it represents a spectrum of systems, 
which includes the previously mentioned private health insurance manifestations 
(HMOs, PPOs and POS plans) (Haubrock, 2000, p. 22).  
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To satisfy the movement toward managed care, the HMO Act was signed into law in 
1973. Consequently managed care entities started participating in Medicare and Medi-
caid directly, controlling costs and clinically integrating healthcare delivery as early as 
the 1990s (Rosenbaum, 2011, pp. 875-876). Insurers began to influence healthcare de-
livery as many provider organizations created their own insurance platforms in order to 
reduce costs and maintain operating margins. However, a managed care backlash oc-
curred in the late 1990s as operators of the HMOs deprived essential medical services 
to patients in order to maintain margins, inspiring distrust from patients (Schmid and 
Himmler, 2015, p.11). As a result, new forms of insurance coverage exist today that 
focus on the preferably full integration of coverage and care. The system pays providers 
less for the volume of treatment that they deliver compared to FFS, but offers providers 
the ability to recover those lost revenues through enhanced health promotion and care 
delivery for their patients. The system is capitated, meaning that the providers receive 
a fixed, covered budget through which all medical expenses must be paid. The advantage 
of this model is that the providers have the incentive to cost-effectively treat patients 
and save money by avoiding overtreatment in efforts to recover the unused part of the 
budget (Folland et al., 2007, pp. 242-243).  
HMOs, on the other hand, restrict patient provider choice, requiring patients to stay 
within their network in an ambitious attempt to improve the value of care.  Compared to 
the HMO model, the PPO model consists of groups of healthcare providers who have 
agreed with an insurance company or a third party administrator to provide care at a 
reduced rate to the insurer’s or administrator’s beneficiaries (Getzen, 2010, pp. 124-125). 
PPOs provide the most patient choice and have the highest beneficiary satisfaction rates 
in all categories besides cost, as such expansive selection often results in higher treatment 
costs. These organizations, due to their popularity among patients, currently represent 
48% of all privately covered lives, the largest portion by far. 
An attempt at an optimal system, the POS system, includes the positive aspects of HMO 
and PPO systems, such as the diminished costs, but inevitably carries some of the nega-
tive aspects as well, most significantly a diminished choice of providers for patients. 
Enrollees in a POS plan are requested to choose a primary care physician from within 
the plan’s network, who acts as the patient’s point of service. For care provided out of 
network, the insurer reduces provider compensation and raises patient out-of-pocket 
costs, encouraging both parties to stay within the network. In addition, the insurer per-
forms all paperwork on behalf of the beneficiary for care provided in-network, whereas 
the patient handles those duties and the additional non-covered costs for care provided 
out-of-network (Health Coverage Guide, 2016). 
In 2007, HDHPs with Savings Options were established on the private insurance mar-
ketplace. HDHPs are the only plans that allow an enrollee to contribute to health savings 
accounts into which they can deposit tax-exempt income to spend on future care tax-
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free. These accounts are needed due to the plan’s excessively high deductibles, which 
are more than $6,000 for an individual and $12,000 for a family. HDHPs only cover 
preventive care before the deductible is reached, meaning that the enrollee must pay for 
all not-preventive medical care out of pocket until the deductible is reached, after which 
point all care is covered based on the beneficiary’s coinsurance rate. Fortunately, many 
HDHPs have complete coverage after the deductible, thereby covering catastrophes. 
These relatively new plans currently represent 29% of all privately insured patients, the 
second greatest portion of the sector (Health Insurance Resource Center, 2017). 
5.3 The Problem of Uninsurance in the U.S. 
In 2016, 29 million Americans, just under 10% of the population, had no health insur-
ance for the entire calendar year. Although a significant number, it is a decrease of 13 
million people since 2013 when the ACA took effect. The decrease is primarily the result 
of Medicaid expansion and private insurance enrollment through the exchanges. Being 
uninsured, especially in the U.S., is a major problem because it comes with many con-
sequences: poorer health status, less healthcare access, less preventive care, delayed 
treatment for serious disease, poorer control of chronic diseases, and lower life expec-
tancy (Kaiser Family Foundation, 2002). The majority of the uninsured are low-income 
adults and families that are either without access to or could not afford employer-spon-
sored coverage (Folland et al., 2007, p. 217). Additionally, some fall in the window be-
tween being too poor to afford private insurance but too rich to qualify for Medicaid, 
resulting in no coverage at all in the end. Illegal immigrants and those who do not legally 
qualify for insurance of any type in the country make up a small, but still significant, 
portion of the total uninsured population. Lastly, the prohibitively high cost of insurance 
causes some to risk paying out-of-pocket costs as opposed to risk-abating insurance, 
looking at it as a financial gain to go uninsured (Kaiser Commission on Medicaid and 
the Uninsured, 2016, p. 1).  
6 Politics 
6.1 Situation before the implementation of the ACA 
Political measurements can lay the foundations for counteracting high rates of uninsur-
ance. When President Barack Obama signed the ACA into law in March 2010, he fun-
damentally affected the future of healthcare in the U.S. Before the ACA, it was legal 
for insurance companies to practice Risk Rating in combination with Medical Under-
writing. If insurers predicted higher costs for a person, they could look out for their own 
interests by lowering the number of these high-risk people they insured e.g. by denying 
them coverage (Doonan and Katz, 2015, p. 747). These tactics led to 47 million U.S. 
residents lacking insurance coverage before the ACA was implemented (Neuss, 2015, 
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p. 203). The uninsured had poor access to the services of private physicians,  so these 
patients previously received care from safety-net providers such as federally qualified 
health centers, emergency rooms, and charity care. Although patients could buy insur-
ance directly from insurers or through a state’s high-risk pools, the high costs of both 
insurance and care itself made patient much more likely to skip seeking care altogether 
(Doonan and Katz, 2015, p. 747). 
6.2 ACA 
A major aim Barack Obama had during his presidency was to reform the fragmented 
U.S. healthcare system and move toward universal health insurance (Béland et al., 
2016b, p. 42). In March 2010, he signed the ACA into law as the most significant health 
legislation since Medicare and Medicaid were established in 1965. Although it initiated 
much change, it had four main aspects which will be described in the following para-
graphs. 
First, the individual mandate requires all U.S. citizens and legal residents to either have 
insurance coverage that meets federally defined essential benefit standards of face a tax 
penalty. By requiring everyone to be covered, the pool of insured persons would be large 
enough for the cheaper, healthy individuals to cover the expenses for more costly, sick 
individuals (Béland et al. 2016b, p. 51). 
Second, the employer mandate requires employers with more than 50 employees to 
either provide health benefits to full-time employees or face a steep financial penalty. 
By forcing employers to provide insurance to their employees, the number of insured 
persons increases (Kaiser Family Foundation, 2016b). 
Third, the act expanded Medicaid coverage. As of now, 31 states have expanded Medi-
caid coverage in one way or another and received 90-100% of additional needed capital 
from the federal government (Béland et al., 2016a, p. 92). Not all states have chosen to 
expand coverage due to the Supreme Court decision National Federation of Independ-
ent Business v. Sebelius that ruled Medicaid expansion was a state right and therefore 
could not be forced upon states by a federal declaration. 
Lastly, at a high, general level adolescents can stay on their parents’ health insurance 
policies until age 26, caps on total insurance benefits and denial of coverage due to 
preexisting conditions have been eliminated, and the individual insurance marketplace 
exchanges have been established. The ACA also subsidizes insurance costs for low-
income beneficiaries and requires all insurers to offer 10 essential health benefits, in-
cluding maternity care and preventive services (Obamacare Facts, 2017). 
However, as a partisan act, the ACA has received much criticism from the political right-
wing supporters across the country. In 2013, during an episode of the NBC News, a 
Republican Representative stamped the ACA as, “The single worst piece of legislation 
that’s been passed in modern times in this country.” Nearly a year later, and for the 
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fiftieth time, the Republican-controlled House of Representatives voted to repeal or alter 
the ACA (Béland et al., 2016b, pp. 40-41). 
6.3 Plans under the Trump Administration 
On May 3, 2017, the House of Representatives passed the American Health Care Act 
(AHCA), which had the main purpose of repealing and replacing large fragments of the 
ACA. The bill was sent to the Senate for deliberation (Young, 2017). As explained 
above, the ACA requires individuals to gain health insurance and companies to offer it 
to their employees. The Republican bill was expected to repeal mandates that encour-
aged broader insurance coverage by imposing penalties. Such a step may have incited 
healthy people to stay uninsured, raising the prices for those who are older or sick. In 
order to limit unaffordability for those who need insurance, the Republican plan pro-
posed a “continuous coverage incentive”, charging residents in the individual market a 
30% penalty for lapses in health insurance coverage (Park and Sanger-Katz, 2017). Fed-
eral funding animating Medicaid expansion (especially to cover low-income adults) 
would be reduced by capping it based on how much the state enrollees were living in 
was spending. After 2020, states that expanded Medicaid would receive less federal 
support, and those that did not undergo Medicaid expansion would be prohibited from 
doing so (Lee, 2017). Under the ACA, subsidies are tied to income and premiums, 
whereas the Republican bill would have provided U.S. residents with refundable tax 
credits to purchase health insurance, allotted mainly based on the age of the recipient. 
Some protections for those with pre-existing conditions would also be repealed: states 
could apply for waivers to allow insurers to offer slimmer policies, enabling them to 
charge higher premiums to those with chronic medical issues. Those states would then 
have to establish programs, such as high-risk pools, in order to protect insurers from 
patients causing high costs. Funds worth more than $130 billion would have been set up 
to finance and support high-risk pools and patients with pre-existing conditions (Lee, 
2017). The provision in the ACA which lets children stay on their parents’ insurance 
plans until the age of 26 would be one of the few pieces to not be repealed and replaced. 
However, this bill supported by the Trump Administration would have left 24 million 
fewer people insured by 2026 than under Obamacare (Lee, 2017).  
On June 22, 2017, 13 Republican Senators drafted the Senate’s substitute version of the 
AHCA, releasing the first discussion draft for an amendment to the bill (Ku et al., 2017, 
p. 2). However, this alternative was returned to the calendar on July 28, 2017 after the 
Senate rejected a third Republican amendment to repeal the ACA (Parlapiano et al., 
2017). Since Donald Trump signed an executive order to change ACA regulations in the 
beginning of his time as President, it is presumable that the efforts to do so will continue 
in the future despite the fail of the AHCA (Amadeo, 2017).  
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7 Conclusion 
All in all, the U.S. healthcare system is a fragmented complex that remains unclear in 
structure. Since the new AHCA has failed, it is unsure if future efforts will help to 
achieve the Triple Aim, but the U.S. healthcare system will likely face more problems 
if Congress is successful in repealing the major enhancements of the current system. 
Even after the passage of the ACA, the American healthcare system did not show any 
progress in terms of reduced costs. Expanded choice of insurance plans did not optimize 
quality of care at a lower cost. Large and small U.S. companies provided more insurance 
options for high deductible plans that have lower premiums, but higher out-of-pocket 
costs. As evidence indicates, these plans are more attractive to younger, healthier con-
sumers, pushing older and sicker employees into conventional plans which raise their 
rates. High administrative costs also contribute to the inefficient healthcare system, mak-
ing it difficult to reach the Triple Aim (Lave et al., 2011, pp. 139-144). To counteract 
higher costs, innovation centers were founded under the Medicare and Medicaid pro-
gram as a result of the ACA. These centers are meant to establish measurable and lasting 
improvements in payment systems providers utilize. Ideally, payment should be linked 
to patient outcomes instead of merely services provided. However, the interests of the 
providers and those of patients differ strongly (Neuss, 2015, p. 2013). While the final 
structure and outcome of the U.S. healthcare system is unknown, these disagreements 
between providers, patients, insurers, and political parties will be instrumental in shap-
ing the healthcare provided to Americans.  
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Repeal, Replace, Reform – Current Issues in U.S. Health Politics 
Laurenz Waider 
With the election of Donald Trump as President of the United States, the start of a 
new chapter of uncertainty in health policy has begun. The Trump administration 
aimed to repeal the Affordable Care Act (ACA) and replace it with the American 
Health Care Act (AHCA). In March 2017, the AHCA was withdrawn before being 
voted on. However, it was passed by the House of Representatives with changes in 
May 2017. Based on this development, this essay analyzes and reviews the ACA 
and the AHCA on (1) access, (2) affordability, (3) quality of care and individual 
health, as well as (4) costs giving an overview about the ACA, the AHCA and their 
effects. This paper shows the ACA increased insurance coverage by 20 million 
Americans. However, Americans still face issues in affording healthcare due to high 
deductible plans while the American healthcare system is confronted with rising 
costs in the future. The AHCA would be cutting costs in the federal budget by an 
estimated $935 billion, but approximately 24 million Americans would lose their 
health insurance. Under the AHCA, costs for individual plans for Americans above 
the age of 50 as well as the actual out-of-pocket expenses for Americans would 
increase. Instead of improving shortcomings of the ACA, the AHCA would exac-
erbate these by increasing the uninsured rate and out-of-pocket expenses. Although 
being passed by the house, the bill was not passed by the Senate. At this point, it 
remains unclear how future political reforms will look like. 
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1 Introduction 
On November 8, 2016, the Republican candidate Donald Trump won the presidential 
election and the Republican party retained the majority in the House of Representatives 
and the Senate (Wilensky, 2017, p. 21). As the presidential leadership of the United 
States of America (US) changes, health policy is likely to change as well (Obama, 2017, 
p. 297). With the triumph of Donald Trump and the Republicans, the start of a new 
chapter of uncertainty in health policy in the US has begun (Oberlander, 2017a, p. 1). 
During the election campaign Donald Trump repeatedly pledged to “repeal and replace” 
the Affordable Care Act (ACA), a healthcare policy enacted by his predecessor Barack 
Obama (Butler, 2017, p. 244). On March 6, the first proposal to replace the ACA, the 
American Health Care Act (AHCA), was released by the Trump administration drawing 
much criticism, even from Republicans (Steinhauer, 2017). Less than three weeks later, 
the bill was withdrawn from consideration before it was even voted on in the House of 
Representatives (Oberlander, 2017c, p. 1,497). After this, the bill was slightly changed 
by the GOP leadership and the administration, leading to its passing by the House on 
May 4 (Flegenheimer, 2017). However, the bill failed a Senate vote afterwards (Par-
lapiano et al., 2017). 
Based on these current developments in American health policy, this essay will provide 
a broad overview and analyze the ACA and the AHCA on the basis of (1) access, (2) 
affordability, (3) quality of care and individual health, as well as (4) costs. Key elements 
and the effects of the ACA and AHCA will be discussed in the following sections. Based 
on the results of the analysis, a conclusion will be drawn from the most important find-
ings. 
2 Methods and Areas of the Analysis 
Figure 1: The areas of the analysis 
 
Source: Own representation. 
Access Affordability
Quality of 
Care/ 
Individual 
Health
Costs
Repeal, Replace, Reform – Current Issues in U.S. Health Politics 
31 
In previous analyses of the ACA, criteria including access, affordability, quality of 
care/health, and costs were applied (Geyman, 2015, p. 209). Within the category of ac-
cess, the effects of the ACA and AHCA in terms of insurance coverage is reviewed. The 
affordability category assesses the ability of people being able to pay for healthcare ser-
vices under the bill. Within the quality of care and individual health section incremental 
quality and health improvements under the reform are reviewed. In the category of costs, 
budgetary effects of the bills are considered. 
Within this paper, both bills, the ACA and the AHCA, their performance, and their ef-
fects will be assessed and hypothetically forecasted in the mentioned categories. For the 
AHCA, it can be stated, that an assessment of the quality of care or the influence on the 
overall health of individuals or the population cannot be evaluated at this time. For the 
other areas, a review of the literature was performed in the databases and search engines 
Web of Science, Science direct, J-Stor and Google Scholar. Abstracts of relevant articles 
were screened and then selected for the analysis.  
3 The Affordable Care Act 
3.1 General Approach 
After a controversial political debate, the Affordable Care Act (ACA) was signed into 
law by President Barack Obama on March 23, 2010 (French et al., 2016, p. 1,735). The 
ACA has struck out as the most significant change to the US healthcare system since the 
enactment of Medicare and Medicaid in 1965. The intention of the bill was to address 
the three main challenges in US healthcare: access to healthcare, costs of healthcare and 
the delivery of healthcare services (Blumenthal, Abrams and Nuzum, 2015, p. 2,451). 
In 2010 elements of the law went into effect immediately but the major part of the law 
became effective in 2014. The following bullet points show the overall approach of the 
ACA to improve healthcare in the US (Kaiser Family Foundation, 2017a): 
- Most US citizens and legal residents are required to have health insurance 
o People without coverage usually must pay a tax penalty 
o A tax penalty is imposed on employers with 50 or more employees that 
do not offer health insurance meeting government standards is imposed 
o Young adults are eligible to stay on parent’s plan until the age of 26 
o Insurance companies are not allowed to neither neglect patients nor 
charge them higher premiums due to pre-existing conditions 
- Implementation of state based health insurance exchanges 
- Provision of refundable premium tax credits 
- New insurance market regulations 
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- Insurance coverage for ten essential health benefits and no-cost preventive ben-
efits 
- Expansion of Medicaid eligibility to 138 percent of the federal poverty level as 
an option for states 
- Extension of the funding for the Children’s Health Insurance Program to 2015 
- Enhancement of preventive benefits in Medicare and closing of the doughnut 
holeReduction of Medicare spending 
- Establishment of an independent Payment Advisory Board and the Center for 
Medicare and Medicaid Innovation 
3.2 Access 
The ACA has succeeded in increasing insurance coverage. Since the enactment of the 
ACA in 2010, 20 million Americans obtained health insurance coverage by February 
2016 (Uberoi, Finegold and Gee, 2016, p. 1). This has been the largest decline of the 
uninsured rate since the introduction of Medicare and Medicaid in 1965 (Obama, 2016, 
p. 527). The largest reductions were recorded in the uninsured rate among low-income 
individuals, people of color, as well as young adults (Kaiser Family Foundation, 2016, 
p. 6). Coverage has mainly increased by the expansion of Medicaid and operation of 
health insurance exchanges. Americans with annual incomes between 138 and 400 per-
cent of the federal poverty became eligible for federal subsidies to be able to afford 
insurance coverage (Geymann, 2015, p. 210). Further, consumer protection became 
more important with the introduction of the ACA. Insurers are not allowed to deny pa-
tients with pre-existing conditions anymore (Blumenthal and Collins, 2014, p. 276). Fur-
thermore, 7.8 million young adults aged 19 to 26 gained coverage by enrolling in the 
parents’ plan. Most of them would not have been eligible without the enactment of the 
ACA (Blumenthal and Collins, 2014, p. 275). 
However, even if the ACA was not repealed by the current Trump administration, 27 
million Americans would remain uninsured in 2025. Within this uninsured group, less 
than one third would be undocumented immigrants and approximately 56 percent would 
be people who opted out. The remaining 10 percent would be people suffering from 
poverty in states that did not expand Medicaid (Hellander, 2015, p. 707). The US Su-
preme Court ruled in 2012 that states may choose to expand or not expand Medicaid. 
Although the federal government would pay 100 percent of the expansion initially, grad-
ually phasing down to 90 percent in 2020, only 26 states decided to expand Medicaid. 
This caused 4.8 million people still being uninsured and is known as the Medicaid gap 
(Geymann, 2015, p. 211). In terms of access, it can be concluded that overall insurance 
coverage in the United States increased by 20 million. However, the healthcare system 
is still not close to achieving universal coverage for the US population as 27 million 
citizens still remain uninsured. 
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3.3 Affordability 
As the previous part shows, the ACA increased the number of Americans with insurance 
coverage. But the affordability of healthcare also relies on factors like costs, prices, the 
value of insurance coverage, the household’s income levels and other living expenses 
(Geymann, 2015, p. 213). An eleven-country survey published in 2016 found Americans 
are far more likely to go without healthcare because of high cost than in other countries 
(Osborn et al., 2016, p. 2,327). According to the survey, US adults were the most likely 
to report financial barriers to healthcare services. In 2016, 33 percent of Americans went 
without the recommended care, did not see a doctor when they were sick or failed to 
pick up a prescription because they could not afford it (Osborn et al., 2016, p. 2,328). 
The percentage decreased from 37 percent in 2013 by 4 percent over 3 years. However, 
in countries like Germany or Great Britain only 7 percent of the population experienced 
such problems (Osborn et al., 2016, p. 2,329). Furthermore, in October 2014 an Associ-
ated Press poll found stated one quarter of insured Americans feel insecure about their 
ability to pay for healthcare bills (Geymann, 2015, p. 213).  
According to the Commonwealth Fund’s measure of underinsurance, people are under-
insured if the deductible is 5 percent or more of the total household income (Collins et 
al., 2014, p. 2). The share of employer-sponsored health plans having a deductible in-
creased from 55 percent in 2006 to 80 percent in 2014. The average deductible of $1,217 
more than doubled compared to the deductible of $584 in 2006 (Collins et al., 2014, 
p.1). A survey of the Commonwealth Fund in 2014 found that 13 percent of privately 
insured adults have a deductible which is 5 percent or more of their household’s income 
(Collins et al., 2014, p. 3). In this survey, 43 percent of privately insured adults with a 
deductible plan claimed that their deductible caused them financial troubles or it was 
impossible to afford (Collins et al., 2014, p. 4). About 20 percent of the ACA enrollees 
are covered by Bronze plans, with an actuarial value of 60 percent. Enrollees in bronze 
plans face an average deductible of $5,331 for an individual per year. Some of these 
plans even require that the full amount of the deductible must be paid before any drugs 
get covered by the insurance (Hellander, 2015, p. 708). The assessment of affordability 
reveals that although more people gained insurance coverage by the ACA, the afforda-
bility of healthcare is still relatively low compared to other industrial countries. 
3.4 Quality of Care and Health of Individuals 
The intention of the ACA was to increase the access to care, enable the provision of 
preventive services without cost sharing, make payment changes attempting to encour-
age quality of care, establish accountable care organizations (ACOs), and expand the 
use of electronic-health records (EHR) and establish the Patient Centered Outcomes Re-
search Institute (PCORI) (Geymann, 2015, p. 214). After the enactment of the ACA, the 
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USA had some improvements in quality of care (Obama, 2016, p. 528). The rate of 
hospital acquired infections decreased by 17 percent from 145 per 1,000 discharges in 
2010 to 121 per 1,000 discharges in 2014 (Agency for Healthcare Research and Quality, 
2015, p. 1). Considering research on the relationship between hospital-acquired illnesses 
and mortality, the Agency for Healthcare Research and Quality estimated that the de-
cline of hospital acquired conditions led to a prevention of cumulative 87,000 deaths 
over four years (Agency for Healthcare Research and Quality, 2015, p. 4). However, the 
policies initiated by the ACA might not be the only reason for this decline (Agency for 
Healthcare Research and Quality, 2015, p. 6). In addition to lower rates of hospital ac-
quired infections, the readmission rate within 30 days after discharge of Medicare pa-
tients declined from 19.1 percent in 2010 to 17.8 percent during 2015 as well (Obama, 
2016, pp. 528-529).  
The expansion of insurance coverage may have positively influenced the health of 
Americans at some point as well. Given the results of the 2008 Oregon Health Insurance 
Experiment, a randomized controlled trial of Medicaid expansion, Medicaid expansion 
and insurance coverage is valuable for an improvement in health status but may not be 
as valuable as hoped due to a fragmented and inefficient system (Skinner and Chandra, 
2016, p. 497) Newly insured individuals used more primary and hospital care than indi-
viduals without insurance and even received more preventive services as well. Further-
more, individuals had a better self-reported physically and mental health in addition to 
being less likely to suffer from medical debts and bankruptcy (Finkelstein et al., 2012, 
p. 1,057). However, there are limitations of increasing insurance coverage to improve 
population health, as hypertension and diabetes control did not change in comparison to 
the control group (Taubman et al. 2014, p. 263).  
A true improvement in the health of individuals cannot be concluded at this point. There 
is no high-quality data, which demonstrates clearly a substantial improvement in health 
outcomes directly related to the ACA. The health outcomes above, hospital acquired 
infections and readmission rate more likely reflect process measures of care. Improving 
the health of an individual or an entire population takes much more time than the period 
since the ACA was enacted. Thus, the effects of the ACA on individual or population 
health cannot be quantified at this point (Bauchner, 2016, p. 492). Furthermore, social 
determinants of health, as a much more influencing factor for health than healthcare 
itself, must be considered here as well (Lantz, Lichtenstein and Pollack, 2007, p. 1,253).  
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3.5 Costs 
Figure 2: Growth of costs 
 
Source: own representation. 
The implementation of the ACA has been less expensive than expected. This has helped 
lower federal deficits. The Congressional Budget Office estimates that in terms of over-
all costs of the ACA, the insurance coverage provisions from 2015 to 2019 have de-
creased 29 percent from 2010 estimate of $716 billion to $506 billion estimate in 2015. 
This decrease is caused by favorable factors like a low healthcare inflation but also fac-
tors like the Medicaid expansion in some states and the low number of enrollments in 
the exchanges (Emanuel, 2016, p. 1,331). 
Overall, the healthcare system of the United States is the most expensive healthcare 
system in the world. In 2014 healthcare spending composed 17.1 percent of the US GDP 
compared to 12.3 percent for the OECD average (World Bank, 2017). From 2015 to 
2025 health spending is estimated to grow by 5.8 percent on average. This rate would 
be 1.3 percent faster than the growth of the gross domestic product (GDP) and would 
represent 25 percent of the US total economy by 2025. The main drivers of the national 
health spending are expected to be the effects of the ACA (healthcare spending and 
insurance coverage beginning in 2014), increases in economic growth, faster growth of 
medical costs and population aging (Keehan et al., 2016, p. 1,522). 
However, before 2014 and in the first years after the ACA was passed, the bill was 
supposed to help keep healthcare inflation modest. An analysis conducted by the Robert 
Wood Johnson Foundation-Urban Institute found that national health expenditures are 
expected to be $2.6 trillion (11 percent) lower from 2014 through 2019 than projected 
before the ACA was enacted (McMorrow and Holahan, 2016, p. 10). The five years 
between 2009 and 2013 had historically low growth of healthcare cost of 3.7 percent 
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(Martin et al., 2016, p. 150). Unfortunately, the expansion of high deductible health 
plans, which discourage the use of healthcare services, might be attributable to the low 
level of inflation as well (Emanuel, 2016, p. 1,331). Besides that, some analysts attribute 
this low healthcare inflation to a slow economic growth due to the economic recession 
(Blumenthal, Stremikis and Cutler, 2013, p. 2,551). A significant share of cost savings 
also derived from ACA measures slowing down the growth of reimbursement rates in 
Medicare (Center for Healthcare Research & Transformation, 2014, p. 2). A list of se-
lected payment reform policies and initiatives of the ACA is shown below (Table 2.1). 
 
Table 1: Selected payment reform initiatives 
Policy/Initiative Description 
Project Cost Savings 
Over Ten Years 
Disproportionate 
Share Hospital 
Payments 
Reduction of Medicare & Medicaid dis-
proportionate share hospital (DSH) 
funding as more patients gain insurance 
coverage 
$36 billion 
Hospital-Acquired 
Conditions 
Reduction of Medicare payments by 1 
percent for hospitals with relatively 
high rates of hospital-acquired condi-
tions 
$1.5 billion 
Hospital Readmis-
sion Reduction 
Program 
Issues penalties of up to 3 percent of 
payment to hospitals with relatively 
high preventable hospital readmissions 
among patients with defined conditions 
$7 billion 
Market Basket Up-
dates 
Reduction of rate of reimbursement 
growth through changes to providers’ 
annual market basket updates and inclu-
sion of productivity adjustments into 
such updates 
$160 billion 
Medicare Durable 
Medical 
Equipment 
Expands competitive bidding for dura-
ble medical equipment from 70 to 91 ar-
eas; requires that all payment rates are 
subject to competitive bidding or that 
rates are adjusted using the competi-
tively bid rates 
$1 billion 
Prescription Drug 
Rebates 
Increases minimum Medicaid drug re-
bate amount and expands scope of 
drugs covered by the rebate require-
ment; expands rebate requirement to 
drugs provided through Medicaid man-
aged care organizations 
$38 billion 
Source: Own representation based on Center for Healthcare Research & Transformation, 2014, p. 2. 
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4 The American Health Care Act 
4.1 General Approach 
The AHCA is the plan of the current Trump administration and the Republicans to repeal 
and replace Obamacare. Less than three weeks after the first introduction of the bill, it 
was withdrawn from consideration by GOP leadership and the Trump administration 
before it was voted on in the House of Representatives. Although Republicans hold a 
majority in the House of Representatives, it was very unlikely that this version of the 
bill would have been passed by the House (Oberlander, 2017c, p. 1,497). The Republi-
can party was divided over the bill. For very conservative Republicans, such as the 
House Freedom Caucus, the bill was too much like the ACA and did not go far enough 
in deregulating healthcare markets and decreasing government spending. On the other 
hand, less conservative Republicans felt that the bill would go too far in eroding health 
insurance coverage (Andrews, Bloch and Park, 2017). Republican leadership finally 
changed some provisions of the AHCA to get the votes of the House Freedom Caucus. 
The bill was passed by the house on May 4 (Flegenheimer, 2017). 
Although the AHCA aimed to originally repeal and replace the ACA, it actually pro-
poses to retain important elements of it. Therefore, it would keep the ACA mostly intact 
(Oberlander, 2017b, p. 2). This similarity to the ACA is not surprising. A lot of Obamac-
are elements are quite popular in the American population. According to a Kaiser Family 
Foundation analysis, 90 percent of Democrats and 82 percent of Republicans have a 
favorable opinion of the provision allowing young adults on the parent’s plan until the 
age of 26 (Kirzinger, Hamel and Rousseau, 2017). Furthermore, the ACA is a conserva-
tive reform model with ideas previously supported by Republicans. By fully repealing 
this bill, Republicans would have certainly renounced their own ideas in healthcare 
(Oberlander, 2017b, p. 2). According to the AHCA proposal, insurers are still not al-
lowed to neglect patients with pre-existing conditions. However, a loophole for insur-
ance companies is created within this bill. If a person does not continually have insur-
ance for two months, insurers can charge an additional 30 percent premium surcharge 
when the individual seeks insurance. In the reworked bill of the AHCA, which has 
passed the house in May, more state options to waive provisions were enacted. States 
could waive retained essential health benefit requirements as well as the prohibition on 
health status rating for individual market applicants, who have not maintained continu-
ous coverage (Kaiser Family Foundation, 2017b). Besides those alterations, young 
adults until the age of 26 are still allowed to stay under their parents’ coverage (Stark, 
2017, p.1). The overall approach of the AHCA including the amendments as of March 
20, 2017 includes the following major elements (Kaiser Family Foundation, 2017b; 
Stark, 2017, pp. 2-3): 
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Table 2: Major elements of the AHCA 
Major elements of the AHCA 
Individual and employer insurance 
- Repeal of individual and employer mandate immediately, standards for 
health plan actuarial values in 2020 and premium and cost sharing subsi-
dies in 2020 
- Retain health insurance marketplaces and annual enrollment periods 
- Modification of community rating from 3:1 to 5:1 
- Impose late enrollment penalty for people who do not have continuous 
coverage 
- Modification of ACA premium tax credits based on age instead of income 
o Credit starts at $2,000 for 18-year-olds and gradually increases to 
$4,000 as people age. $14,000 is the maximum for a family 
o People, who purchase catastrophic health insurances without the 
current ACA benefits mandates, can receive tax credits 
o Expansion of health savings accounts (HSA) by increasing tax free 
contributions  
 to $6,550 per year for individuals 
 to $13,000 per year for families 
Medicaid 
- Conversion of federal Medicaid funding to a per capita allocation 
- Limit growth beginning in 2020 by using 2016 as a base year 
- State option to receive block grant for non-expansion adults and children 
or non-expansion adults only 
- Implement state option requiring employment/work as a condition of eligi-
bility for nondisabled, nonelderly, non-pregnant Medicaid adults 
Funding of States 
- Establishment of State Innovation Grants 
o Over the next nine years, states would receive $130 billion federal 
funding and additional funding of $8 billion over 5 years for states 
that elect community rating waivers 
o States could use the money for financial help to high-risk individu-
als, promote access to preventive services, provide cost-sharing 
subsidies and other purposes (in states that do not successfully ap-
ply for grants, money is used for reinsurance) 
- Repeal of funding for Prevention and Public Health  
o Cancelation of any unobligated funds at the end of fiscal year 2018 
o Provision of supplemental funding for community health centers of 
$422 million for fiscal year 2017 
Other 
- Repeal of Medicare high income tax increase and other ACA revenue pro-
visions 
- Prohibition of federal Medicaid funding for Planned Parenthood clinics 
Source: Own representation based on Kaiser Family Foundation, 2017 and Stark, 2017. 
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4.2 Access 
Figure 3: Estimated development of uninsured population 
 
Source: Own representation based on CBO, 2017, p. 2. 
The CBO and the Joint Committee on Taxation (JCT) estimate that the number of unin-
sured would increase under the AHCA by 14 million in 2018. Repealing the penalties 
associated with the individual mandates would be the main reason for this increase, be-
cause many people chose to be enrolled just to avoid the penalty under the ACA. In 
2020, the number of uninsured people would be expected to rise further to 21 million 
and in 2026 to 24 million. This increase in the number of uninsured people would be 
caused by changes to subsidies for insurance purchased in the non-group market and 
changes to the Medicaid program within the AHCA (CBO, 2017, p. 2). 
Another important factor for access to insurance and healthcare is also the premium. 
Coverage will presumably drop, if insurance premiums increase (Chernew, Cutler and 
Seliger Keenan, 2005, p. 1,021). According to estimations of the CBO and JCT, premi-
ums for single policy holders in the non-group market would increase by 15 to 20 per-
cent in 2018 and 2019 under the AHCA because of the elimination of the mandate pen-
alties. Because of the elimination, fewer healthy Americans would sign up for health 
insurance plans. Therefore, insurance companies would have higher risk pools and pre-
miums would likely rise (CBO, 2017, p. 3). In 2020, premiums would be decreasing due 
to several factors, such as grants to states from the Patient and State Stability Fund, the 
elimination of a minimum actuarial value (see Affordability) and a younger mix of en-
rollees. In 2026, the average premium would be approximately 10 percent lower than 
under the ACA. In the long term, the AHCA would reduce average premiums. However, 
premiums would differ among different age groups, because insurers would be allowed 
to charge five times more for older enrollees than for younger under the new bill (CBO, 
2017, p. 3).  
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4.3 Affordability 
In general, the AHCA proposal is distinguishing itself from the current ACA legislation 
by giving more money to wealthier people through tax cuts and decreasing government 
support for the low-income population to afford health insurance (Oberlander, 2017b, 
p. 2). The tax credit under the AHCA for a 21-year-old with an income at 175 percent 
of the federal poverty level in 2026 would be $950 less than under the ACA (CBO, 2017, 
p. 16). In terms of affordability, that will result in a growing group of people not being 
able to afford health insurance and healthcare. In addition to that, the AHCA would 
make changes to the actuarial value requirements. An actuarial value is the percentage 
of total cost for covered benefits that the insurance plan pays (Kaiser Family Foundation, 
2011). Under the current ACA legislation, the non-group and small group markets must 
have actuarial values of at least 60 percent. In 2020, the AHCA would allow plans to 
have an actuarial value below 60 percent. Although these plans would still be required 
to cover the ten categories of essential health benefits, the underinsurance would grow 
with the repeal of this requirement (CBO, 2017, p. 14). People would tend to buy plans 
with low premiums and therefore, they would only have limited financial coverage of 
benefits along with high deductibles. When they need healthcare it might be less afford-
able than it used to be under the ACA. 
4.4 Costs 
According to estimations of the CBO and the JCT, the enactment of the AHCA would 
reduce federal deficits by $935 billion over the 2017 - 2026 period (see Table 2.3). How-
ever, other provisions, mostly reduced tax revenues, would increase the deficits by $599 
billion resulting overall in a reduction of approximately $337 billion (CBO, 2017, p. 6). 
Within these reductions, reductions from outlays in Medicaid and the elimination of the 
ACA’s subsidies for the non-group health insurance would account for the largest sav-
ings (CBO, 2017, p. 1). However, by cutting the Medicaid expansion, the number of 
uninsured Americans will increase. Because Medicare makes an additional payment to 
facilities giving care to uninsured patients, Medicare spending would be expected to 
increase by $43 billion over the 2018-2026 period (CBO, 2017, p. 19). The estimated 
budgetary effects are displayed in the table below. 
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Table 3: Cost reducing and offsetting elements 
Cost reducing elements Offsetting cost elements 
Reduction in federal out-
lay for Medicaid 
$880 billion Costs for the new tax 
credit  
$361 billion 
Savings mostly from the 
elimination of ACA’s 
subsidies for nongroup 
health insurance 
$673 billion Reduction in revenues 
from eliminating the 
penalties for unin-
sured 
$210 billion 
Savings mostly associated 
with shifts in the mix of 
taxable and nontaxable 
compensation  
$70 billion New Patient and State 
Stability Fund grant 
program 
 $80 billion 
Savings from repeal of tax 
credit for certain small 
employers providing 
health insurance to their 
employees 
$6 billion Increased Medicare 
spending for unin-
sured patients 
$43 billion 
$1,629 billion $694 billion 
= $935 billion deficit reduction 
- $599 billion increase from other provisions 
= $337 billion deficit reduction overall 
Source: Own representation based on CBO, 2017, pp. 6-7. 
Another analysis of the Robert Wood foundation estimated the reduction in federal Med-
icaid spending to be $841 billion. This estimate is lower than the estimate by the CBO, 
which assumed that many states would cut Medicaid enrollment (Holahan et al., 2017, 
p. 2). However, concluding the budgetary point of view, the AHCA would certainly 
reduce the federal deficit and cut governmental costs in healthcare. 
5 Discussion 
After analyzing both bills in terms of performance and projections in the areas access, 
affordability, quality of care/individual health and costs, the differences and the effects 
caused by the ACA and AHCA become more obvious.  
Access 
In terms of access it becomes clear, that the two bills follow a completely opposite ap-
proach. Since the ACA’s aim is to reduce the uninsured population by having an indi-
vidual mandate and expanding Medicaid, the AHCA would emphasize the aspect of 
freedom of choice as well as reducing costs and premiums. Therefore, the AHCA would 
repeal the mandate and change the Medicaid funding into a block grant leading to indi-
viduals being unable to enroll in Medicaid if the block grant is used up. As shown in the 
previous section of the AHCA the projected increase of 26 million uninsured people by 
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2026 would more than repeal the efforts the ACA made in providing more Americans 
insurance coverage. However, it is questionable if the AHCA is actually proposing real 
freedom of choice to the American population. The vulnerable and poor population, due 
to their financial situation, is very limited in their freedom of choice and therefore the 
proposition of freedom is irrelevant here. Furthermore, individual choices are often lim-
ited due to restrictions of employers, insurers, doctors or pharmaceutical companies 
(Partanen, 2017). 
Affordability 
The analysis in terms of affordability of the ACA showed that although Americans have 
health insurance coverage, they are still facing challenges to afford healthcare due to 
high deductible plans under the ACA. By allowing insurance to have actuarial values 
below 60 percent (CBO, 2017, p. 14), the AHCA would decrease insurance premiums. 
However, insurance benefits would decrease and out-of-pocket costs for individuals 
would increase at the same time. Furthermore, the AHCA would have substantially 
raised costs of individual plans for older Americans (Oberlander, 2017c, p. 1,498). An-
other analysis from the Kaiser Family Foundation showed that 6.3 million people with 
pre-existing conditions would be at risk for higher premiums under the AHCA because 
they had a gap in insurance coverage of 63 days or more (Kaiser Family Foundation, 
2017c). While proposing deep cuts in financial help for low-income Americans for buy-
ing health insurance, the AHCA is giving higher-income Americans and the healthcare 
industry large tax cuts (Oberlander, 2017c, p. 1,498). In terms of affordability, the 
AHCA is therefore not improving conditions for lower-income people at all and health 
insurance in the US can rather be considered as a protection against catastrophic circum-
stances for them. 
Quality of Care/ Indivdiual Health 
After the ACA was enacted, improvements in the rate of readmission of Medicare pa-
tients as well as the hospital-acquired diseases could be demonstrated. In terms of indi-
vidual health there is no reliable data suggesting an improvement at this time. However, 
given the study about the Medicaid expansion experiment mentioned in section 0, it is 
likely that somehow population health has improved by expanding Medicaid coverage. 
Looking at the AHCA, possible effects cannot be stated at this point. However, accord-
ing to the results of the study, the AHCA which would increase the number of uninsured, 
potentially worsening population health. 
Costs 
The most popular part of the ACA, which brings the US closer to universal coverage is 
the most expensive, too (Herzlinger, Richman, and Boxer, 2017, E1). With the major 
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insurance expansion in 2014, the growth in healthcare spending accelerated and is ex-
pected to be faster than the GDP growth by 1.3 percent (Keehan et al., 2016, p. 1,522). 
Costs are found to be one of the major challenges for US healthcare in the future. The 
AHCA is addressing this issue and is estimated to reduce the federal deficit by $935 
million (CBO, 2017, p. 6). However, this reduction would be mainly achieved by cutting 
costs in the Medicaid program and eliminating the ACA subsidies. This comes at a high 
price to lower-income Americans and is throwing the US back to pre-ACA times in 
terms of coverage and access to care. 
6 Conclusion 
This paper aimed to compare the ACA and the AHCA and review their effects in the 
areas of access, affordability, quality of care and health of individuals as well as costs 
and to give the reader a broad overview and a comparison of these two health care bills. 
As the analysis showed, the ACA increased insurance coverage by 20 million Americans 
and therefore it represents a historic step in making health insurance a right in the US. 
However, the analysis also showed that Americans still face issues in affording 
healthcare due to high deductible plans while the American healthcare system is con-
fronted with rising costs in the future.  
The effort of the Republican party to repeal and replace the ACA was a failure at first. 
Only a few weeks after the AHCA was introduced, the bill was withdrawn from consid-
eration by the Trump administration and the House GOP leadership without holding a 
vote in the House of Representatives. However, after the bill was changed in favor to 
the Freedom Caucus movement, it was passed by the House of Representatives in May 
2017. The review showed that while the AHCA would be cutting costs in the federal 
budget by an estimated $935 billion, approximately 24 million Americans would be 
likely to lose their health insurance. Under the AHCA costs for individual plans for 
Americans above the age of 50 as well as the actual out-of-pocket expenses for Ameri-
cans would increase. It becomes obvious that the AHCA would not improve the short-
comings of the ACA, instead it would worsen these. 
Since the AHCA did not pass the Senate, the direction of future legislation is unclear, 
the results on American healthcare will be profound and either take the US healthcare 
system back into pre-ACA times or align with a movement towards universal health 
insurance coverage and healthcare.  
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(Why) Did the Health Insurance Marketplaces Fail? 
Antonia Rollwage 
In 2010, the ACA was signed into law and required states to establish and operate 
health insurance marketplaces for individuals without access to governmental pay-
ment programs or employer sponsored health insurance. Currently, the media is 
flooded with increasing premiums and health insurance companies leaving the mar-
ketplace. This paper aims to analyze the performance of the marketplace in terms 
of (1) enrollment, (2) risk pooling, (3) navigation, (4) financial performance and (5) 
affordability. The analysis showed initial technological problems inhibited a 
smooth launch of the marketplaces and led to skewed risk pools. Enrollment num-
bers are mediocre, reaching only 20 percent of the market’s target population. Indi-
viduals lacking health literacy face a challenging market environment, leading to a 
significant number of enrollees who do not know their exact insurance plan cover-
age and cost-sharing requirements. In the first two years, the financial performance 
of the insurance market was poor, but as more data on enrollees was obtained and 
used for premium calculations the performance of insurance companies slowly 
started to improve. Despite the positive trend, insurers decided to leave the market-
place. However, to offer profitability and maintain insurer participation, a continu-
ing stabilization of the market is needed. Individuals and families, especially, report 
trouble in affording care, financial insecurities, and postponement of care. The es-
tablishment of the marketplaces helped to increase insurance coverage, but also in-
troduced new challenges hindering the marketplace to reach its full potential. Inter-
ventions are needed for the marketplace to become more successful. 
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1 Introduction 
In March 2010, President Obama signed the Patient Protection and Affordable Care Act 
(PPACA), also referred to as Affordable Care Act (ACA) into law (Lammert, 2017, p. 
66). The ACA required the establishment of health insurance marketplaces, where indi-
viduals without access to governmental payment programs and employer sponsored 
health insurance can access information and buy health plans subject to common rules 
regarding coverage, pricing, funding and subsidies (Kaiser Family Foundation, 2010, p. 
1). According to a Gallup survey in 2013, 22 percent of the Americans named the ACA 
as the greatest achievement of the Obama administration. Unfortunately, the law was 
not implemented as smoothly as expected. Four years later in 2017, 36 percent of the 
population named the ACA (also called “Obamacare”) “the biggest mistake”: Major 
problems occurred during implementation, partially some with long-term consequences 
(Brady, 2015, p. 649; Lammert, 2017, p. 66).  
Seven years after passing the ACA, health reform is on the agenda again. Currently, the 
US media is flooded with news about health reform including failures of Obamacare 
and reform plans of the new administration. Major topics of conflict include the increas-
ing prices of premiums, health insurers leaving the marketplace, and, consequently, less 
health insurance options for consumers (Murphy, 2017). Aetna, the third-largest health 
insurer in the US, just announced it will be leaving the marketplaces in all states due to 
a loss of USD 450 million in 2016 and the future uncertainty about the exchanges in 
2018 (Goldstein, 2017).  
This paper aims to evaluate the performance of the health insurance marketplaces under 
the ACA to assess whether the establishment of the marketplaces was successful or 
failed. After an introduction of the marketplace, the performance by the means of (1) 
enrollment, (2) risk pooling, (3) navigation, (4) financial performance, and (5) afforda-
bility ill be examined. Based on the analysis, the paper discusses the major challenges 
the marketplace faces and concludes with key findings. 
2 The Health Insurance Marketplace 
The ACA 
The ACA introduced several changes to the American health care landscape. It (1) man-
dates that all individuals need to have health insurance coverage by 2014, (2) requires 
employers with 50 or more full time employees to provide health insurance coverage 
meeting defined minimum requirements, (3) requires states to establish insurance mar-
ketplaces as a place where individuals and small employers can buy health insurance 
and (4) requires states to expand their Medicaid program to individuals under the age of 
65 with an income up to 133 percent of the Federal Poverty Level (FPL) (Brady, 2015, 
pp. 631-633). 
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The Marketplace 
The health insurance marketplace, also known as the exchange or non-group market, 
was established by the ACA to provide a platform on state-level where individuals and 
small businesses without access to governmental insurance programs or employer-spon-
sored health insurance can compare and purchase health insurance plans starting on Oc-
tober 1, 2013. All health insurance plans offered must meet federal and state coverage 
requirements regarding coverage minimums or price regulations. The marketplace also 
offers help connecting individuals and families to financial assistance by allowing con-
sumers to access tax credits or obtain coverage through governmental payment pro-
grams. Despite these requirements, flexibility was given to the states to allow a variety 
of substantially different marketplace designs (Kaiser Family Foundation, 2010, pp. 1-
4; Robert Wood Johnson Foundation, 2013, p. 1). 
The marketplaces can be run by state governments, the federal government (by default 
if the state government defers its responsibility to the federal level), or a combination of 
both known as state partnership exchange (Robert Wood Johnson Foundation, 2013, p. 
1). The responsibilities for implementation of the marketplaces included core functions 
such as (1) eligibility and enrollment, (2) plan management, (3) consumer assistance (4), 
outreach and education, and (5) fiscal management (Kaiser Family Foundation, 2010, p. 
2). 
Funding 
To promote the establishment of marketplaces by states, the federal government pro-
vided appropriations and more than four billion USD in grants for marketplace planning 
and facilitation (Robert Wood Johnson Foundation, 2013, p. 2; Hellander, 2015, p. 720). 
States were able to choose between operating two separate marketplaces for individuals 
and small businesses or combining both target groups into one marketplace. It was also 
possible to create multistate/regional marketplaces or several marketplaces within one 
state to account for regional differences as long as the marketplace operated for a spe-
cific region (Health Policy Brief, 2013, p. 2; Kaiser Family Foundation, 2010, p. 1).  
Governmental funding for the establishment of the marketplaces was only provided for 
the duration of one year starting in January 2014. Afterwards, marketplaces needed to 
prove that they are self-sustaining. In 2015, many of the state-run marketplaces ran at 
deficit and still relied on leftover funding. To achieve self-sustainability, the market-
places could charge user fees to participating health insurance companies or pursue other 
alternatives to generate funding (Kaiser Family Foundation, 2010, p. 1; Hellander, 2015, 
p. 720).  
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Eligibility and Coverage 
Individuals, including U.S. citizens and legal immigrants, qualify for the marketplaces 
if they are not eligible for governmental payment programs and have no access to em-
ployer-sponsored health insurance. Health plans are not allowed to discriminate against 
individuals on the grounds of age, disability, or expected length of life. Previously, these 
aspects were considered in the design of benefit packages or reimbursement schemes to 
benefit health insurers. (Kaiser Family Foundation, 2010, pp. 1, 3). 
According to the ACA, all health insurance plans offered must cover at least the essen-
tial health benefits: 
- Ambulatory patient services 
- Chronic disease management 
- Emergency services 
- Hospitalization 
- Laboratory services 
- Maternity and newborn care 
- Mental health benefits and substance abuse disorder services 
- Pediatric services including oral and vision care 
- Prescription drugs 
- Preventive and wellness services 
- Rehabilitative and habilitative services and devices 
Further, states can require additional benefits be covered by plans (Kaiser Family Foun-
dation, 2010, p. 3). In practice, more than half of the health plans purchased on the mar-
ketplace use higher standards than required by the law (Collins and Garber, 2013, p. 1). 
To make the comparison of different plans easier, all insurance plans are offered with 
four coverage levels depending on how much the insurer pays:  
- Bronze: Benefits equal 60 percent of the actuarial value 
- Silver: Benefits equal 70 percent of the actuarial value 
- Gold: Benefits equal 80 percent of the actuarial value 
- Platinum: Benefits equal 90 percent of the actuarial value 
All insurances must offer at least one silver and one gold plan on each marketplace 
where the insurance operates (Kaiser Family Foundation, 2010, p. 3).  
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3 Challenges and Problems  
3.1 Enrollment 
Before the launch date of the marketplace, one of the immediate challenges for all 50 
states was ensuring that all eligible individuals could enroll in a timely manner and that 
recipients of subsidies de facto enroll in health plans (Collins and Garber, 2013, p. 1). 
However, one of the biggest difficulties the ACA has faced was the initial rollout of the 
federal website healthcare.gov, which was dysfunctional for several weeks due to fail-
ures affecting the consumer’s interface as well as the back-end of the website. In ad-
vance, enrollees were promised that buying health insurance coverage would be as easy 
as shopping on Amazon.com, a website many Americans were familiar with. Based on 
the 30,000 simultaneous users at the launch of the marketplace, government officials 
expected the typical website traffic to be between 50,000 and 60,000 simultaneous vis-
itors. The actual number of 250,000 simultaneous users exceeded these planned num-
bers, though, and lead to several glitches, error messages, and long waits. During this 
timeframe, the sign up option for health insurance had even been rendered unusable. In 
the first few days, the website was visited more than eight million times (Brady, 2015, 
p. 638). 
Although technological problems were resolved by making additional servers available 
and updating the software, critics of the Obama administration still disapproved and 
sentiment that the federal government was not competent enough to administer the mar-
ketplaces remained (Hall, 2014, pp. 1,036-1,037; Brady, 2015, p. 639). Thousands of 
Americans discovered that the website made mistakes by denying coverage, enrolling 
individuals in the wrong insurance program, and incorrectly calculating their subsidies. 
To address these problems, more than 20,000 Americans filed appeals with the govern-
ment, a process that was complicated by a non-existent complaint system for the mar-
ketplaces. Until the technological challenges were resolved, some enrollees had to pay 
more or were left without coverage at all (Brady, 2015, p. 639). Nevertheless, more than 
twelve million individuals were enrolled through the marketplace by 2017. Comparing 
this number to potential marketplace population, enrollees only make up to 40 percent 
of the target population (Kaiser Family Foundation, 2016; Kaiser Family Foundation, 
2017a). 
3.2 Risk Pooling 
The more severe concern, however, was that the complicated enrollment affected the 
type of enrolling individuals. Sick and older people were more motivated to fight their 
way through the marketplace to get coverage for preexisting conditions, leading to un-
balanced risk pools (Hall, 2014, pp. 1,038-1,039). There were also concerns about spill-
over effects into the subsequent year (Hall, 2014, p. 1,054). For the marketplace to work 
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successfully, individuals of all types – healthy and sick, young and old – must sign up 
to ensure a balanced risk pool. Although the marketplace is not a system offering uni-
versal health care, the system works in the same way: The healthy and young use less 
resources than they pay into the system, offsetting the cost of the old and sick. Because 
of the non-discrimination requirement in the ACA, health insurance companies cannot 
turn down sick or older individuals. Further, the insurer is not allowed to discriminate 
by age when setting premiums, making health insurers reliant on young people to sign 
up to cover the expenses of older, sicker individuals. If expenses cannot be covered, it 
could lead to a death spiral: Insurance companies being forced to increase premiums, 
making health insurance for low-risk individuals too expensive and leaving the market-
place more attractive. The remaining group is then more expensive than the calculated 
premium, leading to another premium increase and people leaving the insurance pool 
until the market eventually collapses. Therefore, the penalty for individuals without in-
surance coverage is essential to force young people to enroll and balance the risk pools 
(Brady, 2015, p. 639). The penalty was gradually increased from USD 95 in 2014, where 
only 27 percent of the enrollees were between the ages 18 and 34, to USD 695 or 2.5 
percent of household income in 2016 (whichever is greater) (Brady, 2015, pp. 641-642). 
3.3 Navigation 
Looking at problems consumers face with their health plans, there is growing evidence 
that a lack of health literacy makes navigation on the marketplace more challenging. 
Health illiterate individuals do not fully understand the coverage and cost-sharing pro-
visions of their health plans. Enrollees who report problems affording health care are 
reported to have lower levels of health literacy and were more likely to not understand 
what their health plans covered (see Figure 1). The group reporting “paying premium 
was difficult” was also not more likely to be uninsured before the ACA was introduced. 
This suggests the complexity of the available health plans leads to great confusion, es-
pecially for those experiencing trouble affording their coverage (see Figure 2) (Tolbert 
and Young, pp. 5-6). 
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Figure 1: Understanding of health insurance among nonelderly adults with marketplace coverage, by 
affordability of premium 
Source: Author’s own presentation, data from Tolbert and Young, 2016, p.1. 
 
Figure 2: Problems with health plans among nonelderly adults with marketplace coverage, by 
affordability of premium 
Source: Author’s own presentation, data from Tolbert and Young, 2016, p.1.  
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3.4 Financial Performance 
Figure 3: Average medical loss ratio by year 
Source: Author’s own presentation, data from Cox, Levitt and Claxton, 2017. 
An analysis by the Kaiser Family Foundation found that the performance of key insurers 
operating on the marketplaces declined after opening the marketplaces but had stabilized 
in 2016. The study included two indicators for financial performance: the average med-
ical loss ratio (the share of health premium paid out as claims) and the average gross 
margin per member per month. Since implementation of the ACA, the insurers remained 
profitable at all times, although performance worsened as changes accompanying the 
ACA came into effect in 2014 and 2015. Medical loss ratios should usually not exceed 
85-90 percent for an organization to remain profitable. Nevertheless, after the ACA be-
came effective the average medical loss ratio grew past this percentage and even up to 
103 percent (see Figure 3). In 2014, the transition of the insurance market came with 
several changes and insurance companies had little experience in pricing the plans for 
the new population. On average, insurers set the premiums too low and they were not 
able to cover the cost of the plans. This mispricing was likely due to a smaller share of 
young and healthy enrollees than initially expected. Other factors, including competitors 
who strategically underpriced their plans and the retention of ACA non-compliant plans, 
increased the mispricing effect. In 2015, claims still outgrew premiums leading to an 
increase of medical loss ratios to an average of 103 percent. During the same year, pre-
miums remained stable due to an ongoing lack of information and pricing knowledge 
on behalf of insurers, and ongoing competition for issuing the lowest-cost plan (Cox, 
Levitt and Claxton, 2017). 
In addition to higher medical loss ratios, average gross margins per member fell with 
the transition to the marketplace from USD 37.20 in 2013 to USD -10.17 in 2015 (see 
Figure 4). Although gross margins are a great indicator of performance, a positive mar-
gin does not automatically translate into a higher profitability since they do not take 
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administrative expenses into account. Despite the medical loss ratio decreasing per in-
dividual, the total premium income is higher compared to pre-ACA conditions due to a 
higher total number of enrollees (Cox, Levitt and Claxton, 2017). 
 
Figure 4: Average gross margins per member per month 
 
Source: Author’s own presentation, data from Cox, Levitt and Claxton, 2017. 
In 2016, the third operating year of the marketplace, insurance companies were finally 
able to analyze more meaningful data to set more reasonable premium rates. For the first 
time, the premiums grew faster than cost claims leading to decreasing market loss ratios. 
Medical loss ratios fell by 7 percent to 96 percent but remained higher than the 2013 
level of 80 percent. If insurers want to return to pre-ACA margins, the conditions still 
need to improve to include steady marketplace enrollment with premium increases and 
no substantial increase in claims. For the ACA’s success it is essential that the market-
place remains stable and maintains the willingness of insurers to participate on the mar-
ketplace. Insurers will only be interested if long-term profitability is not at risk (Cox, 
Levitt and Claxton, 2017; Kaiser Family Foundation, 2017b). 
 
Figure 5: Average number of insurers participating on the marketplace 
Source: Author’s own presentation, data from Cox, Long, Semanskee, et al., 2016. 
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Due to the retained losses of insurance plans operating on the marketplace, health insur-
ance companies like UnitedHealth and Aetna announced their decision to leave some 
local markets or the ACA marketplace completely. In 2017, the average number of in-
surers participating on the marketplace will be 3.9 (see Figure 5), ranging from one in-
surer in five states and 15 insurers in Wisconsin. Per state, the number of available health 
insurers is decreasing with 21 percent of states having only one health insurer in 2017 
compared to 2 percent of states having only one available insurer in 2016 (see Figure 6) 
(Cox, Long, Semanskee et al., 2016). On a county level, those numbers look more alarm-
ing: The number of counties with just one marketplace insurer is likely to increase from 
225 counties in 2016 to 974 in 2017 due to the exit of UnitedHealth, which was formerly 
the second largest insurer in rural areas (Cox and Semanskee, 2016). 
 
Figure 6: Insurer participation and choice of enrollees 
 
Source: Author’s own presentation, data from Cox, Long, Semanskee, et al., 2016. 
3.5 Affordability 
Although subsidies are available to lower costs of private health insurance plans for 
individuals, 25 percent of the population have trouble affording premiums, deductibles 
and out-of-pocket costs when they receive health care services. Focusing on premiums 
only, a third of the marketplace enrollees find affording their premium somewhat diffi-
cult or very difficult compared to 17 percent of enrollees in an employer-sponsored 
health insurance (see Figure 7). These findings are consistent with other reports indicat-
ing that 36 percent of marketplace enrollees with a deductible are dissatisfied compared 
to 17 percent of employer-sponsored insurance enrollees (Tolbert and Young, 2016, p. 
1). 
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Figure 7: Difficulty affording health insurance premiums among nonelderly adults, by insurance cov-
erage 
Source: Author’s own presentation, data from Tolbert and Young, 2016, p. 1. 
Comparing both population groups, with and without difficulties in affording coverage, 
both groups shared similar characteristics regarding income, age, and health status. The 
only difference is the group with difficulties was more likely to have dependent children 
(49 percent versus 16 percent) (Tolbert and Young, 2016, p. 2). Available subsidies for 
health insurance are based on the family’s income rather than on a percentage of the 
health plan’s cost. Thus, families do not pay more for coverage than childless individuals 
because they chose a family plan. Rather, families face higher household expenses due 
to additional cost for housing, food, or education which can stress the family budget, 
especially for lower income families. This can lead to trade-offs between paying for 
health insurance or household essentials (Tolbert and Young, 2016, pp. 2-3). 
Individuals with having trouble paying their premiums were also more likely to feel 
financially insecure than the population without trouble. Further, the insecurity over 
medical cost was not fully eased for the insured population with trouble affording their 
premiums, including usual and major medical cost. Medical debt was a major cause for 
personal bankruptcies (see Figure 8) (Tolbert and Young, pp. 3-4). 
 
Figure 8: Financial insecurity over medical costs among nonelderly adults2 with marketplace cover-
age, by affordability of coverage 
 
Source: Author’s own presentation, data from Tolbert and Young, 2016, p. 3. 
People facing difficulties in paying for health care were also more likely to use health 
services and to have higher unmet health needs than those without difficulties in paying 
                                              
2 Includes adults aged 19-64. 
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for care (38 percent versus 19 percent). For families with already strained budgets, ac-
cessing care put another burden on families perceiving their insurance coverage as un-
affordable (see Figure 9). Worryingly, individuals facing challenges in affording their 
premiums were also more likely to postpone care and cost was often mentioned as a 
factor (Tolbert and Young, 2016, pp. 4-5). 
 
Figure 9: Unmet needs for care among nonelderly adults with marketplace coverage, by affordability 
of premium 
Source: Author’s own presentation, data from Tolbert and Young, 2016, p 4. 
The initial premiums were based on the actuarial assumptions regarding age and health 
status mix of an unknown population (Hall, 2014, p. 1039). Due to the previously men-
tioned substantial losses of health insurances participating in the marketplace and the 
phasing out of the ACA’s reinsurance program, insurance companies started to increase 
premiums. For the second-lowest priced silver plan, which serves as the benchmark plan 
for financial assistance, the premium for a 40-year-old non-smoker ranges from USD 
299 in Cleveland, Ohio, to USD 904 in Anchorage, Alaska, before tax credits are taken 
into account. The largest increases in premiums were recognized in Phoenix, Arizona, 
with up to a 145 percent increase from USD 207 to USD 507 (Kaiser Family Foundation, 
2016). The increase in premiums was one major issue publicly debated with critics and 
defenders citing negative and positive aspects of a system with subsidies: younger, 
healthier people pay more for their insurance than older, sicker population pays (Hall, 
2014, pp. 1044-1045). On average, insurers participating on the marketplace raised pre-
miums substantially by 22 percent from 2016 to 2017 (Cox, Levitt and Claxton, 2017). 
On the contrary, the premium projections of the Congressional Budget Office of the year 
2009 show a different picture: The average nationwide premium for the benchmark plan 
for the year 2016 was USD 5,200 a year compared to an actual USD 4,583 or 12 percent 
lower than originally projected. Even if premiums rise by nine percent in 2017, the av-
erage premium still remains below the cost projections of the Congressional Budget 
Office. Potential explanations are intense competition, underpricing, and a slowdown in 
healthcare cost suggesting some reason for optimism (Levitt, Cox and Claxton, 2016). 
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4 Discussion 
After analyzing the marketplace in the areas of enrollment, risk pooling, navigation, 
financial performance and affordability the reasons for the failure of the marketplace 
become more evident. 
Enrollment 
Although the initial failure of the website healthcare.gov affected enrolling individuals, 
the problems have been resolved and the government has likely learned from its mis-
takes. More than twelve million individuals are enrolled in a marketplace plan as of 
2017. Nevertheless, the share of the actual enrollees in relation to the marketplace po-
tential was unfortunately only 40 percent in 2016, leading to a mediocre performance of 
the marketplace which was far from reaching its full potential. 
Risk Pooling 
The automatic risk selection process which happened due to the failure of the website is 
the more severe problem because the risk pool was not as balanced as needed. Having 
more old and sick people in the risk pool risks starting the death spiral, which poses a 
substantial risk to health insurances due to repeated premium increases and individuals 
leaving the marketplace. Eventually, healthy individuals weigh the costs and benefits of 
paying for health insurance coverage versus paying the fine. The government should set 
incentives to ensure that as many people as possible enroll on the marketplace so the 
risk pools are large enough and balance the number of high- and low-risk individuals. 
This is essential to stabilize the market and make operations profitable for participating 
health insurance companies. 
Navigation 
A lack of health literacy makes it harder for individuals to understand their coverage and 
the cost-sharing provision they receive. Individuals who report having trouble affording 
their premium were especially more likely to lack health literacy and not understand 
their health plans. Also, this population was less likely to know what they must pay in 
case they see a provider. This suggests the marketplace and its website healthcare.gov 
confuses individuals so that coverage and cost of health plans are not fully understood. 
Healthcare.gov offers many plans with various cost-sharing options so that comparing 
plans is not a simple task even for educated people. Since being covered by health in-
surance is not enough to improve health outcomes, the marketplace should improve its 
efforts to assist customers by presenting information as clearly as possible.  
Financial Performance 
Due to an initial lack of knowledge of the future marketplace population and a lack of 
pricing skills, the financial performance of health insurers declined after entering the 
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marketplace. The average medical loss ratio, typically not higher than 85 percent, in-
creased with a spike at 103 percent in 2015. A similar negative development could be 
seen with the average gross margins per member per month which declined to a low of 
a negative gross margin of -10.17 USD in 2015. After insurance companies gained more 
data and improved their pricing schemes, the average medical loss ratio started to de-
cline and the average medical gross margin started to rise. To return to pre-ACA condi-
tions in the perspective of health insurers, the positive trend needs to continue. There-
fore, the stabilization of the marketplace is essential to maintain the participation of in-
surers. 
Despite the fact that the marketplace enrollees only make up a small part of the business 
insurers receive, the first insurance companies which decided to leave the marketplace 
decreased the choice of the consumer considerably. 21 percent of states have only one 
insurer left on the marketplace; bearing in mind that low competition is not beneficial 
for individuals in terms of price and quality, this number is alarming.  
Affordability 
Due to incorrect initial premium projections, the financial performance of insurers de-
clined. As insurers were able to recalculate premiums in the second year of the exchange, 
premiums increased significantly. From 2016 to 2017, premiums were again increased 
by an average of 22 percent, making this a major topic of critique in the media. Consid-
ering the premium projections of the CBO, the premium increase is put in a different 
perspective: The 2016 premium was lower than projected in 2009, deflating the argu-
ments of critics.  
The goal of health insurance is to make health care services affordable to the general 
population. Despite the substantial increase in the number of individuals with health 
insurance coverage, a third of the marketplace enrollees still face challenges in affording 
their insurance premiums, deductibles and out-of-pocket costs. This puts an especially 
large burden on families with children who have higher household expenditures in gen-
eral, leading to families weighing their choices of paying for health insurance or house-
hold essentials because health care seems unaffordable. Further, enrollees who have 
trouble paying their premiums also felt more financially insecure and were more likely 
to have unmet health needs than the individuals without difficulty. Troublingly, individ-
uals having issues affording care were also more likely to postpone care, likely due to 
cost. Although the Affordable Care Act was meant to increase access to care and make 
health services more affordable, many enrollees still struggle in paying for their care and 
perceive healthcare as still unaffordable. Since premiums increased rather than de-
creased, financial assistance programs might be a starting point to lift the financial bur-
den. 
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5 Conclusion 
This paper aimed to evaluate the performance of the marketplace in terms of (1) enroll-
ment, (2) risk pooling, (3) navigation, (4) financial performance, and (5) affordability to 
give a broad overview of the current challenges enrollees and insurers face. As the anal-
ysis showed, the initial problems of the marketplace such as technological challenges 
are resolved, but the marketplace still suffers from the aftermath in terms of a skewed 
risk pool composed of higher-risk individuals than intended. Since the outreach has been 
mediocre after 3 years of operation, it is essential to increase the enrollment rate to sta-
bilize the market. Penalizing individuals without health insurance in a reasonable way 
is key for building up a balanced risk pool. Additionally, the navigation of the market-
place is complex. Achieving a balanced risk pool requires more assistance and a simpler 
presentation of information to assist individuals lacking health literacy so they can fully 
understand the coverage provisions and cost sharing requirements of marketplace plans.  
The initial financial performance of insurers operating on the market place was poor and 
reached the lowest point in 2015. Due to additional data used for price calculations, the 
financial situation of insurers has steadily improved and the market is stabilizing again. 
Nonetheless, the first insurers deciding to leave the marketplace in some or all states did 
so because of significant losses in 2016. Premiums increased again to make marketplace 
operations for insurance companies more profitable, but these higher rates also increased 
the financial burden on individuals. A third of marketplace enrollees, especially families 
with strained budgets, reported trouble in affording their insurance premiums, deducti-
bles or out-of-pocket costs. Unfortunately, this leads to individuals suffering from fi-
nancial insecurity and deciding to postpone care. Increasing the budget of financial as-
sistance program could be one way to lift the financial burden off of individuals and 
making sure that everyone can afford to receive care. 
Finally, the establishment of the marketplace was an approach which helped many peo-
ple gain insurance coverage and did not fail entirely. Unfortunately, the implementation 
of the ACA has not happened as smooth as expected. Some challenges which occurred 
were only temporary – like the failure of website – but other problems still persist and 
hinder the marketplace. These issues prevent the marketplace from reaching its full po-
tential and explain why its implementation was not successful. By examining the reasons 
for the failure of the marketplace, potential solutions have also come to light and may 
lead to future success of the marketplace.  
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Accountable Care Organizations 
Franziska Distler 
In the historically fragmented U.S. health care system, care has been delivered by 
multiple providers with little or no coordination, raising issues with access, cost, 
and quality. Under the Affordable Care Act (ACA), the Centers for Medicare and 
Medicaid Services (CMS) is guiding several experimental programs in health care 
payment and delivery. A fundamental element of this reform is the development of 
Accountable Care Organizations (ACOs), which offer providers financial rewards 
if they can reduce Medicare cost expansions and ensure quality standards. Alterna-
tive payment models are not only in the center of current U.S. government efforts, 
but have also gained international attention. Due to their heightened importance, 
this essay provides a general overview of ACOs based on a theoretical analysis of 
the existing body of literature. Evaluation of cost reduction and quality improve-
ment of early ACOs show promise but also unintended incentives for providers 
through the benchmarking methodology. Enacting the Final Medicare Shared Sav-
ings Rule in 2016, the government is making continuous efforts to reset providers’ 
incentives to strengthen their satisfaction and maintain ACO participation. 
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1 Healthcare Delivery in America: Shift from Volume to Value 
The American government is making a great effort to change payment models for 
healthcare delivery. The shift from current fee-for-service (FFS) payments to alternative 
payment models aims to provide not only better care for patients but also lower costs 
(CMS, 2016a, p. 1). Turning away from incentivizing providers to increase the volume 
of services, the government strives to tie payments to quality and value. Improving 
healthcare delivery, Accountable Care Organizations (ACOs) have a strong impact on 
making this shift. Through this model, a set group of providers are held contractually 
accountable to payers for the cost and quality of the care they provide for a specific 
population (Cimasi, 2013, p. 1).  
The aim of this essay is to provide a general overview of ACOs in America. After ex-
plaining the formation process of accountable care in the 1970s, this paper focusses on 
basic structures of ACOs, like important definitions, compensation information, and par-
ticipating players. The Status Quo in Section 4 contains how ACOs are spread around 
the United States and how they performed so far. For a better understanding of current 
benchmarking challenges, Section 5 points out unintended incentives, resulting ineffi-
ciencies, and the government’s response. It is followed by a conclusion with forecasted 
developments.  
2 Accountable Care: From Managed Care to ACO 
While ACOs have only recently become popular in the American healthcare industry, 
the concept of accountable care is found in the origin of the managed care movement. 
The Health Maintenance Organization Act of 1973 provided prepaid group practice 
plans as an alternative to America’s traditional fee-for-service system. The act author-
ized $375 million for the development of Health Maintenance Organizations (HMOs), 
which are “prepaid health plan model[s] that use provider networks with a system of 
primary care gatekeepers and capitated provider reimbursement incentivizing decreases 
in utilization and increases in the efficiency of care for HMO members” (Cimasi, 2013, 
p. 5). Reducing the separation between medical service provision and compensation, 
capitation succeeded in controlling healthcare costs in a variety of settings, leading not 
only to an expansion of managed care in the private sector but in the public as well 
(Lagoe et al., 2005, pp. 5-6). The managed care approach flourished all over the United 
States and reached its high point in the mid-1990s. Employers widely accepted these 
less costly HMOs, leading to the enrollment of around 65 million Americans in these 
plans in 1996 (Cimasi, 2013, p. 5; Lagoe et al., 2005, pp. 7-8). While managed care 
performed well in reducing costs, individual providers opposed non-physician control 
over the medical profession and resisted changes in reimbursement models. Parts of the 
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cost-reduction were also due to physicians underproviding services for fear of surpas-
sing their spending thresholds (Cimasi, 2013, p. 5). As a result, patient dissatisfaction 
rose as they saw both their access to care restricted and a decline of medical quality 
(Blendon et al., 1998, pp. 80, 83). This so called managed-care backlash describes a 
dramatic drop of the approach in the late 1990s (Enthoven, 2005, p. 101). History clearly 
indicates that integrated organizations have great potential to reduce costs, but ensuring 
quality and patient’s acceptance is essential for these plans to remain viable. Currently, 
most states have laws ensuring wider public choice and access for still-existing managed 
care plans (Cimasi, 2013, p. 6). 
McClellan et al. (2010) describe the American health system as “neither effective nor 
sustainable” (McClellan et al., 2010, p. 982), characterized by high medical expendi-
tures, overuse, and fragmentation. Compared to all 34 OECD countries, America not 
only spends the greatest share of its gross domestic product on healthcare but also shows 
the greatest relative growth in health expenditures (OECD, 2017). In 2011, almost all 
Medicare spending was FFS payments, creating strong financial incentives for physi-
cians to increase the volume of services they delivered with little incentives to ensure 
value or quality of care (Meyer, 2011, p. 1,228). Against this background, there is great 
interest across the United States in improving health care delivery, performance, and 
payment mechanisms.  
Required by the Affordable Care Act, the Centers for Medicare & Medicaid Services 
(CMS), an agency within the Department of Health & Human Services (HHS), estab-
lished the Medicare Shared Savings Program in 2012. Using Medicare, the nearly uni-
versal coverage program for older adults, the program aims to provide better care for 
patients, achieve better health for communities, and lower costs through improvements 
in healthcare delivery (Barnes et al., 2014, p. 1 and CMS, 2016a, p. 1). In 2015, for the 
first time in history of the Medicare program, HHS set explicit goals for alternative pay-
ment models. Turning away from FFS payments, it is targeting to tie 85% of all Medi-
care payments to quality or value by the end of 2018 (HHS, 2015). In addition to this 
self-commitment, the statement signals healthcare providers to get involved in alterna-
tive payment models, such as bundled payment. In March 2016, HHS announced that 
they reached the interim goal of tying 30% of Medicare payments to quality ahead of 
schedule. ACOs, which experienced a boom through the MSSP, represent about three 
quarters of this success, allowing health care providers to better coordinate care for Med-
icare patients (HHS, 2016). 
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3 Basic Structures of Accountable Care Organizations 
3.1 Definition and Objectives 
CMS defines ACOs as “groups of doctors, hospitals, and other health care providers, 
who come together voluntarily to give coordinated high-quality care to their Medicare 
patients” (CMS, 2017a). If providers can slow the growth of patient healthcare costs, for 
example by reducing unnecessary services, while ensuring good quality of care, they 
will receive financial rewards. Contrary to the fragmented care that often results from 
FFS payments, ACO providers are striving to deliver seamless, high-quality care for 
Medicare beneficiaries across different care settings (CMS, 2016a, p. 2). 
Known as the Three-Part Aim (originally called Triple Aim), proponents believe that 
ACOs will deliver better quality and outcomes, improved patient experience, and low-
ered per capita costs (Berwick et al., 2008, p. 760 and IHI, 2007, p. 2). While ACO-like 
models have been implemented in the private sector for years, ACOs for Medicare pa-
tients were established nationwide with the Affordable Care Act in 2010 (Auerbach et 
al., 2013, p. 1,781). Intended to shift the delivery of health services from an emphasis 
on volume to an emphasis on value, ACOs constitute an innovative model in America 
(Hofler and Ortiz, 2016, p. 1).  
3.2 Variations in Medicare-ACO Models  
While ACOs administered by CMS receive the most attention, the numerous commer-
cial ACOs are more flexible in individual contract agreements as they are only subject 
to ordinary legislation. The coexistence of various kinds of ACOs creates an ideal envi-
ronment of learning and improvement (Schulte et al., 2017, pp. 373-374). The following 
provides an overview of different types of Medicare ACOs. Besides the regular program, 
CMS is constantly developing and testing different models with a smaller number of 
participants to expand their knowledge for future ACO development.  
With 480 ACOs, the permanent Medicare Shared Saving Program (MSSP) is the most 
popular model administered by CMS. An ACO must apply and meet certain criteria to 
participate, requiring a service population of at least 5,000 Medicare FFS patients and 
participation for at least three years. ACOs can either chose a one-sided risk model, 
where they may receive shared savings but are not liable for shared losses, or the more 
ambitious two-sided model, where they may receive a greater portion of shared savings 
but also share losses (CMS, 2016a, p. 4).  
The Advance Payment ACO Model ran from 2012 to 2015 and was mainly designed for 
physician-based and rural providers. It supported them with upfront and monthly pay-
ments instead of retrospective shared savings, providing the startup capital necessary to 
grow infrastructure and finance staff for care coordination (CMS, 2017b). Maintaining 
the idea of pre-paid shared savings, the ACO Investment Model started in 2015. Building 
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on knowledge gained through Advanced Payment ACOs, it aims to encourage ACOs to 
take on greater financial risk and to set up new ACOs, especially in underserved areas.  
The more advanced Pioneer ACO Model only addressed providers with previous expe-
rience in coordinating care and managing the appropriate infrastructure. Running until 
2016, Pioneer ACOs took on higher levels of shared savings and risks than any other 
ACOs in the MSSP and were designed to test innovative ways of compensating and 
regulation (CMS, 2017f). For example, they derived most of their clinical service reve-
nues from value-based payments of private insurers, with some ACOs converting parts 
of their FFS reimbursements into a monthly population-based payment (Pham et al., 
2014, p. 1,636). Even with experienced leadership, this ACO model turned out to be 
very challenging. While only 8 of the initial 32 Pioneer ACOs remained in the fifth and 
final performance year, most switched to the less ambitious and lower risk MSSP. Grow-
ing from these experiences, CMS announced the Next Generation ACO Model at the end 
of 2016, providing 44 organizations with the opportunity to take high levels of financial 
risks and rewards. The model provides better predictability of financial targets through 
refined benchmarking and tools to support patient engagement and care (CMS, 2017e).  
Finally, the Comprehensive ESRD Care Model strives to improve care for beneficiaries 
with End-Stage Renal Disease (ESRD). As this disease is causing complex health needs 
and requires multiple provider visits, the model aims to create incentives for improved 
patient-centered and coordinated care as well as reduce medical costs associated with 
this condition (CMS, 2017d).  
3.3 Healthcare Providers  
Any Medicare-enrolled provider or supplier is free to join an ACO. The collaboration 
can be composed of a range of healthcare organizations such as hospitals, independent 
practice associations, multi-specialty medical collaborations and groups of doctors or 
other providers (Goldsmith, 2011, p. 33). The Medicare ACO programs do not specify 
a set composition of providers that must be included, requiring only a minimum service 
population of Medicare beneficiaries (Colla et al., 2016, p. 432).  
3.4 Compensation via Benchmarking  
Healthcare providers participating in Medicare ACOs receive regular remuneration for 
covered Medicare services through the FFS system. Additionally, ACO annual perfor-
mance is measured against an individual benchmark calculated by CMS that indicates 
whether the ACO generated savings or losses for the Medicare program. The benchmark 
is an estimation of “what the total Medicare Fee-For-Service […] expenditures for as-
signed ACO beneficiaries would otherwise have been in the absence of the ACO” and 
is updated every year (CMS, 2016a, p. 4). Following the idea of value-based payments, 
a combination of efficiency and quality is needed for reward (McCellan et al., 2014, p. 
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1,509). Therefore, only “ACOs that meet or exceed a minimum savings rate (MSR), 
satisfy minimum quality performance standards, and otherwise maintain their eligibility 
to participate in the Shared Savings Program are eligible to receive a portion of the sav-
ings they generate” (CMS, 2017a, p. 3). The CMS quality measurements are classified 
in four, equally weighted domains: patient experience, care coordination/patient safety, 
preventive health, and at-risk population. Over the three-year implementation period, 
CMS payments shift from ACOs simply reporting these measures to the entities bearing 
risk for meeting performance targets (MedPac, 2016, p. 3). 
3.5 Patient’s Assignment 
Unlike HMOs and managed care programs, ACOs do not limit patients in their choice 
of healthcare provider. Beneficiaries are freely able to choose any Medicare-enrolled 
provider regardless of their participation in an ACO (MedPac, 2016, p. 1). However, if 
an attributed patient chooses a provider outside of the ACO, the ACO remains respon-
sible for the costs. This incentivize physicians to provide patients with exceptional care 
in order to maximize ACO retention (MedPac, 2016, p. 1). From a patient’s perspective, 
coordinated care and quality improvements are intended to lead to less paperwork and 
fewer repeated medical tests due to electronic health record utilization (Barnes et al., 
2014, p. 2).  
Nevertheless, CMS has to assign beneficiaries to an ACO since the yearly performance-
measurement is based on a defined patient population. In most cases, the assignment is 
made retrospectively at the end of each year based on the population served during that 
period. For advanced two-sided models, a prospective method uses data from one year 
to assign patients to the ACO for the following year (CMS, 2016a, p. 6). Generally, 
prospective methods avoid problems of free-riding and resource expenditure on patients 
who are not attributed to the ACO, while retrospective methods ensure a larger overlap 
of the assigned and the treated populations (Lewis et al., 2014, p. 592).  
4 Status Quo – ACOs in America 
4.1 Number of ACOs 
The consulting company Leavitt Partners estimates a total of 838 public and private 
ACOs in January 2016, showing a significant increase in previous years as shown in 
Figure 1. With an estimated 28.3 million people, ACOs are covering 8.9% of the Amer-
ican population (Muhlestein and McClellan, 2016). 
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Figure 1: ACOs Over Time 
 
Adapted from: Muhlenstein and McClellan, 2016. 
More than 600 ACOs are managed by CMS. Currently they register 480 MSSP ACOs, 
45 Investment Model ACOs, 37 Comprehensive ESRD Care Model ACOs and 44 Next 
Generation Model ACOs. Still, contracts of private payers usually cover lager numbers: 
The 17.2 million lives covered by private payer ACOs dwarfs the 11.1 million covered 
by MSSP ACOs in 2016 (Muhlestein and McClellan, 2016). 
4.2 Composition of Healthcare Providers  
More than half of ACOs include a hospital, which generally provides more capital, ad-
vanced data sharing, and better engagements of providers across the care continuum 
(Colla et al., 2016, p. 437). Additionally, hospital care influences several ACO quality 
measures, such as readmission rates and medication reconciliation. Still, findings indi-
cate that “ACOs with a hospital do not report significant differences in their capabilities, 
compared to their counterparts without a hospital” (Colla et al., 2016, p. 437). Hospitals 
might not be able to fully commit to reducing spending as they typically own many 
players of the health care provider team, such as laboratory services, rehab facilities etc. 
Targeting savings within the ACO might thereby reduce the revenue of their own hold-
ings (Brennan, 2016). The fact that physician-led and integrated (physician-hospital 
partnerships) ACOs are more likely to achieve shared savings, supports this assumption 
(Muhlestein et al., 2016). Besides fewer bureaucratic layers, physicians might be able to 
negotiate better prices for external services and can generate savings by reducing emer-
gency department and hospital admissions, which lower revenue for hospitals (Finne-
gan, 2017). Contrary to previous concerns that hospitals dominate ACO leadership be-
cause of their managerial strengths and resources, physicians have a major impact, lead-
ing 51% of ACOs alone and 33% jointly with hospitals (Colla et al., 2014, p. 694).   
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According to the 2015 Medicare report, the best-performing ACOs are not only physi-
cian-led but also older and smaller. Older ACOs are at an advantage since they have had 
more time to improve their health care delivery models and their internal structures. In 
pursuit of finding the best service provision model, smaller ACOs also succeed by adapt-
ing to changes quickly (Brennan, 2016). The smallest ACOs with about 5,600 patients 
generated savings of $114.70 per beneficiary while the largest ACOs with about 46,600 
patients generated losses of $23.93 per capita (Muhlestein et al., 2016). Even if CMS 
was taking great efforts to encourage the creation of large, consolidated health systems 
to increase efficiency and functional integration in the past, the 2015 results suggest that 
it might be more important to emphasize the performance of smaller ACOs (Muhlestein 
et al., 2016). 
4.3 Geographical Distribution 
A key marker of where ACOs are forming is pre-existing provider integrations such as 
hospital systems and large groups of primary care physicians (Auerbach et al., 2013, pp. 
1,786-1,787). As shown in Figure 4.2, most MSSP ACOs are located in metro areas like 
Atlanta, Chicago, Dallas, New York, Philadelphia and San Francisco, with 62% of 
ACOs found in high population density areas and only 12% in low population density 
areas (CMS, 2017c). 
Interestingly, MSSP ACOs are not preferentially located in areas with high per capita 
Medicare spending or a high percentage of the area’s Medicare population (CMS, 
2017c). Even if it seems intuitive that high spending indicates unnecessary care and a 
great potential of future cost reduction, Auerbach et al. (2013) found out that a lack of 
key infrastructure and limited ability to integrate care characterize these regions. This 
might decrease strategic options for ACOs and therefore make these areas less preferred 
locations.   
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Figure 2: MSSP ACO Assigned Beneficiary Population by ACO by Country 
 
Source: CMS, 2017c. 
4.4 Prerequisites and Performance 
Through today’s expanding knowledge of healthcare costs, growing opportunities in big 
data, and experience in collaborating with other health care providers, ACOs have a 
higher likelihood to succeed compared to the managed care approaches of the 1990s. 
Patient freedom to use ACO services and select a provider independently reduces mis-
trust and dissatisfaction in the population (Emanuel, 2012, pp. 2,263-2,264). Expanded 
physician governance increases acceptance, as physicians prefer an ACO model that 
permits a greater level of independence and self-governance (Cimasi, 2013, p. 6). Addi-
tionally, providers do not have to take on as much financial risk as those in HMOs, 
which carried up to 100% of the risk, and can now use electronic health records to inte-
grate care (Barnes et al., 2014, pp. 5-6). In the following, performance results of Medi-
care ACOs are focused because they are subject to a mandatory and independent evalu-
ation through CMS. As there are no such regulations in private sector, results of com-
mercial ACOs might be published incompletely or biased (Schulte et al., 2017, pp. 539-
540).  
According to CMS, Medicare ACOs generated more than $466 million savings in 2015 
and a total of $1.29 billion from 2012 to 2015. Even if more ACOs received shared 
savings than in previous years, the number remains less than one third of all ACOs. To 
share in savings, ACOs not only have to satisfy minimum quality performance standards 
but also meet the MSR. While 8 of all 12 Pioneer ACOs generated savings, only six had 
sufficient savings to receive a portion of them (CMS, 2016c). Looking at individual 
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results, many ACOs missed their benchmarks by millions of dollars. An analysis by 
Introcaso and Berger (2015) revealed that the $341 million in shared savings in 2014 
were highly concentrated among the 86 most successful ACOs.  
Generally, high-risk ACOs remain unpopular. In January 2017, the clear majority of 438 
MSSP ACOs (91%) are participating in the one-sided model while 9% has chosen the 
two-sided model (CMS, 2017c). Summarizing the financial results of MSSP ACOs in 
2015, more ACOs saved rather than lost relative to their benchmarks. While Medicare 
saved $429 million, it paid out $646 million in shared savings to MSSP ACOs. The net 
program losses of $216 million are due to the high proportion of one-sided ACO models 
that receive shared savings but are not liable for losses (MedPac, 2016, p. 4). CMS uses 
pilot ACOs to evaluate how incentives can increase ACO enrollment and convince pro-
viders to take higher risks. Organizations identify lack of capital, absence of integrated 
IT systems, and deficiency of evidence-based treatment protocol data as the obstacles in 
forming ACOs (AMN Healthcare, 2011). Additionally, according to Hofler and Ortiz 
(2016), joining an ACO can raise costs for primary care providers up to 10%, meaning 
higher costs per patient visit during the first several years. Implementing essential ACO 
infrastructure, such as an electronic health record system and hiring the necessary ad-
ministrative staff, can be very costly. 
CMS describes a constant increase in the quality of services, reporting that ACOs im-
proved on 84% of the quality measures. Significantly, all 12 Pioneer ACOs improved 
their scores from 2012 to 2015 by over 21 percentage points (CMS, 2016c). While CMS 
results suggest great success in Medicare ACOs, they only cover a small share of the 
American healthcare market and the results have a relatively small sample size. Even if 
a final evaluation about ACO success cannot be made at this point, the rising number of 
ACOs indicates widespread organizational faith in the program and significant saving 
potential. 
5 Challenge Benchmarking: Unintended Incentives and CMS Response 
The ACO benchmarking system was strongly criticized in years past. At the start of 
MSSP, every ACO can choose between the one- or two-sided risk model for its first 
three-year period (see Chapter 3.2). For that time, CMS sets a spending target for the 
ACO to receive shared savings. The benchmark is a weighted average of the healthcare 
costs for the attributed patients over the last three years, including annual adjustments 
for patient characteristics and anticipated growth in Medicare FFS expenditures (Harvey 
et al., 2014, p. 123). Assuming that more recent spending is more predictive of current 
ACO expenditures, the most recent year receives the highest weight. For example, for 
an ACO that started in 2016 spending for patients served in 2015 received a weight of 
0.6 while spending in 2014 and 2013 received weights of 0.3 and 0.1, respectively (Dou-
ven et al., 2015, p.143). 
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CMS uses the same method to recalculate the benchmark at the start of each new three-
year contract term. This process implies that ACOs which still show high Medicare ex-
penditures at the end of the first term will receive a higher benchmark and hold greater 
potential to generate savings in the second term. Similarly, ACOs that generated signif-
icant savings in the first term receive tightened benchmarks in the second. In order to 
receive shared savings, these well-performing organizations do not only have to main-
tain previous expenditure levels but also achieve additional cost reductions. This creates 
hardship on ACOs in this position, with fewer safe and effective saving opportunities 
remaining for an ACO to take in upcoming terms.  By “placing an ACO in a race against 
itself” (Harvey et al., 2014, p. 122) and penalizing previous cost reductions with lower 
benchmarks for the next period instead of rewarding, the MSSP creates unintended in-
centives (Douven et al., 2015, pp. 143-144). Instead of reducing unnecessary medical 
services, ACOs may be constrained to increase spending, especially shortly before new 
benchmark calculations, to receive a better benchmark for the future. One estimate sug-
gests that “for every dollar increase in spending in the last year before an ACO starts a 
new three-year contract, the ACO will get back between $1.48 and $1.90 during the 
contract period” (Douven et al., 2015, p. 143). This turns out to be profitable for ACOs 
but describes the opposite of the original target to reduce Medicare expenditures (Dou-
ven et al., 2015, pp. 143, 146). 
In June 2016, CMS announced the Final Medicare Shared Savings Program Rule in 
order to “continue broad-based program participation and improve program function 
and transparency” (CMS, 2016b). In effect, CMS modified the process for resetting 
benchmarks for the second and subsequent agreement periods, beginning in 2017. In-
stead of using national Medicare spending data, CMS will now use regional spending 
growth trends to update ACO benchmarks while removing the adjustment that accounts 
for the savings generated in the period shortly before the new agreement. Because re-
gional spending is determined by all providers in the area, this change limits the link 
between ACO performance and future benchmarks (Rose et al., 2016, p. 441). The re-
based historical benchmark will now reflect ACO efficiency in relation to other regional 
providers (CMS, 2016b). 
Although very promising, the use of regional data and the resulting convergence in 
benchmarks between ACOs with spending above and below local average FFS spending 
could cause less-well-performing ACOs to leave the program, as the new spending tar-
get falls below their reach (Rose et al., 2016, p. 441). To avoid this circumstance, CMS 
also announced a phased-in approach for ACOs with higher-than-average regional 
spending that applies a lower weight to the benchmark’s regional adjustment component 
in the beginning (CMS, 2016b). 
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Oppositely, with the new benchmark reflecting the average of high- and low-spending 
providers in the area, Rose et al. (2016) highlight, that well-performing ACOs with be-
low-baseline spending may not be incentivized to further improve their performance. 
Recognizing that a shift to a two-sided model promises the greatest savings to these 
organizations, CMS provided the opportunity for one-sided ACOs to extend their initial 
benchmark contract for an additional year before the shift to the two-sided model (CMS, 
2016b). Future evaluations will show if the adapted benchmark methodology can reach 
its goals of both strengthening provider satisfaction and increasing ACO participation 
rates.  
6 ACOs - Opportunities and Limitations 
Auerbach et al. (2013) describe ACOs as “the heart of the government’s efforts to trans-
form healthcare delivery in the United States to a more coordinated, high-quality and 
efficient system” (Auerbach, 2013, p. 1,786) and underline that the cooperation and con-
tinued growth alongside private-sector ACOs has the potential to change the orientation 
of care systems in America. Trying to avoid circumstances which caused the managed 
care backlash, ACOs differ in several aspects from HMOs. Voluntary participation, less 
financial risk, more advanced outcome measurements, and knowledge of care manage-
ment increases provider acceptance while more coordinated and better quality care at-
tracts and retains patients. Nevertheless, ACOs might also face serious problems, as they 
gradually take on greater financial risk that could negatively affect the quality of care 
through rationing, denial of care, or ACO organizational instability. Additionally, con-
solidation of providers could lead to expanded market power and monopolization, re-
sulting in higher prices (Barnes et al., 2014, pp. 5-6). To prevent future setbacks, CMS 
strives to improve the position of ACOs through policies such as adapting the bench-
marking methodology to accommodate variably performing organizations.  
Even as the number of ACOs increases and innovative ACO models raise international 
awareness of alternative payment models, Barnes et al. (2014) underline the limited im-
pact of ACOs on health expenditures. They may lower costs marginally, but overall, 
expenditures will remain high unless the demand for acute medical care and the price of 
care decrease. Thus, socio-economic factors like food supply, unemployment and envi-
ronment have to be simultaneously targeted as the origin of medical demand (Barnes et 
al., 2014, p. 7).  
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Patient-Centered Medical Homes 
Catharina Harms and Iris Ruckdäschel 
The Patient-Centered Medical Home (PCMH) is an interdisciplinary institution de-
signed to secure and stabilize the primary care of the population. This form of care 
is characterized by a high degree of cooperation between individual specialist dis-
ciplines, the involvement of all participants (patient, relatives and nurses) and the 
constant clarification of the course of treatment. Especially in the US, which is char-
acterized by its vastness and large rural areas, this model could improve medical 
care and facilitate access for people living there. However, it is necessary to gener-
ate and implement standards, particularly for the evaluation and implementation of 
these facilities, in order to demonstrate comparability of the performance achieved. 
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1 Introduction 
Frustration with the U.S. health care system is on the rise, and therefore, a variety of 
critiques exist including the rise of out-of pocket costs and the lack of accessible health 
care. One major problem is the lack of implementation of a primary care system and the 
resulting overuse of emergency departments, as well as the decline in the numbers of 
primary care physicians (Phillips and Bazemore, 2010, p. 807; Berry and Mirabito, 
2010, p. 157). Rural areas, especially, have significant problems with providing primary 
care (Ewing and Hinkley, 2013, p. 1). These issues require that new paths should be 
chosen which would encourage delivery system innovations (Berry and Mirabito, 2010, 
p. 158). One important and possible innovation is “patient-centered medical homes” 
(PCMH), which promise to reinforce the primary care system. The origin of the concept 
of a “medical home” was in 1967 (Klein, Laugesen and Liu, 2013, p. S82; Braddock et 
al., 2013, p. 141). Medical homes were designed as a coordinated-care model for chil-
dren and a number of specialty pediatric clinics to manage patients with complex med-
ical problems. These medical homes, re-imagined as the PCMH, entered the discussion 
on American health care because of some problems with primary care in the 2000s. One 
core component of this model is the formation of a primary care basis to improve the 
value of healthcare and reduce health care spending (Stange et al., 2010, p. 601; Klein, 
Laugesen and Liu, 2013, p. S82). These principles could be a real solution for the prob-
lems of primary care provision in rural areas. 
This essay aims to assess the strengths and challenges the of PCMH as an innovative 
approach to primary care of rural areas. In the first section, an overview of primary care 
in general and primary care in rural areas is presented, followed by the theoretical frame-
work of PCMH and their strengths and challenges. Finally, a critical evaluation of the 
suitability of the PCMH as an innovative approach to primary care of rural areas is pro-
vided. 
2 Primary Care and Rural Areas in the United States 
2.1 Primary Care in the United States 
The U.S Institute of Medicine (IOM) defines primary care as the provision of integrated, 
accessible health care services (Donaldson et al., 1996, p. 2). Additionally, primary care 
providers should be the first access point of the health care system (Berry and Mirabito, 
2010, p. 158; Stange, 2009, p. 201). Primary care is a crucial factor for an effective and 
efficient health care system. Through primary care, a large majority of personal health 
care needs should be addressed and a sustained partnership between physician and pa-
tient should be established (Donaldson et al., 1996, p. 2). In order to reach these aims, 
five core attributes of primary care, as shown in Figure 5.1, are to set: accessibility, 
comprehensiveness, coordination, continuity and accountability (IOM, 1978, p. 16). 
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Figure 1: Five core attributes of primary care 
 
Source: Own figure, based on IOM, 1978, p. 16. 
Access to needs-based primary care services can maintain and improve health care, 
which is characterized by lower rates of illness and premature death (Starfield, Shi and 
Macinko, 2005, p. 457; Ewing and Hinkley, 2013, p. 1). Moreover, countries which have 
implemented an advanced primary care system achieve lower health care costs, en-
hanced outcomes and greater satisfaction overall. Population health in the U.S. federal 
states with improved primary care services is better than in those without (Macinko, 
Starfield and Shi, 2007, p. 123; Starfield and Shi, 2002, p. 213). However, due to various 
reasons, there is a lack of implementation of a primary care-centered health care system 
in the United States, and as a result, when scoring the availability and use of primary 
care, the U.S. has very low ratings (Sandy et al., 2009, p. 1,136, p. 1,140; Bates, 2010, 
p. 998). 
The reasons for the poorly developed primary care system in the U.S. are multi-layered 
and are based on political, economic, policy and institutional factors. One reason is the 
lack of national policies regarding the proportion of generalists versus specialists, which 
leads to a dominance of hospitals, especially of teaching hospitals and their focus on 
specialist care. More important is the failure of public policy to prevent the disintegra-
tion of primary care (Sandy et al., 2009, p. 1,140). Due to the focus on specialist care, 
the number of primary care physicians is declining, which in turn hampers the efforts to 
meet the current demand. Additionally, the high fragmentation of the health care system 
and the regular use of the emergency room as an access point to primary care complicate 
the implementation. Another issue and a source of dissatisfaction lies in the long waiting 
times for primary care, which can vary significantly from just a few days to a few months 
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(Berry and Mirabito, 2010, pp. 157-158). However, there are plenty of reasons for opti-
mism due to the growing recognition of the importance of primary care (Sandy et al., 
2009, p. 1140). The high costs of U.S. health care system may be reduced by a well-
developed primary care system (Berry and Mirabito, 2010, p. 157; Reid et al., 2009, p. 
e71). 
2.2 Rural Areas 
First of all, it is essential to define the term “rural areas” due to the stark differences 
which distinguish rural and urban areas in the U.S. (USDA, 2017b). The different re-
gions can be defined on the basis of administrative, land-use, as well as economic indi-
cators. Therefore the results vary considerably in terms of socio-economic factors and 
well-being (Cromartie and Bucholtz, 2008). The U.S. Census Bureau defines rural areas 
as those areas that are outside of urban areas and urban clusters. The definition of urban 
areas is based on the population density and other measures of dense development 
(Ratcliffe et al., 2016, pp. 1-2). According to the National Rural Health Association 
(NRHA) approximately 20 percent of U.S. citizens live in rural areas (though due to the 
different definitions, the percentage can vary from 17 to 19 percent) (NRHA, n.D.; 
Cromartie and Bucholtz, 2008). The following figure illustrates the distribution of rural 
and urban areas. 
 
Figure 2: U.S. Census Bureau’s urban and rural areas, 2010 
 
Source: USDA, 2017b; U.S. Census Bureau, 2015. 
Generally, rural areas face specific and distressing obstacles: high poverty rates, less-
educated inhabitants, increased numbers of uninsured people, effects of the demo-
graphic shift such as the increasing elderly rural population, as well as the additional 
rise in demand for primary care as an impact of the Affordable Care Act (NRHA, n.D.; 
Patient-Centered Medical Homes 
89 
Ewing and Hinkley, 2013, pp. 1-2; Bates, 2010, p. 998; USDA, 2017a). Consequently, 
the health of rural populations and their health-specific issues are significantly different 
from those in urban areas. When measuring health, the results show a health disad-
vantage for the rural population, especially in terms of the premature mortality rate (be-
fore 75 years) is higher (Eberhardt and Pamuk, 2004, p. 1,682). 
When looking to the obstacles of primary care, rural areas have a lower primary care 
physician ratio with 39.8 physicians per 100,000 inhabitants than urban areas (53.3 phy-
sicians per 100,000) (Hing and Hsiao, 2014, p. 4). Due to this uneven distribution, there 
is concern about the health care of the population in rural areas. Moreover, the lack of 
accessible and efficient primary care in rural areas can be explained by the large geo-
graphical areas which have to be served by physicians. Rural health care is therefore 
characterized by long travel times and the partial deficit in hospitals and other health 
care facilities (Ewing and Hinkley, 2013, p. 1; RHIhub, 2017). A further impact is the 
aging rural physician workforce due to a demographic shift. As a consequence, approx-
imately 28 percent of the primary care physicians in rural areas are going to retire during 
the next few years (Fordyce, Doescher and Skillman, 2013, p. 6). 
Meeting the current demand for primary care is a significant issue which will continue 
to worsen in the near future, and the availability of primary care is a growing concern 
(Ewing and Hinkley, 2013, p. 1). 
In conclusion, primary care services will face several obstacles, especially with respect 
to the availability of accessible and efficient primary care in rural America and the recent 
demographic trends. As a result, several states of the United States have tried to reinforce 
the role of non-physician providers in the supply of primary care (Ewing and Hinkley, 
2013, p. 1). In the development of new approaches, the Rural Policy Research Institute 
Health Panel defined five core attributes similar to the key components of primary care 
that should be considered: affordability, accessibility, high quality of care, community 
focus and patient-centeredness as well as patient engagement (Mueller et al., 2016, p. 
3). 
3 The Patient-Centered Medical Home 
3.1 Definition of the Model 
The PCMH was developed as an alternative primary care model with the aim of cost 
reduction, improved supplier coordination and higher quality of care, resulting in better 
health outcomes (Klein, Laugesen and Liu, 2013, p. S82). It is an attempt to reinvigorate 
the delivery of outpatient healthcare and is one of the keystones of a national health care 
reform (Braddock et al., 2013, p. 141). A medical home is not simply a place, but a 
concept which delivers the core functions of primary care (AHRQ, n.D.). Moreover, 
medical homes provide the opportunity to have a personal physician who coordinates 
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each step of treatment and serves as a liaison for comprehensive care (Starfield and Shi, 
2004, p. 1,495). This structure removes the doctor from the traditional role as a gate-
keeper. 
A further important distinction of medical homes, which enables the proactive and pa-
tient-oriented design of patient panels, is the formation of interdisciplinary teams with 
the support of health information technology (Klein, Laugesen and Liu, 2013, p. S83). 
The PCMH, specifically, is a team-based model which is integrated into the community. 
A further aim is to optimize the basic attributes of the primary care system, which should 
encourage new ideas about the provision of primary care and changes to the health sys-
tem (Stange et al., 2010, p. 602). The five key attributes of the PCMH, as shown in 
Figure 5.3, are based on the five key attributes of primary care and will be explained in 
detail in the following section (AHRQ, n.D.). 
 
Figure 3: Five core attributes of PCMH 
 
Source: Own figure, based on AHRQ, n.D. 
1) Comprehensive Care 
The core attribute Comprehensive Care is defined as the care of a large majority of 
physical and mental conditions both acute and chronic, as well as a focus on prevention 
and wellness. This demands a cooperation of the different suppliers of care. In other 
words, this means building a team-based care system, which includes medical providers, 
pharmacists, behavioral health providers and other care coordinators. Because of the 
different case complexities, different interdisciplinary levels and, consequently, differ-
ent teams are required. These teams can be settled in clinics or operate as virtual teams, 
thereby connecting patients and providers in the community (AHRQ, n.D.; Maragakis 
and O’Donohue, 2015, p. 4). 
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2) Patient-centered Orientation  
Health care in a PCMH is marked by patient-oriented performance and a relationship-
based system. Consequently, it is not only the patient with his or her unique condition 
who is at the center of interest, but also his or her informal background, culture, values 
and personal situation, which should be understood and respected. His or her family is 
also involved so that they can assist in the treatment process and the management of care 
(AHRQ, n.D.; Maragakis and O’Donohue, 2015, p. 4). 
3) Coordinated Care 
The PCMH coordinates and contains all necessary elements of comprehensive health 
care, including specialty care, hospital, home health care, and community of service and 
supports. The importance of Coordinated Care emerges from the need for a smooth 
process when patients are discharged from the hospital. Furthermore, open and clear 
communication between the patients, their family, the medical home, and members of 
the broader care team is an outstanding characteristic of medical homes (AHRQ, n.D.). 
4) Accessible Service 
A further goal of the PCMH is to shorten waiting times for urgent cases. Therefore, the 
PCMH offers increased in-person hours, a 24-hour service via telephone or electronic 
access to medical staff, as well as other alternative communication methods such as e-
mail. The medical home practice focuses on the individual preferences of their patients 
regarding method of access (AHRQ, n.D.). 
5) Quality and Safety 
The last attribute of the PCMH involves the use of evidence-based practices and clinical 
decision-support devices to accompany treatment, since quality and quality improve-
ment are of particular concern. In order to support decision-making with patients and 
families, technologies such as electronic health records are used. In this way, perfor-
mance can be measured and, if necessary, improvements can be made. In addition, pa-
tient satisfaction plays an important role. Quality and safety data, along with improve-
ment activities, are subsequently published, which is a good indicator of a system-level 
commitment to quality (AHRQ, n.D.; Maragakis and O’Donohue, 2015, p. 6). 
3.2 Strengths of Patient-Centered Medical Homes 
The implementation of PCMHs can change the primary care system fundamentally, and 
therefore change the role and the processes of patients and physicians (Cassidy, 2010, 
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p. 5). When the aims of the PCMH model are considered, several strengths can be iden-
tified such as quality of care, patients’ experience, cost of care and professional working 
experience (Maragakis and O’Donohue, 2015, p. 11). However, not every setting can 
qualify as a PCMH. Six program standards developed by the National Committee for 
Quality Assurance must be met to achieve PCMH recognition, as shown in Figure 5.4. 
 
Figure 4: PCMH Content and Scoring 
 
Source: Own figure, based on NCQA, 2014a, p. 3. 
In order to maintain the performance of PCMH, three different levels of PCMH status 
are defined. These standards target the key aspects of primary care. The respective set-
tings can obtain points based on the number of factors that the provider fulfills. Quality 
and performance are constantly monitored (Maragakis and O’Donohue, 2015, pp. 8-9). 
It is a method to increase standardization and to help PCMHs develop a good reputation. 
The more elements that are fulfilled by the PCMH, the higher becomes the point value. 
The point value determines the classification in the scoring level, and the PCMH then 
gets the certification. By this system the standardization, and therefore the certification, 
of such facilities should be easier and clearer (NCQA, 2014b, p. 21). 
A positive change in the working environment of physicians is the smaller number of 
patients to be treated, which reduces the scope of work and leads to a reduction in the 
risk of burnout (Cassidy, 2010, p. 5; Reid et al., 2009, p. e76). A further goal of the 
PCMH is to improve the patient experience, the obtainment of which has been shown in 
multiple studies (Maragakis and O’Donohue, 2015, p. 12). A better patient experience 
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resulted in significant improvement in doctor-patient interaction and access to care (Reid 
et al., 2009, p. e75). While some studies showed no significant change or no change in 
multiple aspects, it can be generally assumed that due to their interdisciplinary nature, 
the well-trained teams will enhance the organization and coordination of the treatment 
path as well as patient satisfaction through a high level of information exchange (So-
limeo, Stewart and Rosenthal, 2016, pp. 378/379; Hoff, Weller and DePuccio, 2012, p. 
637; Jaen et al., 2010, p. S57; Zutshi et al., 2014, p. 48). 
The term quality of care can be split in this context into the factors processes of care, 
health outcomes and mortality. Both the procedures in the care processes, as well as 
health outcomes can improve (Reid et al., 2010, p. e77; Grumbach, Bodenheimer and 
Grundy, 2009, p. 1; Zutshi et al., 2014, p. 48). However, the effects on mortality do not 
have statistically significant results (Maragakis and O’Donohue, 2015, p. 12). Another 
important issue is that in primary care, patients with chronic diseases such as diabetes, 
cardiovascular problems, asthma and hypertension are predominant, and they often need 
time-intensive care and regular check-ups. With the conversion and integration of 
PCMHs, an improvement of care and health outcomes for these patients may be reached. 
Moreover, multi-morbid middle-aged patients can be treated more effectively due to the 
interdisciplinary nature of PCMHs (Hornberger and Freeman, 2015, pp. 46-47). It is 
precisely these chronically ill patients, who require more help with the correct treatment 
of their illnesses and advice on preventative behavior, who stand to benefit most from 
the PCMH model. In addition, the interdisciplinary nature of PCMHs can lead to a re-
duction of redundant services while increasing preventive services (Hoff et al., 2012, p. 
622). A further quality enhancing factor of the PCMH is evidence-based medicine, 
which is supported by the core attributes (Rogers, 2008, p. 370). 
PCMH can achieve a reduction in health expenditures through increased use of primary 
care, and thus, a reduction in emergency and specialty care (Maragakis and O’Donohue, 
2015, p. 12). With regard to the use of emergency service, in some studies positive ef-
fects were shown with the PCMH model. However, the actual objective of effective cost 
reduction could not be clearly demonstrated in the investigation (Zutshi et al., 2014, p. 
48). 
In principle, the PCMH model can be presented as an efficient model for the US health 
system. Significant cost savings could be generated and preventive activities expanded 
and strengthened. Patients and their families are involved in the entire treatment process 
and are always kept up-to-date (Klein, Laugesen and Liu, 2013, p. S89). 
3.3 Challenges of Patient-Centered Medical Homes 
There are, however, some limitations and gaps in the system. Well-organized practices 
are faced with the problems of underfunding – PCMH are introduced within the scope 
of the Medicaid care (Klein et al., 2013, p. S84) – and underemployment. There is still 
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a need for further development in the implementation of the model and the efficient use 
of existing resources in order to ultimately achieve top performance (Klein, Laugesen 
and Liu, 2013, p. S89). Another problem may be rejection of this model by the primary 
care workforce, as well as a fear of change. Moreover, the PCMH is still in its early 
stages, and therefore unintended consequences cannot be foreseen. The lack of resources 
such as money and time can block the implementation of changes to the health care 
system (Hoff, Weller and DePuccio, 2012, p. 641; Rogers, 2008, p. 372). Because of the 
partially negative relationship with the term "medical home," this system was a source 
of confusion for some patients. To reduce this misunderstanding, a new terminology has 
been considered: advanced basic care. However, the organization of health care for 
young and healthy people is made more difficult since it would not represent a cost-
effective model for them. A proposal for a more effective solution would be the coop-
eration of PCMH with other integrated care models (Cassidy, 2010, p. 5). 
Due to the large number of payment models that underpinned the PCMH, a series of 
debates were raised to decide which model is the best (Berenson et al., 2016, pp. 2-3). 
When looking at the supply side more closely, some payment methods limit personal 
contact between the service providers and the patient, which could solve the problem 
with time, but in turn, counteracts the PCMH principle of promoting communication. 
On the demand side, the patient is encouraged to visit medical homes for care. A mod-
erate cost participation and value-oriented insurance design promote a more cost-effi-
cient processing of the available services. Through management approaches, care pro-
viders and payers are given the authority to monitor and manage patient care (Berenson 
et al., 2016, p. 7). This model, including the key attributes of PCMHs, should help to 
reduce the administrative costs. Because of the high number of health insurance provid-
ers and their different methods of reimbursement and individual contracts, the PCMH 
should be responsible for the standardization, centralization and coordination of work 
of providing care to reduce the level of complexity and optimize the medical care for all 
people (Martin et al. 2004, p. S12, Neumann, 2014, pp. 37/38). 
The individual PCMH models differ in their structure, culture as well as existing re-
sources, and are independent in the design of their interdisciplinary teams. Unfortu-
nately, no uniform standards are currently being followed and a direct comparison of 
performance is hampered. Therefore, a balance between standardization and innovation 
is needed. If the objectives of uniformity, and the implementation of a standardized 
model as well and multi-regional acceptance are to be met, the PCMH should be further 
developed through more rigorous evaluations (Klein, Laugesen and Liu, 2013, p. S87). 
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4 Discussion and Conclusion 
Considering the previous analysis, it can be concluded that the fundamental pillars of 
the PCMH model take into account the core attributes of primary care. The PCMH rep-
resents a comprehensive, patient-centered, coordinated and accessible primary care 
model. However, patient-centeredness and the community play a greater role within the 
PCMH as can be seen from the core attributes (see 3.1). The PCMH is a successful 
innovation, and therefore is an important part of health care reform. Optimizing the 
PCMH model could fundamentally change the status of primary care in the health care 
process and can help to enhance the degraded position of primary care (Bates, 2010, p. 
998). 
Although, as shown above, the PCMH has many strengths and innovative approaches, 
it could be an overrated approach due to the fundamental political, economic and social 
barriers in the health care system (Sandy et al., 2009, p. 1,141). The implementation of 
PCMH models could be hampered by the different structures of the individual states of 
the U.S. and the differing values both within and across these states. A further obstacle 
for realization could be a lack of uniform electronic health record systems, especially of 
rural regions (Bates and Bitton, 2010, p. 619). In addition, a necessary infrastructure for 
PCMH should be implemented at the respective providers’ locations in order to utilize 
the potential of the model (Klein, 2009, p. 128). This, in turn, requires a high level of 
commitment from providers and patients. The latter must proactively participate in man-
aging their health, which could lead to difficulties in patient adherence, especially 
among those with low socioeconomic status. Consequently, these obstacles and the high 
costs could lead to incomplete implementation, especially in rural areas, and a full inte-
gration is necessary for comprehensive improvements. Furthermore, the high fragmen-
tation of the American health care system poses a problem that is unlikely to be solved 
by merely further developing a new system (Sandy et al., 2009, p. 1,140). New systems 
also require a sufficiently high number of patients to implement them, and due to the 
very low partial patient volume, adverse effects on reliability, validity and utility may 
be a problem (Moscovice, Johnson and Burstin, 2017, p. 259). Additionally, especially 
in rural areas, the dwindling workforce of primary care physicians is an obstacle which 
cannot be solved simply by the implementation of another system. This workforces need 
to have special skills for their new role as care integrators and also support the changes 
to the system (Mueller et al., 2016, p. 4). This may be a special problem among the 
elderly health care workforce in rural areas. 
However, the PCMH has many promising features to address the long-time national 
challenge of health care workforce shortage (Collins, 2016, p. 99). Especially in rural 
areas, the urgency to find solutions for maintaining an adequate primary health care 
workforce has risen (Collins, 2016, p. 99). With the opportunity to change the image of 
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primary care through the PCMH, the profession of primary care physician could be re-
invigorated with the interdisciplinary approach and the increased involvement of health 
technologies. Even if the popularity of becoming a primary care physician changes with 
the PCMH model, there may be further steps needed to attract more students to rural 
areas. One solution may be to intensify the recruitment of students from these rural com-
munities to complete their education and community-based residency training. During 
this training, the students could be placed into underserved areas (Carolina GME Advi-
sory Group, 2014, pp. 12/13). Another approach to increase the number of students 
working in rural areas is the loan repayment programs of different states (Carolina GME 
Advisory Group, 2014, p. 32). As a result of these and other efforts, more medical stu-
dents may decide to become primary care physicians, which in turn could solve the 
problem of declining numbers of physicians, and ease the demand-supply situation 
within rural areas. In conjunction with the PCMH these approaches could reduce the 
workforce shortage. 
A further problem of primary care, especially in rural areas, that the PCMH may solve 
is the inadequate payment provided to primary care physicians. The income gap between 
specialist and primary care physician is steadily rising, leading many graduates to fre-
quently avoid primary care careers (Berenson and Rich, 2010, p. 613; Bodenheimer, 
2006, p. 862) because a significant decisive factor for the choice of a specialty is the 
chance to earn money (Carolina GME Advisory Group, 2014, pp. 31/32). Due to the 
integral payment reform feature of the PCMH, the number of students who are interested 
in this profession could rise (Berenson and Rich, 2010, p. 613). This new payment model 
would be especially beneficial in rural regions with a workforce shortage. For example, 
this model could address the considerable increase in the number of working hours and 
the long travel distances in rural areas. There are already some rural physician grant 
programs that use an enhanced reimbursement as a retention strategy for physicians 
leading primary care teams in rural areas. This represents an ongoing incentive to work 
in rural areas as a primary care physician (Carolina GME Advisory Group, 2014, pp. 
31/32). With payment reform and efforts to enhance the attractiveness of working in 
rural areas, the PCMH could help ensure better primary care provision in rural areas. 
The PCMH is an interdisciplinary approach and increases the involvement of health care 
technologies, and can therefore help to improve the coverage of extensive areas, and in 
particular, of the elderly. Through the increased use of telemedicine, the coordination 
with specialty care providers can be eased in rural areas. The rural primary care physi-
cians could benefit from the advanced practice of urban specialty doctors in case of a 
complex indication areas, and the patients can achieve better and faster treatment (Car-
olina GME Advisory Group, 2014, p. 35). The travel times for the physicians may even 
be partly reduced. In addition, the high involvement of family members and the high 
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level of information exchange among all participating parties could improve health sta-
tus and patient adherence, particularly in rural regions where the elderly people are often 
dependent on family support and sometimes live a long distance from the nearest hos-
pital.  The PCMH provides a highly coordinated and patient-centered model with high 
dependency.  
The PCMH is already implemented in approximately twenty-one states. The PCMH 
model of Arkansas was designed as a flexible model, which can adapt to variations in 
the efficiency of primary care processes (Müller et al., 2016, p. 9). With this model and 
a benefit system linked to provider participation, the primary care and the health of rural 
populations was reinforced by overcoming a number of hurdles. The implementation of 
a PCMH model in Alaska brought a recorded reduction in the use of the emergency 
room, which in turn reduced costs (Driscoll et al., 2013, p. S48). The implementation of 
a PCMH model by the Veterans Health Administration also resulted in an improvement 
in the primary care system, including an increase in telephone and electronic encounters, 
as well as an improvement in post-hospitalization follow-up (Rosland et al., 2013, p. 
e263). 
Finally, the PCMH’s core attributes represent the key components of an effective rural 
health system, and community and patient-centeredness play a great role within both 
rural health systems and PCMH. Additionally, the approach of the PCMH both at the 
micro (processes) and macro (society) perspective offers a comprehensive concept that 
could solve the problems particularly of rural areas. These are indicators that the PCMH 
can be an innovative approach for changing the U.S. rural health system. 
To conclude, the PCMH is a promising and innovative care concept in primary care in 
general, and especially for primary care in rural areas. However, additional studies are 
needed to further refine the efficacy of the model and adapt it to the appropriate needs 
so that the triple aim of health care (better quality, improving experience, reducing cost,) 
can be achieved sustainably (Zutshi et al., 2014, p. 1, p. 56). 
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The Geisinger Model 
Patrick Walberer 
Despite having one of the highest health expenditures internationally, the US health 
system for many years has only achieved average care outcomes. Additionally, the 
quality of care is not adequately considered in reimbursement processes. Insuffi-
cient individual access to medical care, fragmented care structures, as well as the 
still high number of uninsured Americans, represent great challenges across the na-
tion. Geisinger Health System, an integrated healthcare delivery system located in 
Pennsylvania which has operated for more than 100 years, has set a goal to counter  
sprawling healthcare costs with innovative service, insurance, and remuneration 
structures. Therefore, Geisinger Health System relies in particular on innovations 
in information technology, which are based on an electronic health record system 
that spans all institutions. The approach and implementation of innovations as well 
as some directive innovations of the Geisinger Health System are examined in this 
essay. The value added for the patient as well as for Geisinger will also be discussed. 
Finally, prospects and limitations will be presented to evaluate if and how the inno-
vative thinking of Geisinger Health System can be seen as a beacon for other US 
healthcare providers. 
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1 Status and Hurdles of Health Care Delivery in Rural US Regions 
Historically, there exist various parallel healthcare and insurance systems in the United 
States of America (US) which operate as a "highly inefficient, … extremely fragmented 
whole" (Smith and Medalia, 2014). The insurance coverage of the US population, de-
fined as access to medical care, is a very heterogeneous mixture of mainly private insur-
ance as well as many state support programs, without a general insurance obligation. 
Fee-for-service reimbursement dominates the insurance market, but some plans reward 
good treatment and outcomes (Yuan et al., 2017, pp. 12-14). With costs of $9,403 per-
capita in 2015, the US health care system ranks third most expensive in the world, while 
the treatment quality is only rated as average (World Bank, 2017). Constantly rising 
treatment costs as well as dissatisfaction of the patients with the care they are provided 
causes further problems for the health care system. 
Usually, US healthcare structures consist of various spatially and organisationally sep-
arated outpatient medical practices, emergency services, and inpatient service providers. 
However, this organisation of care structures no longer corresponds to the demands and 
possibilities for patient care in the 21st century. Innovative care models are only very 
slow introduced into healthcare delivery. A well thought-out medical care restructuring 
including innovative supply components is urgently needed (Prince and Graf, 2015, p. 
16). 
All the problems previously mentioned resulted in a loss of value in the healthcare sys-
tem and created the necessity for reorganisation and innovation. This leads to the fol-
lowing research question, which is to be answered within the scope of this paper:  
2 Classification of Legal Background, Basic Conditions, and Necessities 
Access to medical care in the US depends on an individual’s insurance protection 
through an appropriate health plan. As described in the previous chapter1, health insur-
ance in the US means any type of program that is designed to cover and pay for illness 
expenses. This includes privately purchased insurance and government funded insur-
ance (Medicare) or social welfare program (Medicaid) (Shi and Singh, 2013, p.139; 
KFF, 2017; Torgan, 2013).  
Fragmented, uncoordinated, and highly variable treatment procedures can be identified 
within this system. Fragmented healthcare structures often lead to safety risks as well as 
wasted resources, two main reasons for the low value of US healthcare, defined as the 
outcome depending on the cost of the input (Porter and Olmsted-Teisberg, 2006, p. 4). 
The aim of this essay is to examine if and how the Geisinger model can be seen as an 
example for innovative healthcare delivery in the US and describe what generalizable 
implications can be derived from it for other providers. 
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Private health insurance companies, in particular, negotiate health plans with individual 
supply conditions and payment models with different service provider groups, creating 
a lot of bureaucracy and inefficiency (Chua, 2006, p. 4; Torgan, 2013).  
Governmental reform measured previously proposed mostly focused on better access to 
care or cost control of healthcare. Thereby, both approaches ignored the basic problem 
of lower healthcare value for a long time (Porter and Olmsted-Teisberg, 2006, p. 4; Tor-
gan, 2013). It is important to increase the value of healthcare and maximize the benefits 
of high healthcare expenditures. Productivity and efficiency gains, which are common 
in other industrial sectors, barely exist or are non-existent in the US healthcare sector 
(Paulus et al., 2008, p. 1,235). To increase the value of healthcare, a well-thought-out 
health care system strategy as well as the associated organisational capacity to change 
is needed. Sustainable healthcare value can only be created when the various stages of 
the care process are abolished, automated, delegated to appropriate but more cost-effec-
tive personnel, or otherwise made more efficient (Porter and Olmsted-Teisberg, 2006, 
pp. 4-6; Torgan, 2013). 
Key components for an innovative change in care processes are:  
 Consumers and patients who are actively directed to behaviour that alleviates ill-
nesses or increases the patient-centred performance. 
 Safer and more effective medicines or medical devices are used 
 Physicians who provide faster, more appropriate and reliable patient-centred care 
 Costs of the supply chains are systematically reduced and the value of healthcare 
increased 
These changes offer the greatest sustainability within a supply system, in which the fo-
cus is on the creation of value and the output of innovation is measured and appropriately 
rewarded in the market (Porter and Teisberg, 2006, pp. 4-6; Paulus et al., 2008, pp. 
1,235-1,236). 
The US healthcare system is not just struggling with the existing lack of value; it also 
has geographical barriers. The geography and settlement structure can be characterized 
by a two-track development - various metropolises of millions and many sparsely pop-
ulated rural regions. The organisation and assurance of an adequate supply structure, 
especially in rural areas, is often challenging. This is also the case for Pennsylvania, a 
state in the northeast of the USA with an area of about 120,000 km2 and a population of 
12,702,379. This corresponds to an average population of 106 inhabitants per km2. The 
median age is 39.6 years, with an age cohort between 18 and 64 years comprising 62.3% 
of the population. The number of men and women are almost equal. The Geisinger 
Healthcare System (GHS), headquartered in Danville, Pennsylvania, is predominantly 
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active in Pennsylvania and is therefore subject to the issues in design of its care structure 
described above, especially since the system services rural regions. 
3 Geisinger Healthcare System as an Innovator of Need-based Healthcare 
in the USA 
3.1 Historical background, Ideas, and Development of the GHS 
More than 100 years ago, in 1915, Abigail Geisinger founded her own hospital modelled 
on the Mayo Clinic in rural Pennsylvania and set a mission "to make it the best" (Paulus 
et al., 2008, p. 1,236). Today, this single hospital has developed into its own healthcare 
system consisting of around 30,000 employees, distributed into three hospitals and 110 
network-clinics allocated over 45 counties in Pennsylvania (GHS, 2015, p. 17; Paulus, 
2009, p. 123; O´Connell, 2016). The primary care physicians in the 45 mostly rural 
counties ensure the basic outpatient care of GHS patients in spoke facilities1 and func-
tion as gatekeepers for the downstream and inpatient GHS care provider structures. In 
these downstream care settings, specialists treat patients who have been recommended 
to be seen by a specialist within three hospitals, which act as hubs2 (McKinley et al., 
2002, pp. 574-575).  
 The GHS works as a not-for-profit provider of care in Pennsylvania. The reason GHS 
places importance on offering innovative healthcare solutions is an established culture 
of reinvesting a large amount of their profit every year. In 2016, GHS spent 15% of their 
operating expenses on community support. This amount of community service is three 
times greater than the necessary amount to meet the standards of a charitable organisa-
tion in Pennsylvania. Compared to for-profit organisations, which focus on maximizing 
their revenue and potentially neglect the quality of care, the GHS mission is to develop 
a care model based on innovation and value to enhance the quality of care. Because of 
its clinical and financial success, the not-for-profit mission of GHS is a model for other 
healthcare organisations nationwide (GHS, 2017).  
The GHS was initially an integrated healthcare delivery system3 (IDS) and later devel-
oped into a HMO with central and north-eastern Pennsylvania as the main area of activ-
ity4  (Paulus et al., 2008, pp. 1,236-1,237). As an HMO, the GHS offers four main types 
                                              
1 Spokes are to be understood as facilities for the provision of health services, which serve as the first 
point of contact in the treatment of patients (Porter and Olmsted-Teisberg, 2006, p.197; McKinley et al., 
2002, pp. 574-575). 
2 Hubs are large and centralized health care provider facilities (Porter, Olmsted-Teisberg, 2006, p.197; 
McKinley et al., 2002, pp. 574-575). 
3 An IDS is a network of healthcare organisations where physicians network with or without hospitals 
(Evashwick and Meadors, 1994). 
4 A health maintenance organization (HMO) is a provider for health services as well as a medical insur-
ance group that offers health plans (Kovner and Knickman, 2011, p.31). 
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of health plans: one for children, a plan for individuals and families, a plan specific to 
Medicare recipients, and separate plan for Medicaid recipients (Geisinger, 2017). In 
2015, the Geisinger Health Plans (GHP) had 540,172 members, of which approximately 
31% were on the Medicaid plan. A total of over 2,640,000 ambulatory patients were 
seen and over 213,000 patients were treated in the emergency room (GHS 2015). The 
referrals to GHS facilities are not limited to GHS doctors, but can also be made by doc-
tors outside the GHS (Paulus et al., 2008, pp. 1,236-1,237). With a volume of 33% of 
the GHS total turnover, the proportion of treated GHP patients is significantly lower 
than non-GHP patient population (Paulus et al., 2008, p. 1,236). This figure demon-
strates that recommendations for patients from outside providers are important to the 
success of GHS (Paulus et al., 2008, pp. 1,236-1,237). 
The GHS can particularly be characterized by its strong affinity toward and focus on 
improving healthcare delivery. In order to design innovative insurance and reimburse-
ment models, the GHS has always been ready to take risks, believing in the future suc-
cess of the projects. Their conviction in high-value treatment quality is particularly clear 
since Geisinger started to offer a reimbursement of costs a few years ago to patients who 
were not satisfied with their treatment (Burke, 2017; Casale et al., 2007, pp. 613-623).  
Geisinger´s decision to take part in the Medicaid managed care program required –es-
pecially for the rural areas of Pennsylvania – a suitable and cost-effective strategy for 
treatment options for patients living in these regions. This was the starting point of an 
innovative care model, for which e-visits and telemedicine based expert consultations 
were actively researched (Prince and Graf, 2015, p. 16). Geisinger's understanding of 
how healthcare is provided is subject to rapid change in treatment options, remuneration 
models, and communication technologies particularly influenced by demographic 
changes. Geisinger's strength as a participant in healthcare delivery is that it can effec-
tively adapt to these trends and other conditions. To deliver healthcare that patients need 
most, GHS has tested various care models, focusing on innovations in the medical, in-
surance, and technological context. GHS has continually improved these models 
through adaptations and further developments over time. Furthermore, this positive and 
innovative image as a healthcare supplier can play a crucial role as a competitive pa-
rameter (Prince and Graf, 2015, p. 16; Housley, 2011).  
3.2 Understanding the Systematic Implementation of Innovation at 
Geisinger 
To understand GHS´s insight and passion for innovation, it is important to take a closer 
look at its historically justified guiding culture and principles. The development and 
implementation of innovation is a very labour intensive undertaking, according to 
Geisinger. Many other healthcare providers simply add innovative concepts to existing 
processes. For further development and implementation of GHS´s supply and financing 
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structures, it is essential to place this task in the hands of an inter-professional team. 
Such a team at GHS, especially in the case of large innovation projects, consists of GHS 
employees of different professions, for example clinicians, operators, controllers, pay-
ers, and, increasingly, also patients or customers. This team is expected to first assess 
changes in the patient care and disease spectrum, evaluate the required and available 
technologies, and examine existing insurance and reimbursement structures. Even 
though the team members all belong to the same healthcare system, each has their own 
viewpoint, motivation, and goals. In addition, the group is striving at the beginning of 
each innovation process for an answer to a simple yet rarely asked question: Which 
realistically viable care model5 can most reliably deliver the highest value of health care? 
Subsequently, there is a continuous search for new options for insurance, reimburse-
ment, and healthcare models to be added to the GHS. This ability to assess and respond 
adequately to the changes that underlie different inputs is a very important element for 
future success in GHS´s opinion (Prince and Graf, 2015, p. 16; Paulus et al., 2008, p. 
1,237). 
Prior to designing a new care model, a clinical business plan is developed that includes 
the expected outcomes based on the appropriate processes, outcome measurements, and 
management responsibilities for each implementation step. The development teams are 
supported by clinical evidence of existing workflows, analyses of financial reimburse-
ment policies, and legal frameworks. To redesign specific supply and reimbursement 
models, Geisinger pays particular attention to the following four areas:  
- Service providers with the greatest impact on the patient population or resource 
consumption  
- Services with the greatest degree of unauthorized variations  
- Models with evidence-based or consistently derived best-practice and easily acces-
sible outcome measurements  
- Healthcare services with the highest expected diversity in outcome performance  
In addition, GHS managers are particularly focused on initiatives that are expected to 
have a noticeable effect on the healthcare system as soon as possible. Newly designed 
supply processes are linked directly to expected efficiency and quality goals. After com-
pletion of the new approach to clinical care, the reimbursement, incentive structures, 
and non-financial remuneration are negotiated between managers of the service provider 
units and GHP executives (Paulus et al., 2008, p. 1,238). 
                                              
5 In this context, the care model is defined as a step-by-step approach, personalized to provide preventive 
care as well as diagnoses, treatments, management, and involvement of ill patients resulting in increased 
value (Paulus et al., 2008, p. 1,237). 
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For the introductory stage of innovation projects GHS usually tries to address the "sweet 
spot”, the one-third of the patients with a GHP for whom Geisinger is financially re-
sponsible as well as their primary medical service provider. These innovations are not 
kept from the other two-thirds of GHS´s patient group, but this approach makes it easier 
for Geisinger to measure the impact of the innovation on the medical as well as on the 
financial aspects of healthcare. Particularly in the case of new GHP reimbursement mod-
els, GHS service providers are given the opportunity to experiment extensively on 
whether new interventions have the potential to develop commercial market models for 
quality and value-based care. As a marketing aspect for any GHP, only patients with a 
GHP enjoy the privilege of being the first to benefit from such innovations (Paulus et 
al., 2008, p. 1,237; Stock et al., 2014, pp. 1,540-1,548). 
To evaluate the innovative approaches and create measurement data for ongoing process 
improvements, Geisinger relies on scientifically recognized methodologies, which in-
clude continuous quality improvements, six-sigma, or lean restructuring. These meth-
odologies examine the influence of the approaches on the healthcare supply and also 
show potential for further improvement for subsequent innovation efforts. This system-
atic approach to developing, introducing, and evaluating innovations at the same time 
allows GHS to create a culture of self-learning and draw conclusions from its own set-
backs for future projects. To that end, the members of the innovation team build modular 
innovation components which can be utilized to further develop functions, technologies, 
or components of already successfully established healthcare supply models at every 
stage of development. Such reusable innovation model components, for example, con-
sist of the use of human resources, hardware and software tools, technologies, or analy-
sis instruments. In addition, this approach and the use of modular innovation compo-
nents allows the GHS to design future supply models faster, creating an optimized and 
cost-effective process. (Paulus et al., 2008, p. 1,238). Previous experience associated 
with the GHS innovation culture shows that the failure rate of innovation projects has 
declined since the introduction of this procedure, and the share of expectations that have 
been reached or even surpassed has risen. This process of scientifically supervised and 
evaluated innovation is repeated over and over again, and thereby plays a decisive part 
in increasing the production of value in the healthcare system (Paulus et al., 2008, p. 
1,238). 
In 2013, the GHS launched a new business unit called Geisinger Ventures (GV), whose 
task is to improve the introduction and growth of new business areas as an extension of 
existing structures in healthcare. Up to now, GV has been supporting the implementation 
of different retail clinic6 model projects in various organizational forms. These GHS 
                                              
6 Retail clinics or micro clinics are small primary care facilities, staffed by nurse practitioners or un-
manned through use of telemedicine applications (Dunn, 2014). 
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retail clinics exists as a number of walk-in business model facilities, including in-store 
clinics, stand-alone retail clinic sites, and combined models with basic healthcare prac-
tices and emergency services at the same site. For each model, various benefits and 
challenges arose in terms of patient care, marketing, personnel composition, and clinical 
integration. However, this was effectively countered by GV through the ability to access 
various modular innovation components and the efforts to create innovative supply mod-
els which can be continually optimized (Prince and Graf, 2015, p. 16). 
3.3 Milestone Innovation Examples from Geisinger Healthcare System 
The following examples illustrate pioneering innovations of GHS.  
In 1995, the platform for an electronic health record (EHR), which covered the complete 
array of outpatient services, was introduced. Today, all inpatient facilities have fully 
implemented integrated EHRs in place (Paulus et al., 2008, p. 1,237). The approach of 
the Geisinger-EHR is innovative in that physicians who are not part of the GHS, but are 
involved in the treatment process of a GHS patient, receive reading and writing author-
ization via a web portal. Even patients can access their own data via the web portal 
online, albeit to a limited extent. This gives patients direct access to their data and helps 
them to become partners within the care system. Providing patients digital tools within 
the EHR enables them to better manage their own care and improve the value of treat-
ment given (Paulus et al., 2008, pp. 1,244-1,245). Geisinger has also aided in the imple-
mentation of integrated electronic systems and centralization of innovation and quality 
support in many freestanding medical practices and small independent hospitals. This 
approach divides the best practices of GHS into individual care process steps and inte-
grates these steps into decision support and other tools that are designed to help deliver 
performance at the right place and at the right time (Paulus et al., 2008, pp. 1,244-1,245). 
GHS´s innovative and transparent culture of digital data workflows and the integrated 
EHR infrastructure within the healthcare system also enable a strategic analysis of long-
term, comparable supply data. In addition, this digital data and workflow make it possi-
ble to provide most of the services with high value near to the patient, minimizing long 
trips for the patient to treatment hubs (Paulus et al., 2008, p. 1,237).  
In 2007, Geisinger launched the community health initiative called MyCode. MyCode 
is a system-wide genomic biobanking program and a platform for value-based precise 
medicine. It links DNA-samples and EHR data for broad research use, particularly pro-
jects focused on learning more about DNA and patient outcomes. The DNA-samples are 
used to generate molecular data, including a comprehensive genotype and exome se-
quence data. Key elements for MyCode are the stable patient population, EHR infra-
structure, and the integrated health system. MyCode is free for all GHS patients and is 
also open to primary care and emergency patients. More than 90,000 people now partic-
ipate in MyCode, with an additional average enrolment rate of 4,000 people per month 
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and consent rate of about 85%. Compared to traditional clinical research approaches, 
the MyCode model is more flexible, faster and more cost-effective. Because the model 
is nearly unlimited in scale, it can be adapted across multiple platforms to create and use 
an even broader range of data with growing resources. MyCode and genomic medicine 
is seen to have the potential for disruptive innovation. Furthermore, the value of 
healthcare can be increased using this kind of precise medicine. Mycode underscores 
the importance of an EHR, because without the underlying EHR infrastructure this in-
novative model of healthcare is not able to work (Carey et al., 2016, pp. 906-913; 
Avellino et al., 2013, pp. 151-152; Faucett and Davis, 2016, pp. 33-35; Wade et al., 
2014, pp. 112-116). The complete and integrated EHR at Geisinger enabled more than 
MyCode; it also paved the way for one of the latest innovations positively influencing 
healthcare delivery - the use of big data technologies in a clinical context (Cohen, 2017).  
Innovative, analytical big data technologies are already used successfully in many 
branches of industry worldwide. However, the breakthrough of this technology-based 
analysis methodology, which processes and systematically uses large, unstructured, and 
digitally collected data packages, is still largely absent in healthcare, despite the large 
amount of digital health data which are collected every day (Dedic and Stanier, 2017). 
The main obstacles to this breakthrough are data protection concerns, legal restrictions, 
as well as a lack of technical possibilities or internally available knowledge (Erskine et. 
al., 2016; Cohen, 2017). A basic prerequisite for the use of big data analysis at GHS was 
the complete conversion to electronic data collection, storage, and use in the form of an 
integrated EHR in 1996, as described at the beginning of this section. To structure the 
collected data and to make it strategically usable, a multi-stage innovation process 
within the EHR was needed, which required the definition of standards for all process 
steps. The lack of uniform standards and lack of compatibility of individual information 
systems are the biggest obstacles for most hospitals seeking to implement big data tech-
nologies.  
In 2015, GHS introduced an IT system called Unified Data Architecture (UDA). The 
UDA can import the huge amounts of data into the data analysis and management sys-
tems already present at GHS. The synthesis of the data enables Geisinger to not only 
record the outcome parameters of their patients, but also evaluate them in a structured 
manner and derive conclusions or patterns from them. Furthermore, a correlation be-
tween the clinical care data and the genomic sequences of individual patients from My-
Code can be established, as well as the visualization of health data on patient cohorts 
and care provider networks (Erskine et al., 2016; Cohen, 2017).  
The data gathered and stored by GHS, for example from clinical department systems 
such as radiology, patient satisfaction surveys, and data from various health-related 
apps, enable Geisinger to create detailed long-term reports of their patients. However, 
Geisinger's Big Data usage strategy is not limited to the data collected individually in 
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its institutions. Rather, with the patient´s prior consent, Geisinger tries to incorporate 
health-related data from outside sources into the UDA. These include, for example, data 
from grocery shopping and loyalty programs from various traders, as well as smartphone 
and app data. The UDA offers each patient extra storage space and has designed soft-
ware to ensure that the addition and storage of data is very easy. With the UDA, 
Geisinger pursues the goal of closing the gap between data, which are digitally collected 
and stored in many areas of life, but are not systematically and structurally linked to 
each other. This is a common challenge for conventional health data systems. Processing 
large amounts of data and importing them from a variety of sources is no longer a prob-
lem for GHS, making it a unique system (Erskine et al., 2016). At present, Geisinger has 
the largest big data application in health care with the UDA. (Erskine et al., 2016).  
4 Geisinger Health System as a Beacon for Change in US Healthcare 
Geisinger Healthcare System is an innovative microcosm in national healthcare which 
can serve as an example for other systems. Their willingness to continue ongoing devel-
opment of healthcare delivery and insurance structures centred on the 21st century pa-
tient´s needs makes it an exceptionally innovative US healthcare provider system. Parts 
of Geisinger´s approaches for offering health-insurance plans as well as delivering 
healthcare are unique and influence decision-makers of other health plans and organiza-
tions (Paulus, 2009). Its health plans, reimbursement structures, and, especially, its focus 
on innovation and value-based treatments are a beacon for change in US healthcare. As 
described in the previous sections, two central ideas can be derived from Geisinger's 
experience in innovation to solve the initially described problems in US healthcare de-
livery and possibly effect national health policy (Robeznieks, 2015). 
Develop and align incentives and reimbursement structures toward value for the patient 
to improve experience and generate financial success  
Geisinger´s integrated health system is both a service provider system and an insurance 
provider. For its GHP patients, it can offer better incentive structures, as opposed to 
other traditional health care provider organisations. Because of its innovative care mod-
els and its financial success, it is easier for GHS to use monetary and non-monetary 
incentives to attract physicians. The ability to cross-subsidize unprofitable services is 
another advantage of the GHS. Even offering patients the right to reclaim payments for 
treatment if they are unsatisfied is an attractive marketing strategy (Paulus and Steele, 
2008, pp. 1,243-1,244; Casale et al., 2007, pp. 613-620). Beside the innovative incentive 
and reimbursement structures, the digital-based business models are also important as-
pects of GHS´s pioneering role in healthcare delivery.  
Digital-based business models and infrastructure are essential to create sustainable 
changes in healthcare provision:  
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The central element of nearly all GHS technological innovations is based on the inte-
grated use of EHR and the associated digital data workflow infrastructure. This helps to 
automate care processes, overcome geographical barriers, involve patients more closely 
in the treatment process, and increase overall safety and healthcare value. Many of the 
current political discussions in the US suggest that EHRs can fundamentally change 
health care provision. According to the evidence gathered at Geisinger, there are indi-
cations that no fundamental change can be expected from the introduction of an her 
alone, but this can be the starting point of a long-term digital change, and thus funda-
mentally change way in which health services are provided. Nevertheless, there are some 
barriers, such as prohibitive implementation costs and low acceptance of EHR technol-
ogy in some areas, as well as the need for stable patient populations. The local applica-
bility and use of EHR technology can be difficult if these requirements are not met.  
These lessons from GHS have the ability to guide other health organizations and insur-
ance providers towards healthcare which is value-based and beneficial to patients as well 
as future innovation. Putting these ideas into action through US policy could dramati-
cally change not only Medicare and Medicaid programs, but transform the entire health 
delivery system.  
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The UMHS Samuel and Jean Frankel Cardiovascular Center 
Laura Veigl 
The paper Illustrates potential benefits the University of Michigan Health System 
would gain with the implementation of a specialty hospital for cardiovascular care 
in an existing healthcare complex in Michigan. Through an introduction of some of 
the many business strategies of healthcare delivery in the American healthcare sys-
tem, an overview of delivery within a specialized hospital is provided. Benefits of 
these various strategies are examined in the specific context of the University of 
Michigan Health System and the Samuel and Frankel Jean Cardiovascular Center. 
The Integrated Care Model of the Michigan Health Complex creates numerous ben-
efits, including economy of scale and avoidance of double examination. Through 
the new construction of the Cardiovascular Center, the patient flow through the sys-
tem could be improved. With a concentration on a business strategy of specialized 
care, they can enhance excellence in patient values and product differentiation 
through the focus on cardiovascular diseases.  
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1 Demand for new strategies at the hospital market in the United States 
Porter and Teisberg (2006, p. 20) define the U.S. healthcare system as a “dangerous 
path, with a toxic combination of high costs, uneven quality, frequent errors and 
unlimited access to care”. Evidently, the system faces a few challenges such as rising 
health care expenditures1 (OECD, 2017b), an aging population2 (OECD, 2017a) and 
increasing availability of technologies. The demographic change and the new 
technologies cause an increasing demand for healthcare services, and an increasing 
availability of tests and procedures (Denton, 2013, p. 183). As a result, providers need 
to improve the efficiency of the healthcare delivery systems, which would result in 
decreasing costs while improving access to care (Denton, 2013, p. 75). The challenges, 
economic trends and demographic changes in this system (Denton, 2013, p. 182) require 
health care provider to plan and coordinate health care resources (Denton, 2013, p. 75). 
The problems in healthcare delivery are primarily due to structural and managerial 
weaknesses (Porter and Teisberg, 2006, p. 149). Healthcare delivery is becoming 
increasingly challenging and complex for providers, who must incorporate stringent 
regulatory requirements, integrate new medical technologies and constantly improve 
services. This is further complicated by the lack of a proper strategy, direction or focus. 
Success or failure of the health system is in part attributed to the way patients receive 
care as well as how medicine is practiced. As a result, every organization has to develop 
a strategy in which kind of business it will operate, which services they want the offer 
and how they want to differentiate themselves from their competitors (Porter and 
Teisberg, 2006, pp. 149–151).  
The paper will aim to answer the question of which structure of  facility and which 
strategy of healthcare delivery an implementation of a specialty hospital in an integrated 
care system would provide additional benefits. This will be answered by highlighting a 
strategy of healthcare delivery on the business case and the delivery of high-end care at 
the Frankel Cardiovascular Center (CVC) in Michigan.  
2 The concept of integrated care delivery 
2.1 Building a business strategy in health-care delivery 
The hospital market is one of the largest industries in the U.S. and operates in a unique 
institutional setting (Gaynor and Town, 2012, p. 524). Hospitals or health delivery 
providers need a clear strategy to compete and establish themselves in the hospital 
market (Porter and Teisberg, 2006, 151). One guiding point is to focus on increasing the 
value for the patients. The value3, in this case, can only be understood at the level of 
                                              
1 e.g. 12,5 % of share of domestic product in 2000 to 16,9% in 2015 
2 e.g. 12,4% of population are 65 or older in 2000 to 14,9% in 2015 
3 Defined as „the health outcomes achieved per dollar of cost compared to peers” (Porter and Teisberg, 
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medical conditions,4 including how well the medical condition is treated through all 
activities and specialists (Porter and Teisberg, 2006, p. 158). Therefore, the first step in 
building a strategy is to define the goal they want to achieve, for example “excellence 
in patient value”. The patient value should include management of the strategic and 
operational choices, resulting in informed decisions for delivery of services. When 
providers can achieve good outcomes for patients, they can compete with hospitals that 
offer similar services. The choice which medical conditions for which they want to offer 
treatment should be guided by the questions of whether they can gain excellence in value 
and if they have the frameworks to provide appropriate services (Porter and Teisberg, 
2006, p. 159ff.). With excellence and, hence, an improved reputation, more patients will 
come to the hospital, resulting in greater efficiency and higher margins. (Porter and 
Teisberg, 2006, p. 156) As a result, specialized providers will also have the facility and 
the space to act more profitable. When providing specialized care like cardiac care, they 
can gain high standards on value, have the ability to compete on results, can have 
generous reimbursement rate and also receive the benefit of focus (Porter and Teisberg, 
2006, p. 162). 
Furthermore, the competing hospital providers have to consider geographic and product 
differentiations (Lindrooth, 2008, p. 1). The hospital must know in which geographic 
area they serve and compete with patient care. The concentration on the geographical 
side should be on the national or even regional markets, due to its growth potential as 
well as possibility to form partnerships (Porter and Teisberg, 2006, 158 - 159). An im-
portant decision point for patients is the distance to the hospital, adding weight to the 
importance of the geographical aspect of service provision (Lindrooth, 2008, p. 21). 
Another aspect is product differentiation in the healthcare market. The hospitals should 
concentrate on either clinical or non-clinical patient preferences. (Gaynor and Vogt, 
2000, pp. 3–4). Healthcare providers have the potential to distinguish themselves 
through the quality of the services offered on the clinical or non-clinical level. An ex-
ample for non-clinical preferences is offering patients private rooms with features of a 
four-star hotel. The hospital can also gain advantages compared to their competitors by 
offering specialized treatments that patients cannot get at their local hospital. Patients 
are often willing to travel a longer way to receive the specialized treatments. It can be 
concluded that both product differentiation and geographical focus are thus two under-
lying factors when developing an effective strategy (Lindrooth, 2008, pp. 21–22). 
                                              
2006, p. 154) 
4 Includes “diseases, illnesses, injuries, and natural circumstance such as pregnancy” (Porter and Teis-
berg, 2006, p. 105) 
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2.2 The Approach of Integrated Care 
A frequent challenge in the healthcare sector is to directly provide healthcare services 
more efficiently. As a result, new forms of institutional and contractual arrangements in 
the health care sector, like managed care, can arise. In this context, vertical integration, 
which takes various forms, can be a possibility for providers and insurers to be more 
efficient. (Douven et al., 2014, p. 345 f.). According to expert opinions, 20 percent of 
healthcare expenses can be saved with managed care programs. These programs affect 
patient orientation, efficiency, and quality of health care by using suitable organization 
forms and management principles. Providers utilize different combinations of organiza-
tional models and management instruments. One accepted type of managed care is the 
approach of integrated care (Amelung, 2014, Preface). 
There are many different definitions of integration and integrated care (World Health 
Organization, 2016, p. 3). One definition is from Kodner and Speeuwenberg (2002, p. 
2) and indicates the integration of various methods and models have “the goal to enhance 
the quality of care and quality of life, consumer satisfaction and system efficiency for 
patients with complex, long-term problems cutting across multiple services, providers, 
and settings. The result of such multipronged efforts to promote integration for the 
benefit of these special patient groups is called ‘integrated care’.” This definition points 
out the complex and inter-sectoral character of integrated care. (World Health Organi-
zation, 2016, p. 4) On principle, it is the combination of organizations and professionals 
with the goal to improve outcomes (Curry and Ham, 2010, p. 3). 
There is, therefore, a distinction between different types of integration. In this context, 
the distinction is made between functional, organizational, service and clinical integra-
tion. Functional integration is designated to integrate non-clinical support and back-of-
fice functions, such as electronically organizing patient records. When different 
organizations formally join, by mergers or virtually with coordinated provider networks, 
it is called an organizational integration. The integration of different clinical services at 
the same organizational level as multidisciplinary professionals or teams is known as 
service integration. Clinical integration includes integrated care for patients in a single 
or coherent process within and across professions, for example, through the shared use 
of guidelines and protocols (Contandriopoulos and Denis, 2005 cited in Fulop et al., 
2005, p. 4).  
There is also a difference between horizontal and vertical integration. Horizontal 
integration describes the process of two or more organizations or service deliverer of 
care coming together at a similar level, for example, two or more acute hospitals. Verti-
cal Integration, on the other hand, is the merger between two or more organizations or 
service delivering care at different levels, such as when an acute hospital and community 
health services come together (Curry and Ham, 2010, p. 4). 
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The goal of the integrated delivery system (IDS) is to have integrated care across all 
systems through the coordination of all health services by either providing the health 
services by itself or through purchase. The system has both the medical and financial 
responsibility for all services, and consequently, assumes an insurer function by 
transacting with large employers or by compensating with capitation (Amelung, 2014, 
p. 69). 
 
Figure 1: Characteristic of Integrated Care 
 
Source: Own presentation according to Amelung, 2014, p.70 
The IDS has some important characteristics, shown in Figure 7.1, which lead to inte-
grated care for the population. The first step is functional integration, which leads to a 
coordination of the management levels, and thus, of all non-medical services, like per-
sonnel department and financing. The next step is to implement an integrated 
information system, which is strategically relevant and a core function of an IDS. It 
allows access to all patient information and financial aspects concerning the whole sys-
tem. (Amelung, 2014, p. 70) Providing a continuum of services across the system is also 
part of an IDS, which means that the care has to consists of three service components. 
These components include hospital services, clinical services as well as the possibility 
of an outpatient operation center or day clinic (Sanofi Aventis 2006 cited in Amelung, 
2014, p.70). The IDS has the advantage of the concrete planning of necessary services 
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and hence the precise, internal management of service requirements (Amelung, 2014, p. 
71). Planning the internal care processes leads to a reduction of overcapacity, shifts the 
supply stage to a more economically optimal point and tends to restructure important, 
expensive treatments to be more affordable (Witgert and Hess, 2012 citied in Amelung, 
2014, p. 71). Further advantages of integrated care result from an increased economy of 
scale, because of the avoidance of double examination. Improved communication 
amongst health care professionals leads to optimized and more efficient health care ser-
vices, and provides uniform standards like infrastructure (Amelung, 2014, p. 72). 
2.3 Options for optimizing processes through an integrated system   
The complexity and specialty of healthcare delivery require patients to go to different 
types of physicians in various settings. Furthermore, improving and advancing innova-
tions tend to result in a larger quantity of tests and procedures. This contributes to the 
challenge of provide more quality care at lower costs to the patients (Denton, 2013, p. 
183). One solution to improve patient satisfaction and achieve better outcomes more 
efficiently is to speed up the patient flow through the health systems (Arthur, 2011, p. 
4) for just in time treatment and maximum utilization of available tests (Hall, 2013, p. 
3). It is important to know how disruptions or delays in the patient flow develop, and 
what problems arise because of them. The patient's process through the healthcare sys-
tem starts when a patient becomes ill and goes to see a physician; this process ends when 
the patient becomes healthy or gets discharged from the hospital. However, there are 
lots of steps between the starting point and the discharge. It is possible that there are 
problems in the patient flow, which result in delays of treatments, medical errors and 
poor outcomes (Arthur, 2011, p. 19). There are a few possibilities that cause delays in 
the delivery of healthcare. A lack of physical capacity, missing important informations 
like lab tests, bad planning for use of equipment (Denton, 2013, pp. 183–184) or space, 
as well as inadequate use of technologies (Hall, 2013, p. 72), are all possible reasons. 
There are a lot of approaches and strategies to improve the patient flow through the 
healthcare system. On the one hand, there are simple opportunities for eliminating waste 
and time like lowering the given time in the stages of the delivery process, cutting stages 
and unnecessary treatments, combining stages or reducing the time between the different 
stages (Denton, 2013, p. 184). On the other hand, a possibility to enhance the patient 
flow and the capacity is through the design of the healthcare delivery system. For that 
to occur, there is a need for essential design strategies that will promote contemporary 
capacity and flow management (Hall, 2013, p. 71). A strategy to improve the patient 
flow is depicted by Lean Management, which focuses on slim processes (Töpfer, 2009, 
p. 3). Concentrating on the value of the products or services (Gorecki and Pautsch, 2014, 
p. 1), this strategy reduces  bottlenecks without adding resources. During the average 
hospital stay, 95% of the patients need to wait between several stages (Arthur, 2011, p. 
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21). With this in mind, one opportunity to reduce the time between the stages is with the 
design of the cell. A cell is an arrangement of workstations, machines, and equipment 
to improve the patient and product flow through the system with reducing costly 
transport, minimize delays, saving floor space and decreasing inventory. An example 
for cells is exam rooms in the Emergency Department, which are provided with all nec-
essary resources and equipment, and process patients with a selection of similar prod-
ucts. In order to minimize lab and waiting times, they sometimes are offer CT-Scanner 
or MRI-machines as well (Arthur, 2011, pp. 40–41). 
3 The case of the Frankel Cardiovascular Center at the University of 
Michigan Health System 
3.1 Cardiovascular diseases 
Diseases of the heart and blood vessels, coronary or ischemic heart disease and hyper-
tension etc. are included in the group of cardiovascular disease (CVD). Many of these 
problems and illnesses occur because of atherosclerosis (Tulchinsky and Varavikova, 
2014, p. 257), which means that plaque builds up inside in the wall of the arteries. In the 
worst case, the plaque can result in a blood clot, which stops the blood flow and can lead 
to a heart attack or a stroke (The American Heart Association, 2014). All types of heart 
and cardiovascular diseases are treated in the CVC at Michigan.  
In every country, heart disease is one of the leading causes of death. About 30 percent 
of global mortality is induced by heart diseases (Tulchinsky and Varavikova, 2014, p. 
258). In the United States, heart disease is the number one cause of death for men and 
women (The American Heart Association, 2017b, p. 5). The number of heart-related 
deaths every year includes about 800,937 Americans. Statistically speaking, that means 
one in every three deaths is caused by heart disease (Mozaffarian et al., 2016, p. 185) 
The overall mortality rate of 2013 was 222,9 per 100 000 Americans (Mozaffarian et 
al., 2016, p. 41). 
CVD is not only the most common disease in the U.S. population, but is also the most 
costly (The American Heart Association, 2017b, p. 5). Studies from the American Heart 
Association (AHA) show the continuing rise of the costs and economic pressure due to 
CVD (The American Heart Association, 2017a). 
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Figure 2: Costs of CVD 
 
Source: Own presentation according to The American Heart Association, 2017, pp.5-6 
The AHA released a study in February 2017 in order to forecast the future costs and 
prevalence of CVD. The study showed that CVD costs will continue to rise and will 
result in economic, as well as health-related problems for the United States finances and 
healthcare system. (The American Heart Association, 2017a). The costs are expected to 
climb from current 555 billion dollars with 102.7 million Americans affected, to 1.1 
trillion dollars and 131.2 million Americans with CVD in 2035. Furthermore, the study 
demonstrates that the population from the age of 45 has a 50% risk of  suffering from 
CVD. Past the age of 85, the chance of being affected by at least one sort of CVC in-
crease to 90% (The American Heart Association, 2017b, pp. 5–6).  
3.2 The Frankel Cardiovascular Center at the University of Michigan 
Health System 
The University of Michigan Health System (UMHS) is a not-for-profit institution (The 
University of Michigan Health System, n.d.c), which means that they do not have share-
holders who are entitled to their earned profits (Phelps, 2013, p. 214). The system’s 
philosophy is to offer excellence in research, medical education and patient care (The 
University of Michigan Health System, 2015, p.1). Their vision is to form the future of 
healthcare with research and development, become a national leader in health care, and 
receive health care reform, biomedical innovation, and education. The system consists 
of three hospitals, the University of Michigan hospital, the C.S. Mott Children’s 
Hospital and the Van Voigtlander Women’s Hospital (The University of Michigan 
Health System, n.d.e). Additionally, the health system owns more than 40 health centers 
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and clinics throughout the state of Michigan along with the University of Michigan 
Medical and Nursing School (The University of Michigan Health System, 2015). A few 
specialized health centers and programs are included in this system like the Kellogg Eye 
Center and the Frankel Cardiovascular Center (The University of Michigan Health 
System, n.d.a). Besides offering medical services, the UMHS is also involved in re-
search and community health. To further community health, the UMHS supports pro-
grams and services for a healthy community like “Ann Arbor on Wheels” and the “Bu-
reau for seniors,” services that patients and families can benefit from (The University of 
Michigan Health System, n.d.d) 
 
The Cardiovascular Center of Michigan is a specialty hospital that can offer high-quality 
care at their facility along with the traditional University hospital (Schneller and Smelt-
zer, 2006, p. 159). There is a continuous growth in single specialty hospitals (Al-Amin 
et al., 2010, p. 294), which focus on specific treatments and procedures for patients (The 
United States General Accounting Office, 2003, p. 1). One pending question is how 
these specialty hospitals influence the costs or the quality of care (Barro et al., 2006, p. 
703). They may have advantages like economies of scale, improved quality, decreasing 
costs from the aggregated volume and focus on patients with the same medical services 
(United States General Accounting Office, 2003, p. 1) and be more efficient than general 
hospitals (Kumar, 2010, p. 94). In terms of all specialized hospitals, the cardiac care 
section produces the greatest aggregated revenues (United States General Accounting 
Office, 2003, p. 10).  
The cardiology and heart surgery at Michigan Medicine is nationally ranked 22nd by the 
U.S. News and World Reports amongst all cardiovascular-related hospitals (The U.S. 
News and World Report, 2016). Construction of the CVC was completed on June 11, 
2007, and includes a 350,000 square foot multidisciplinary facility. The facility provides 
space for outpatient visits and tests, an inpatient unit, connecting walkways to university 
hospitals, outpatient clinics and specialized care for children. These elements show that 
the CVC is a central location for coordinated cardiovascular care. The building includes 
beds for surgical post procedures, vascular general/moderate care and rooms for cardiac 
procedures, cardiac and vascular surgery operations and endovascular procedure labs 
(The Samuel and Jean Frankel Cardiovascular Center, n.d.a). For the procedures and 
treatments, they work with the most advanced digital technology, such the 64- slice CT 
scanners, compounding CT, MRI systems and a PET -scanner (The Samuel and Jean 
Frankel Cardiovascular Center, n.d.h). There is a health information system installed in 
the whole building, including computers in the private and consultation rooms, as well 
as in the workstations at the moderate and intensive care unit. These computers provide 
access to all patients’ information. This includes, for example, test and lab results, 
medications and information from the portable monitors, which measure the heart rate 
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and rhythm vital signs, oxygen level. For the patients and visitors, the CVC has private 
rooms (The Samuel and Jean Frankel Cardiovascular Center, n.d.i), an Atrium with 
tropical garden and flowers, an indoor and outdoor garden, quiet  meditation rooms, a 
patient skill lab, a healthy heart café and a Mardigian Wellness Resource Center, where 
health-related questions can be answered (The Samuel and Jean Frankel Cardiovascular 
Center, n.d.c). Patients also have access to a Patient and Family-centered Programm 
(The Samuel and Jean Frankel Cardiovascular Center, n.d.e). The CVC provides a 
multidisciplinary medical team for heart and vascular care. There are specialist from 
different disciplines, such as cardiologists, cardiac and vascular surgeons, as well as 
stroke neurologists helping patients with cardiovascular diseases (The Samuel and Jean 
Frankel Cardiovascular Center, n.d.d).  
4 Additional benefits of the Frankel Cardiovascular Center  
4.1 Benefits through the business strategy 
In this section, the CVC at Michigan will be analyzed in connection to the business 
strategies for health care provider mentioned in Section 2.1 and the Epidemiology of 
CVD in section 3.1 of this paper. The CVC belongs to the UMHS; it is a specialty 
hospital for CVD. Thus they have the possibilities to concentrate in a separate facility 
with more space for CVD to gain excellence in patient value and compete on results 
with the benefit of focus. They can thereby offer unique or rare treatments, which result 
in a better reputation and patients who will travel a longer way to receive that special 
treatment. The new building of the Cardiovascular Center offers a few non-clinical com-
ponents, like the indoor and outdoor garden. The goal is to create a comfortable 
atmosphere for the patients and their families, resulting in increased patient satisfaction. 
Focusing on cardiovascular care has advantages, and since the prevalence of CVD is 
high, and they have the opportunity to incrase the number of patients in their facility. 
Besides that, cardiovascular care treats conditions with generous reimbursements from 
the insurance companies. However studies from AHA show the costs of cardiovascular 
diseases will continue to rise. Therefore, the UMHS aims to work more cost-effectively 
and save money, even within the specialization. 
4.2 Benefits through the integrated system 
The implementation of the CVC in one of the largest healthcare complexes in the world 
(The University of Michigan Health System, n.d.e) cause a couple forms of integrations 
and integrated care. Some contents of Section 2.2. will be revisited in this section, 
though will be focusing specifically on the CVC in Michigan. As previously mentioned 
in Figure 7.2, there are a few characteristics which lead to an integrated care system. 
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First, there is a functional integration of the CVC in the Michigan Medicine Health Sys-
tem, which integrates their nonmedical-services and management. An example of the 
functional integration are the electronic patient records, which are available throughout 
the whole system (The University of Michigan Health System, n.d.b). For that, the CVC 
implements computers at the examination rooms and the workstations in order to have 
a connection to all relevant patient’s information. Thereby they accomplish an integrated 
information system. As a result, the CVC and the UMHS provide a continuum of ser-
vices to their patients. There already is an outpatient clinic and diagnostic unit for car-
diovascular care and the inpatient clinic at the CVC. They have the facilities to combine 
clinical and hospital services, along with an outpatient operation center in the Cardio-
vascular Center. With the connection to the C.S. Mott Children hospital and University 
Hospital, they can integrate a few more services (The Samuel and Jean Frankel Cardio-
vascular Center, n.d.g). There is a walkway to the C.S Mott Children’s Hospital, where 
physicians have access to children suffering from heart diseases. Patients can also be 
transported across a sky bridge to the University Hospital (The Samuel and Jean Frankel 
Cardiovascular Center, n.d.h). At the CVC doctors and nurses from five different disci-
plines like cardiac surgery and vascular surgery work together (The Samuel and Jean 
Frankel Cardiovascular Center, n.d.g). Therefore, they have an improved communica-
tions, and as a result, they can offer optimized and more efficient health services and 
avoid double examinations, which lead to increased economy of scale. 
4.3 Benefit through optimizing processes 
Through the built up of new facility, the UMHS gained a couple of additional benefits 
for enhancing the patient flow. This paper will certainly only give a few possible exam-
ples of the strategies previously mentioned in Section 2.3. At the CVC doctors and 
nurses from five different disciplines including cardiac surgery and vascular surgery 
work together so that the patients can get coordinated care from several specialists, often 
all in one day. (The Samuel and Jean Frankel Cardiovascular Center, n.d.g) For instance, 
the patients don’t have to go to different types of physicians of cardiac care in various 
settings (Denton, 2013, p. 183). As a result, it is likely they can reduce the stages or the 
labs between the stages in the delivery process (Denton, 2013), and consequently, 
decrease the waiting times. The facility also provides a 14 room- diagnostic area at the 
Diagnostic and Outpatient- Unit with, for example, a treadmill stress test, echocardio-
gram, ultrasound exams and a station for blood tests (The Samuel and Jean Frankel Car-
diovascular Center, n.d.g). Just as CT-Scanners in the Cardiac Procedure Unit (The Sam-
uel and Jean Frankel Cardiovascular Center, n.d.f) and in the surgery and intensive care 
level (The Samuel and Jean Frankel Cardiovascular Center, n.d.h). The advantages re-
sulting from this are that they have immediate access to important information and there-
fore reducing waiting times and delays for important data and hence decreasing the time 
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between the stages. The workstations at the moderate care unit and the intensive care 
unit arranged between each pair of the room for the patients and implied computers with 
computerized records with all patient information. (The Samuel and Jean Frankel Car-
diovascular Center, n.d.i) Moreover, a cupboard with all necessary items stands next to 
the doors. This cell design has provided the benefit of reducing ways for the staff, saving 
floor and consequently improve the patient and product flow.  
5 Conclusion 
In conclusion, there are a number of additional benefits the UMHS has gained through 
the construction of the Cardiovascular Center beside their University hospital and in 
their healthcare complex. At first, through the concentration on a business strategy of 
specialized care, they can gain benefits like excellence in patient values, product differ-
entiation through the focus on cardiovascular diseases and by offering unique, special 
treatments. Additionally, they can achieve benefits through offering non-clinical com-
ponents through new construction and offering a great atmosphere to the patient. Besides 
the benefit of a focus on cardiovascular diseases with the implementation of the center 
in a healthcare complex, there are a few benefits associated with establishing a form of 
an integrated delivery system. Benefits such as economies of scale and avoiding double 
examination can be a result of integration. Furthermore, some form of management in-
strument and strategies for optimizing processes could be achieved through the new de-
sign and infrastructure of the building. This leads to enhancing the patient flow through 
the Cardiovascular Center and thus through the University Michigan Health System. 
The assumed strategies mentioned in this paper are only a few of many business strate-
gies in the complex American healthcare system. The goal was to provide an overview 
of some basic strategies of providing health care delivering in a health system with a 
specialized hospital. Besides the benefits, there are of course some negative components 
of specialty hospitals, such as cherry-picking patients (Porter and Teisberg, 2006, p. 
162). However, mentioning all drawbacks would go beyond the scope of this research 
paper. The existing negative components of specialty hospitals in today’s literature are 
often associated with for-profit specialty hospital. (Barro et al., 2006, p. 702) The spe-
cialty hospital in Michigan however, is a nonprofit institution belonging to University 
of Michigan Health System. 
The University of Michigan Health Systems has a great opportunity to differentiate 
themselves from competitors in the cardiovascular field and gain some additional bene-
fits. Furthermore, due to the research and development in their facility, they are able to 
further grow and provide the latest procedures and treatments to the patients, (The Sam-
uel and Jean Frankel Cardiovascular Center, n.d.b). With that in mind, it is possible to 
imagine that in a few years the Cardiovascular Center could reach an even better spot 
than the 22nd, as ranked by the U.S. News and World Reports.  
The UMHS Samuel and Jean Frankel Cardiovascular Center 
129 
References 
Al-Amin, M., Zinn, J., Rosko, M. D. and Aaronson, W. (2010), ‘Specialty Hospital Mar-
ket Proliferation: Strategic Implications for General Hospitals’, Health Care Manage-
ment Review, vol. 35, no. 4, pp. 294–300. 
Amelung, V. E. (2014), Healthcare Management: Managed Care Organisations and 
Instruments, Heidelberg, Berlin, Springer Texts in Business and Economics. 
Arthur, J. (2011), Lean Six Sigma for Hospitals: Simple Steps to Fast, Affordable, Flaw-
less Healthcare, New York, McGraw-Hill. 
Barro, J. R., Huckman, R. S. and Kessler, D. P. (2006), ‘The Effects of Cardiac Specialty 
Hospitals on the Cost and Quality of Medical Care’, Journal of Health Economics, 
vol. 25, no. 4, pp. 702–721. 
Curry, N. and Ham, C. (2010), Clinical and Service Integration, London, The King's 
Fund. 
Denton, B. T. (2013), Handbook of Healthcare Operations Management: Methods & 
Applications, New York, Springer Science+Business Media New York. 
Douven, R., Katona, K. and Shestalova, V. (2014), ‘Vertical Integration and Exclusive 
Behavior of Insurers and Hospitals’, Journal of Economics & Management Strategy, 
vol. 23, no. 2, pp. 344–368. 
Fulop, N., Mowlem, A. and Edwards, N. (2005), Building Integrated Care: Lessons 
from the UK and Elsewhere, The NHS Confederation. 
Gaynor, M. and Town, R. (2012), Competition in Health Care Markets, 2nd edn, San 
Diego, Elservier Academic Press. 
Gaynor, M. and Vogt, W. B. (2000), ‘Antitrust and Competition in Health Care Mar-
kets’, Handbook of Health Economics, vol. 1, no. 1, pp. 1405–1487. 
Gorecki, P. and Pautsch, P. (2014), Praxisbuch Lean Management: Der Weg zur opera-
tiven Excellence, 2nd edn, München, Hanser. 
Hall, R. W., ed. (2013), Patient Flow: Reducing Delay in Healthcare Delivery, 2nd edn, 
New York, Springer Science+Business Media New York. 
Kodner, D. L. and Spreeuwenberg, C. (2002), ‘Integrated Care: Meaning, Logic, Appli-
cations, and Implications: A Discussion Paper’, International Journal of Integrated 
Care, vol. 2, pp. 1–6. 
Kumar, S. (2010), ‘Specialty Hospitals Emulating Focus Factories: A Case Study’, In-
ternational Journal of Health Care Quality Assurance, vol. 23, no. 1, pp. 94–109. 
Laura Veigl 
130 
Lindrooth, R. C. (2008), ‘Research on the Hospital Market: Recent Advances and Con-
tinuing Data needs’, Inquiry - J Health Care Organ Provision Finance, vol. 45, pp. 19–
29. 
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Das, S. R., 
Ferranti, S. de, Després, J.-P., Fullerton, H. J., Howard, V. J., Huffman, M. D., Isasi, C. 
R., Jiménez, M. C., Judd, S. E., Kissela, B. M., Lichtman, J. H., Lisabeth, L. D., Liu, S., 
Mackey, R. H., Magid, D. J., McGuire, D. K., Mohler, E. R., Moy, C. S., Muntner, P., 
Mussolino, M. E., Nasir, K., Neumar, R. W., Nichol, G., Palaniappan, L., Pandey, D. 
K., Reeves, M. J., Rodriguez, C. J., Rosamond, W., Sorlie, P. D., Stein, J., Towfighi, A., 
Turan, T. N., Virani, S. S., Woo, D., Yeh, R. W. and Turner, M. B. (2016), ‘Heart Dis-
ease and Stroke Statistics-2016 Update: A Report From the American Heart Associa-
tion’, Circulation, vol. 133, no. 4, pp. 338-360 [Online]. Available at: 
http://circ.ahajournals.org/content/133/4/e38.long (Accessed May 25, 2017). 
OECD (2017), Demographic References [Online], OECD. Available at: http://
stats.oecd.org/Index.aspx?DataSetCode=SHA (Accessed May 25, 2017). 
OECD (2017), Health Expenditures and Financing [Online], OECD. Available 
at: http://stats.oecd.org/Index.aspx?DataSetCode=SHA (Accessed May 25, 2017). 
Phelps, C. E. (2013), Health Economics, 5th edn, New Jersey, Pearson Education. 
Porter, M. E. and Teisberg, E. O. (2006), Redefining Health Care: Creating Value Based 
Competition on Results, Harvard Business School Press. 
Schneller, E. S. and Smeltzer, L. R. (2006), Strategic Management of the Health Care 
Supply Chain, San Francisco, Jossey-Bass. 
The American Heart Association (2014), What is Cardiovascular Disease? [Online], 
The American Heart Association. Available at: http://www.heart.org/HEARTORG/
Support/What-is-Cardiovascular-Disease_UCM_301852_Article.jsp (Accessed May 
18, 2017). 
The American Heart Association (2017), Cardiovascular Disease Costs Will Exceed $1 
Trillion by 2035, Warns the American Heart Association [Online], The American Heart 
Association. Available at: http://newsroom.heart.org/news/cardiovascular-disease-
costs-will-exceed-1-trillion-by-2035-warns-the-american-heart-association (Ac-
cessed May 29, 2017). 
The American Heart Association (2017), Cardiovascular Disease: A Costly Burden for 
America, The American Heart Association [Online]. Available at: http://www.heart.org
/idc/groups/heart-public/@wcm/@adv/documents/downloadable/ucm_491543.pdf 
(Accessed May 25, 2017). 
The Samuel and Jean Frankel Cardiovascular Center (n.d.), About Our building 
[Online], The Samuel and Jean Frankel Cardiovascular Center. Available at: http://
www.umcvc.org/about-our-building (Accessed May 18, 2017). 
The UMHS Samuel and Jean Frankel Cardiovascular Center 
131 
The Samuel and Jean Frankel Cardiovascular Center (n.d.), About the Samuel & Jean 
Frankel Cardiovascular Center [Online], The Samuel and Jean Frankel Cardiovascular 
Center. Available at: http://www.umcvc.org/about-samuel-jean-frankel-cardio 
vascular-center (Accessed May 18, 2017). 
The Samuel and Jean Frankel Cardiovascular Center (n.d.), Frankel Cardiovascular 
Tour [Online], The Samuel and Jean Frankel Cardiovascular Center. Available 
at: http://www.umcvc.org/frankel-cardiovascular-center-tour (Accessed May 18, 2017). 
The Samuel and Jean Frankel Cardiovascular Center (n.d.), Meet Your Heart Care Team 
[Online], The Samuel and Jean Frankel Cardiovascular Center. Available at: http://
www.umcvc.org/meet-your-heart-care-team (Accessed May 18, 2017). 
The Samuel and Jean Frankel Cardiovascular Center (n.d.), Patient and Family Cen-
tered Care Program [Online], The Samuel and Jean Frankel Cardiovascular Center. 
Available at: http://www.umcvc.org/patient-and-family-centered-care-program (Ac-
cessed May 18, 2017). 
The Samuel and Jean Frankel Cardiovascular Center (n.d.), What's on CVC Level 2? 
[Online], The Samuel and Jean Frankel Cardiovascular Center. Available at: https://
www.med.umich.edu/cvc/pdf/grand%20opening%20fact%20sheets/
CVC%20fl%202%20fact%20sheet.pdf (Accessed May 29, 2017). 
The Samuel and Jean Frankel Cardiovascular Center (n.d.), What's on CVC Level 3? 
[Online], The Samuel and Jean Frankel Cardiovascular Center. Available at: https://
www.med.umich.edu/cvc/pdf/grand%20opening%20fact%20sheets/
CVC%20fl%203%20fact%20sheet.pdf (Accessed May 29, 2017). 
The Samuel and Jean Frankel Cardiovascular Center (n.d.), What's on CVC Level 4? 
[Online], The Samuel and Jean Frankel Cardiovascular Center. Available at: https://
www.med.umich.edu/cvc/pdf/grand%20opening%20fact%20sheets/
CVC%20fl%204%20fact%20sheet.pdf (Accessed May 29, 2017). 
The Samuel and Jean Frankel Cardiovascular Center (n.d.), What's on CVC Level 5? 
[Online], The Samuel and Jean Frankel Cardiovascular Center. Available at: https://
www.med.umich.edu/cvc/pdf/grand%20opening%20fact%20sheets/
CVC%20fl%205%20fact%20sheet.pdf (Accessed May 29, 2017). 
The U.S. News and World Report (2016), Cardiology & Heart Surgery Scorecard, The 
U.S. News and World Report [Online]. Available at: http://health.usnews.com/best-hos-
pitals/area/mi/university-of-michigan-hospitals-and-health-centers-6440110/cardiol-
ogy-and-heart-surgery (Accessed May 18, 2017). 
The University of Michigan Health System (n.d.), Departments & Programs [Online], 
The University of Michigan Health System. Available at: http://www.uofmhealth.org/
departments-programs (Accessed May 18, 2017). 
Laura Veigl 
132 
The University of Michigan Health System (n.d.), Great Lakes Health Connect [Online], 
The University of Michigan Health System. Available at: http://www.uofmhealth.org/
provider/great-lakes-health-connect (Accessed May 31, 2017). 
The University of Michigan Health System (n.d.), UMHS Partnerships & Affiliations 
[Online], The University of Michigan Health System. Available at: http://www.uof-
mhealth.org/umhs-partnerships-affiliations (Accessed May 18, 2017). 
The University of Michigan Health System (n.d.), Welcome to Community Health Ser-
vices [Online], The University of Michigan Health System. Available at: http://
www.med.umich.edu/chs/ (Accessed May 18, 2017). 
The University of Michigan Health System (n.d.), Welcome to Michigan Medicine 
[Online], The University of Michigan Health System. Available at: http://www.uof-
mhealth.org/about (Accessed May 18, 2017). 
The University of Michigan Health System (2015), Leading our Future: Annual Report 
2015, The University of Michigan Health System [Online]. Available at: http://
www.med.umich.edu/pdf/UMHS-2015-Annual-Report.pdf (Accessed May 18, 2017). 
Töpfer, A. (2009), Lean Six Sigma: Erfolgreiche Kombination von Lean Management, 
Six Sigma und Design for Six Sigma, Berlin, Springer Science+Business Media New 
York. 
Tulchinsky, T. H., Varavikova, E. and Bickford, J. D. (2014), The New Public Health, 
4th edn, San Diego, Elservier Academic Press. 
United States General Accounting Office (2003), Specialty Hospitals:. Geographic Lo-
cation, Services Provided, and Financial Performance, United States General Account-
ing Office [Online]. Available at: http://www.gao.gov/new.items/d04167.pdf (Ac-
cessed May 28, 2017). 
World Health Organization (2016), Integrated Care Models:. An Overview, World 
Health Organization [Online]. Available at: http://www.euro.who.int/__data/assets/
pdf_file/0005/322475/Integrated-care-models-overview.pdf (Accessed May 29, 2017). 
 
 133 
 
 
 
Part 3: Innovation in the Medical Technology Industry 
 
 
 
 135 
The Impact of Payment Reform on Industry Strategy 
Carolin Rupprecht 
The following essay examines implications of new Centers for Medicare and Med-
icaid Services payment regulations, especially those stemming from the Medicare 
Access and CHIP Reauthorization Act (MACRA), which the medical technology 
industry faces in the health care market. Providers determine the coverage of med-
ical devices within the constraints of Medicare’s payment systems and therefore are 
affected by new payment regulations. MACRA aims to improve the quality of care, 
advance care information distribution, and reduce health care costs, which can only 
be achieved together through enhanced care coordination and collaboration be-
tween different stakeholders. For the medical technology industry, success means 
that the paradigm shift from volume to value needs to be accepted at all levels. 
Medical device creators must better recognize consumer needs and establish sys-
tems to measure, monitor, and improve patient-centered outcomes. Moreover, com-
panies need to understand their contribution to the full cycle of care through ex-
panded collaboration between different stakeholders and participation in risk-shar-
ing. Collaboration is also needed regarding electronic health records to make patient 
documentation simple and standardized. The medical technology industry is not 
directly integrated in Medicare’s payment reforms. As a result, it is their responsi-
bility to demonstrate their value to patients, providers, and payers. In the long run, 
these different stakeholder needs must be integrated in the research and develop-
ment of novel technologies. 
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1 Push Towards Value-Based Payment Systems 
Without a commensurate gain in health outcomes, the United States spends more per 
capita on healthcare technology and care than European nations. Higher technology 
costs, larger volumes of certain procedures (e. g. hip and knee replacements), and a 
greater supply of doctors and hospitals contribute to higher US spending (Sorenson et 
al., 2013, p. 788). As a result, US payment regulations are undergoing considerable re-
form to lower spending. 
In general, there is a push towards value-based payment schemes. The Patient Protection 
and Affordable Care Act of 2010 and the Medicare Access and CHIP Reauthorization 
Act (MACRA) of 2015 have played a leading role in this shift for Medicare. As the 
single largest healthcare payer in the US (MedPAC, 2016 c), p. 3), Medicare influences 
the payment schemes of private insurers. Using Medicare as a role model, these compa-
nies adjust their reimbursement rates and structures accordingly (Clemens, Gottlieb, 
2013, p. 1). 
Through its prospective payment system, Medicare regulates the cost and coverage of 
most medical devices. This means that within the constraints of fixed prospective pay-
ment, the provider determines the coverage. In this way, the coverage and payment de-
cisions made on an individual basis determine revenues. Explicit coverage decisions are 
made locally (Sorenson et al., 2013, pp. 789, 790).  
Consequently, the payment the Medical Technology Industry (MTI) receives is depend-
ent on the providers who care for Medicare beneficiaries. This suggests that the MTI 
may also be affected when payment regulations for provider’s change, but the effect on 
the MTI remains uncertain. 
This essay analyses possible implications of recent Medicare payment regulations, es-
pecially MACRA, for the MTI and focuses on the inpatient sector through implantable 
medical devices, using hip and knee replacements as examples.  
Although the future of MACRA is unclear, currently available literature and journal 
articles from different stakeholder perspectives provide a window into possible change. 
In this essay, an illustration of the shift from volume to value in healthcare will first lay 
the groundwork for understanding the theory of new payment regulations in the US 
healthcare system. Secondly, details surrounding the current situation of medical device 
payment will act as a starting point for the implications of Medicare policy changes. 
Thirdly, an exploration of political developments that influence Medicare payment, with 
a focus on MACRA, will provide an image of the present leading into the future. Lastly, 
the implications of new payment regulations on the MTI will demonstrate where the 
industry is headed in the coming years.  
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2 Definition of Value in Health Care 
When discussing value in health care, the question “What is value in health care?” arises. 
This question will be addressed in the following section. 
As a whole, value in healthcare is both largely misunderstood and unmeasured, as all 
stakeholders tend to have diverging goals (here and the following Porter, 2010, pp. 
2,477-2,478). As a result, the first goal should be unifying healthcare stakeholders under 
one common goal: creating high value for patients. The following   illustrates value in 
healthcare. 
 
Figure 1: Value in Health Care 
 
Source: Author according to Porter, 2010, p. 2477. 
Value can be defined as health outcomes achieved per dollar spent. However, outcomes 
are multidimensional and, therefore, difficult to measure. Outcomes depend on the con-
dition and no single outcome encompasses the total body of delivered care. Conse-
quently, costs in the equation refer not to individual services but to the total costs of the 
full cycle of care. Altogether, to improve outcomes and reduce costs, there must be a 
push towards expanding measuring and reporting metrics combined with a robust 
method of comparison (Porter, 2010, pp. 2,477-2,478). 
3 Current Payment Situation 
Medicare uses a prospective payment system in the outpatient and inpatient hospital 
sectors. The base rate for each prospective payment system is modified to consider ge-
ographic differences in input prices and type of case or service. Payment rates are up-
dated annually (MedPAC, 2016 a), p. 67). As mentioned in Section 1, coverage for and 
purchase of medical devices is made by providers considering the constraints of Medi-
care’s payment system. 
The decision to use a device is usually determined by the desires of the physician and 
the added value for the patient. Costs for medical devices like hip and knee implants 
account for approximately 30% to 80% of a hospital’s reimbursement for the procedure. 
Similarly, physician preferences account for a large amount of hospitals’ variable costs 
as they choose the devices while the hospital faces the financial burden. Along those 
same lines, a physician can reduce the total cost of care by choosing devices from a 
discounted contracted vendor, but they still have the option to prefer more expensive 
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options, thereby forcing hospitals to pay higher prices (Obremskey et al., 2012, pp. 
1,054-1,055). 
Additionally, setting prices for medical devices does not need to follow requirements. 
Depending on negotiations with group purchasing organizations, device costs for high 
volume items can both be discounted and set individually for each hospital. Conse-
quently, to stay competitive, health systems are increasingly using the services of con-
sulting firms to get insight into the prices paid by similar hospitals. However, even this 
avenue is flawed as hospitals only post prices listed rather than those negotiated with 
various payers, thereby creating a lack of price transparency (Robinson, 2008, p. 1,526). 
Through a fixed, less flexible prospective payment system, hospitals face higher costs 
associated with changes in technology and devices (Clyde et al., 2008, p. 1,632). 
As a result, fragmentation and misalignment of information, incentives, and organiza-
tional capabilities between the hospital and physician are the main obstacles for value-
based purchasing of medical devices (Robinson, 2008, p. 1,524). 
4 Payment Reforms 
In this section, an overview of reforms within the past nine years is given first. Then the 
latest developments in value-based payment will be described. The most common inpa-
tient surgery for Medicare beneficiaries is hip and knee replacement (CMS, 2017 b)). 
For this reason, hip and knee replacement play a key role for the Center for Medicare & 
Medicaid Services (CMS) and therefore will be used as example. 
4.1 Overview of Reforms in Medicare 
Figure 8.2 shows the legislation timeline between the years 2008 and 2019 along with 
associated value-based programs. Providers for Medicare recipients receive incentive 
payments through these value-based programs (CMS a), 2017). 
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Figure 2: Timeline for Value-Based Programs 
 
Source: Author according to CMS a), 2017. 
As shown, a variety of programs that introduce value into payment systems are being 
implemented or are intended to be established. However, since it takes several years to 
implement a program after the passage of legislation, considerable time and resources 
are required to ensure that the program is successfully carried out and evaluated. Under 
consideration and review for years before its recent passage, MACRA is the latest sig-
nificant regulation that impacts payment reform. 
4.2 Medicare Access and CHIP Reauthorization Act  
Final regulations for MACRA were released in 2016 by CMS to repeal the sustainable 
growth rate formula and update the physician fee schedule. The act rewards the delivery 
of high-quality care with quality measurements incorporated into provider payments and 
the development of new policies to incentivize provider participation in alternative pay-
ment methods (APMs), including innovative episode payment models for joint care and 
shared savings program. The Quality Payment Program was created (Department of 
Health and Human Services, 2016, pp. 1-4) to reform Medicare Part B payments for 
more than 600,000 clinicians (specifically for physicians, physician assistants, nurse 
practitioners, clinical nurse specialists, and certified registered nurse anesthetics) (CMS, 
2016). 
The Quality Payment Program consists of the Merit-based Incentive Payment System 
(MIPS) which combines three existing Medicare incentive programs: Physician Quality 
Reporting, Electronic Health Record Meaningful Use, and the Value-Based Payment 
Modifier (Quality Payment Program Service Center, 2017 a)). It also includes Advanced 
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APMs. These programs can apply to a specific clinical condition, an individual care 
episode, or a population (Quality Payment Program Service Center, 2017 b)). 
In aggregate, the budget will stay neutral, but the bonuses and penalties of individual 
physicians will have a significant impact on payments at the individual level. Hence, 
there will be effects on the attractiveness of the APM and MIPS path (MedPAC, 2016 
b), p. 30). If clinicians do not participate in the Quality Payment Program in the Transi-
tion year 2017, it will result in a negative 4% payment adjustment. Eligible clinicians 
are free on what and how they report. They can choose between submitting a minimum 
amount of data, reporting for 90-day period or full participation to avoid the negative 
payment adjustment (CMS, 2016). 
Merit-based Incentive Payment System 
The Merit-based Incentive Payment System (MIPS) determines whether physicians re-
ceive a bonus or penalty on their fee-for-fee-service payments through the quality of 
their performance (MedPAC, 2016 b), 29-30). To begin, physician performance in 2017 
will adjust the payments for 2019, with the anticipated amount of data submitted for the 
transition year of 2017 resulting in neutral to modest positive changes with regards to 
performance (CMS, 2016). The law determines the measurement of performance on four 
components, outlined in Figure 8.3. 
 
Figure 3: Performance Categories in 2017 for payment in 2019 
Source: Author according to Quality Payment Program Service Center a) (2017); CMS (2016). 
The four categories are weighed differently and different measures can be chosen by 
providers. Each of the categories is weighed differently, with quality making up 60%, 
improvement activities 15%, advancing care information 25%, and cost initially making 
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up 0% but increasing over time. Quality of performance is measured with six measures 
of the provider’s choice out of a possible 300 and compared against benchmarks. For 
improvement activities, clinicians can choose from over 90 activities categorized in nine 
different areas, including care coordination and participation in an Advanced APM. Ad-
vancing care information provides more flexibility with two different sets of measure-
ments for reporting based on Electronic Health Record Meaningful Use. Costs are not 
weighed in 2017 (CMS, 2016). 
Existing measurements do not capture many important aspects of quality. Furthermore, 
differences in patient severity influence and conflict measurements as well. Using sim-
ilar measures in the 2016 Value-based Payment Modifier, 96% of physician practices 
were scored “average costs.” Since these measurements are used by smaller practices 
that often do not capture their discretionary service through well-developed episode def-
initions, average scores do little to promote change. This high percentage suggests that 
there is a risk of the same phenomena for MIPS measures, which could limit the useful-
ness of measurements to drive change toward a value-based care system (Clough, 
McClellan, 2016, p. 2,397). 
Advanced Alternative Payment Models 
Advanced APMs are APMs that hold the chance to earn a 5% incentive payment in 2019 
for participation in 2017. Comprehensive ESRD Care, Comprehensive Primary Care 
Plus, Next Generation ACO Model, Shared Savings Program (Track 2), Shared Savings 
Program (Track 3), Oncology Care Model or Comprehensive Care for Joint Replace-
ment Payment Model (CJR) are the seven Advanced APMs in 2017 (Quality Payment 
Service Center, 2017 b)). The concept these programs are based on is that bearing some 
financial risk for spending might contribute to limit spending growth (MedPAC, 2016 
b), p. 33). In Advanced APM the participants share risk, not only for gains, but also for 
losses. However, CMS set the standard higher than many hoped for (Clough, McClellan, 
p. 2,397). In the following section information on the CJR are given. 
Comprehensive Care for Joint Replacement Model 
The CJR Model is classified as an Advanced APM (Quality Payment Service Center, 
2017 b)). 
The most common inpatient surgeries for Medicare beneficiaries are hip and knee re-
placements (here and for the following CMS, 2017 b)). Advanced APMs support better 
and more efficient patient care by using bundled payments and quality measurement 
systems for each episode of care. This improves the quality and coordination of care 
along the extended, post-acute care continuum. 
In the program, participating hospitals are financially accountable for the quality and 
cost of a CJR care episode, including all related items and services paid under Medicare 
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A and B. The system aims to increase coordination among different stakeholders, in-
cluding physicians and hospitals, while raising patient awareness of quality of care. The 
admission of a patient with certain Diagnosis Related Groups (DRGs) to a participant 
hospital is the beginning of the care episode and ends 90 days post-discharge. Actual 
spending for the episode is compared to target episode prices at the end of the perfor-
mance year. Through DRG analysis and CMS’ use of simple risk stratification method-
ology different target prices are set for patients with a hip fracture. Well-performing 
hospitals may receive additional payment whereas poor performers must repay Medi-
care for a certain share (CMS, 2017 b)). 
5 Implications for the Medical Technology Industry 
Medicare reforms are likely to change the entire health care system. Therefore, physi-
cians and other providers need to understand the opportunities represented by MACRA 
to shape the future of payment and medical practice (Clough, McClellan, 2016, p. 
2,397). The MTI needs to both to understand its significance and also their role in im-
proving the outlook of healthcare. 
5.1 Paradigm Shift: from Volume to Value 
Marketing and sales activities of the MTI involve seeking preferred positions through 
discounts, rebates, and volume incentives. Meanwhile, suppliers behave as if their tech-
nologies are interchangeable and demonstrate little effort in justifying their value to cer-
tain patient groups. Competition happens through offering lower prices or incentives 
offered to physicians for using their technologies instead of demonstrating effective re-
sults (Porter, Teisenberg, 2006, p. 285). As a result, a major challenge is the shift from 
volume to value, which depends on results rather than inputs. Value is not measured by 
volume, but rather the outcomes achieved (Porter, 2010, p. 2,477). 
Fortunately, physician medical education programs are beginning to place importance 
on the concept of value in healthcare. Topics including patient safety, quality improve-
ment, team work, and health policy are becoming the third pillar of medical education 
after the basic and clinical sciences (Prina, 2017, p. 191). This goes along with the need 
for a strategy for health care organizations to thrive in a competitive marketplace (Porter, 
Lee, 2015, p. 1,684). 
For the MTI, this means that all activities must be focused on value, requiring a para-
digm shift from volume to value at all levels of a company. Furthermore, developments 
in the customer environment, like education programs and strategies for organizations, 
must be monitored and tackled with appropriate reactions. For example, creating a pur-
chaser strategy together with a provider to solidify a market, establish a price, and create 
a performance feedback loop would better incorporate a member of the MTI into the 
strategy of a healthcare organization. 
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5.2 Demonstrating Value 
A major challenge in determining the value of care is collecting effective data that ob-
jectively influences coverage and reimbursement decisions. Such data are generally not 
required for market approval (Sorenson et al., 2013, p. 792). More obtainable details on 
process measurement and improvement are poor substitutes for outcome and cost meas-
urements. Similarly, providers tend to measure what is in their direct control and what 
is easily obtainable, e. g. providers measure what is billed (Porter, 2010, pp. 2,477-
2,478). It is crucial to track patient-centered outcome measures and make results trans-
parent to the organization and patients to demonstrate delivery of high-value health care 
(Shaikh, U; Roth, A., 2017, p. 1). With that, new kinds of data and analyses are required 
to better measure value and abundant, novel relationships must be formed with provid-
ers. The MTI must work alongside groups of providers to collect and analyze care cycle 
information, since such data has been shown to be difficult to obtain and interpret alone 
(Porter, Teisenberg, 2006, p. 291). Similarly, the training and skills of health profession-
als, especially surgeons using medical devices, have an enormous impact on the accu-
racy and effective use of these devices (Sorenson et al., 2013, p. 793). Surgeons must 
begin to work in networks and communicate to better coordinate care, guiding investi-
gations of patient-centered outcomes and healthcare delivery systems that give the or-
ganization a competitive advantage (Rudnicki et al., 2015, p. 355).  
For the MTI, the impact of a device on patient-centered outcomes must be measurable 
at both the individual and aggregate level to determine the efficacy of both devices and 
providers. This requires communication with providers and stakeholders, particularly 
surgeons using the devices and technology. 
5.3 Creating a Holistic Perspective of Treating a Condition 
When determining the total cost of an episode of care, costs must be evaluated for the 
cycle of care in its entirety rather than for individual steps or parts of treatment along 
the way. Concentrating too narrowly on the technology rather than on the entire cycle 
of care is a common mistake. In making this change, shared resources must be added to 
the costs for individual patients to align with actual use as opposed to equally distrib-
uting costs among all patients. This process would allow for cost comparisons between 
patients with the same medical condition (Porter, 2010, p. 2,481). When determining the 
value of care, there is a tendency to focus on selective indicators for patient benefit than 
overall measures of long-term value (Porter, Teisenberg, 2006, p. 286). The Medicare 
Payment Advisory Commission reported that measuring quality is challenging when the 
number of cases per provider are low, thereby hampering the ability to properly evaluate 
care. Furthermore, the Commission is concerned that quality measurements of Medicare 
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rely too heavily on clinical process measures than on outcomes of interest, such as mor-
tality and readmissions (MedPAC, 2016 a), pp. 54-55). 
For the MTI, this means that their contribution to the full cycle of care through their 
device and applicable add-on services must be communicated to providers and payers 
to negotiate value-based prices. 
5.4 Increasing Collaboration Between Different Stakeholders 
Value encompasses efficiency as outcomes are relative to costs. A potential limit for 
effective care is the consideration of cost-reduction alone without regards to outcomes 
achieved. Value measurements should encompass all services or activities that jointly 
define success in meeting patient needs. For realized savings to have a systemic impact 
on the continuum of care, they must be shared among all involved stakeholders. Value 
is created through combined efforts over the full cycle of care, with effectiveness de-
pending on not one but several interventions. However, joint responsibility for outcomes 
is not widely accepted by physicians (Porter, 2010, pp. 2,477-2,478). Additionally, other 
factors may influence physician choice, such as personal relationships with sales repre-
sentatives and provision of technical support during the procedure from the device com-
pany. In an attempt to align the diverging interests of physicians and hospitals, gainshar-
ing might be an appropriate approach, meaning that both groups share financial savings 
from the collaboration (Obremskey et al, 2012, p. 1,055). 
For the MTI, collaboration with physicians and hospitals must increase in order for the 
industry to contribute to improving the value of healthcare. One possibility would be to 
prove to physicians the cost-effectiveness of one device compared to others while also 
enabling risk-sharing between physicians and hospitals. The MTI can take a particularly 
active part in this effort by taking some risk and base pricing accordingly, a policy that 
fits with the intention of the CJR model. 
5.5 Ensuring Easy Implementation 
Reporting quality measures can be quite expensive due to the time spent by physicians 
and staff participating in direct reporting efforts. Physicians already spend more than 15 
hours per week on average preparing challenging external quality measures while at-
tempting to understand performance reports from their own from payers and other out-
side stakeholders (Casalino et al., 2016, p. 401). With regards to a health system, an 
efficient hospital purchasing strategy consists of a minimal number of relationships with 
medical device manufacturers while simultaneously covering the full range of device 
needs. Although such a model reduces a system’s number of interactions, it also limits 
physician choices of medical devices (Robinson, 2008, p. 1,527).  
For the MTI, these two issues present opportunities to develop strengths as competitive 
advantages. First, through acquisition and development of innovative technologies, a 
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firm’s product offering can increase while the number of hospital vendors decrease 
through the elimination of competing inferior products. Second, a firm’s research and 
development arm can focus on medical devices that target physicians’ interests, thereby 
becoming a preferred company among doctors who impact purchasing decisions. 
Throughout the process, documentation must be standardized and simple. This is best 
realized with EHR-compatible software that not only manages the devices but complies 
with the Advancing Care Information component of the MIPS program.  
6 Conclusion 
The MTI has an opportunity to contribute tremendously to the aim of MACRA through 
quality improvement, care information advancement, and cost reduction while at the 
same time fostering collaboration between stakeholders. Although the MTI is not di-
rectly integrated into reforms of Medicare’s payment systems, the industry must be 
aware of political developments in order to shape their value in and for the healthcare 
market. The industry must act outside of producing and selling devices by building re-
lationships with providers to understand and integrate their needs in product research 
and development both now and in the long run. All payers use Medicare payment regu-
lation as guidance while adjusting to their specific patient population, forcing the MTI 
to face many different approaches when entering the world of value-based payments. 
Therefore, companies should adapt their offers accordingly to meet needs and secure 
business. As a result, segmentation of customers and targeted approaches might be a 
good tactic. No matter which approach is taken, in the end firms must adapt to meet the 
needs of stakeholders to create value, remain competitive, and contribute to a more ef-
ficient US healthcare system.  
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System Partnerships between Medical Device Companies and 
Health Care Providers 
Elisabeth Ludwig 
The American health care system has some of the worst quality outcomes and high-
est costs internationally. In order to address these issues, the Medicare Access and 
CHIP Reauthorization Act (MACRA) was passed in 2015 by Congress. MACRA 
is a new value- and quality-based payment model which rewards providers for high 
quality care and penalizes providers with low quality outcomes. Under the law, two 
health care payment models, the Merit-based Incentive Payment System and Alter-
native Payment Models, put patients as the focus to promote patient-centered health 
care. Providers have difficulties adapting to these new models, but through system 
partnerships they can be supported. System partnerships are relationships between 
medical device companies and providers which are more than common customer-
vendor relationships. In fact, system partnerships aim to develop complex treatment 
solutions together. This paper reviews whether system partnerships can effectively 
lower costs and improve the quality of health care systems. In addition, the ad-
vantages of the system partnerships, such as digitalization, are compared to the risks 
they pose to patients and providers, such as information asymmetries. At present, 
analysis of these factors shows that the advantages outweigh the risks. Therefore, 
the use of system partnerships as a means to lower costs and improve quality is 
recommended.  
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1 Introduction 
The American health care market is one of the largest in the world and acts as a role 
model for other countries. Every legislative change is observed and discussed because 
its size can illustrate problems and advantages more explicitly than other, smaller mar-
kets can.  
This paper will discuss whether system partnerships between medical device companies 
and providers save costs and improve the quality of care. To accomplish this, MACRA 
is briefly explained (section 2) and its impact on providers is detailed in section 3. Sec-
tion 4 presents how the providers deal with the new regulation and what problems might 
occur. A description follows of possible solutions that could be implemented to support 
the providers with adapting to this legislation, emphasizing system partnerships as a 
possible solution (section 5). Thereafter, the advantages and opportunities a system part-
nership provides, the risks presented by these partnerships under MACRA, as well as 
cost savings and quality improvement will be discussed (section 6). At the end, a con-
clusion will be drawn which considers the presented results of the previous sections. 
2 MACRA 
The American health care system has some of the world’s highest expenses for health 
care, but also some of the worst quality outcomes when compared to different countries 
(Squires, Anderson,2015, w.s.). In order to tackle this imbalance, the government intro-
duced the Medicare Access and CHIP Reauthorization Act (MACRA) in 2015 (Medi-
care Access and CHIP Reauthorization Act, 2015, w.s.). With MACRA in place, CMS 
strives to achieve better, more patient-focused care. The system is intended to be under-
standable and flexible for each participating physician. It rewards high-quality patient 
care through two options: The Merit-based Incentive Payment System (MIPS) or the 
Alternative Payment Model (APM). Both payment systems and their rewards are de-
scribed in the following section.  
2.1 Merit-based Incentive Payment System 
The Merit-based Incentive Payment System (MIPS) will affect almost every physician 
because any physician which earns at least $10,000 from Medicare payments is involved 
in this payment reform (Shinkman, 2016, w.s.). The new system combines and unites 
multiple quality and value programs which were formerly separate into one. 
MIPS mainly lays focus on three aspects: quality, resource use, and use of certified elec-
tronic health record (EHR) technology. Performance will be measured and reported in 
four performance categories. The first, quality, will compose 50% of the measurement 
taken in the first years of MACRA and is therefore the most important part of the meas-
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uring. The second one is resource use, which is the only category that is directly meas-
ured by CMS and will compose 10%. The third one clinical practice improvement ac-
tivities has rather lower importance at the beginning of the reporting period because it 
was not included in former laws and needs to be introduced to the physicians. The last 
one is the meaningful use of EHR certified technology (Yaraghi, 2016, w.s.). 
The four performance categories will be pooled together into a MIPS composite perfor-
mance score (CPS). This CPS will be used to decide whether a physician receives an 
upward, downward, or even no payment adjustment to either reward or penalize the 
provider. Quality, resource use, and meaningful use of certified EHR technology were 
present in former laws and have now been modified, extended, and transformed into 
one. The report for quality performance must include at least six measures, one trans-
sectoral measure, and, if possible, one outcome measure (Medicare Access and CHIP 
Reauthorization Act, 2015, w.s.). In lieu of an outcome measure, there is the option to 
add a high priority measure such as patient safety. The required clinical practice im-
provement activity, the only new regulation, addresses population management and care 
coordination. CMS will annually establish a new performance list with additional de-
tailed information about changes to MIPS and the metrics of the CPS after the collected 
data is submitted. 
2.2  Alternative Payment Model 
The second payment system reform option is the Alternative Payment Model (APM). 
To be part of the program, a physician must meet a higher Medicaid revenue or patient 
threshold than under MIPS. It will only affect 5% of health care systems and is used to 
establish some kind of better and newer accountable care organizations (ACO). Most 
ACOs are APMs, but not all APMs are ACOs because there are a variety of possible 
models for APMs. The requirements for an advanced APM are the following: having a 
quality measure component, using EHR certified technology, and either bearing more 
than a nominal financial risk or being part of a Medical Home Model (an expansion 
under the authority of the Medicare and Medicaid Innovation Center) (Medicare Access 
and CHIP Reauthorization Act, 2015, w.s.). Those who participate in the most advanced 
APMs will be upgraded to Qualifying APM Participants (QP). QPs are physicians and 
practitioners who have a certain percentage of their patients or payments through an 
eligible APM. Those who qualify to be a QP gain a 5% bonus payment from 2019 – 
2024 and after 2026 receive higher fee schedule updates than under MIPS as detailed in 
figure 9.1 (Hussey, Liu, White, 2017, pp. 697-705). 
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Figure 1: MACRA fee schedule timeline comparing Fee Schedule Updates, MIPS, and APMs 
 
Source: own illustration 
MIPS will include all eligible clinicians except those who participate in an APM. 
Whereas APMs are designed for larger practices, MIPS is designed for smaller and solo 
practices. APMs have a greater risk, however, and this is rewarded with higher bonuses 
than in MIPS.   
Both models are applicable to payment for Medicare and Medicaid patients. Those two 
forms of public insurance originate from the federal government and cover about 34% 
of the American population (Kaiser Family Foundation, 2015, w.s.). These models often 
align with CMS regulations closely as they consider them important guidelines for 
health care payment system success. 
3 Providers´ challenges with MACRA 
MACRA mainly affects providers, meaning they must now adjust to the new payment 
models, which often implies a difficult process. 
According to MACRA, there are four main domains to which the providers must adjust. 
The first domain is quality, where providers have to measure the quality of their perfor-
mance in six different ways. Within this process, providers can choose their own means 
of measurement (Pullen, 2017, pp. 591-592). This is a difficulty because it might invite 
providers to exploit the system (Yaraghi, 2016, w.s.). Consequently, providers can easily 
manipulate the measurements and present themselves as better than they actually are. In 
general, quality measurement is complicated because the patient as well as the physician 
should ideally describe results of care episodes. Quality is often a personal perception 
and therefore it is challenging to design a conclusive survey which depicts the situation 
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in an objective way. In addition, health care providers do not have the ability to access 
all data being submitted to CMS (Deloitte Report, 2017, p. 5).  
The second domain is resource use, with its performance being calculated by using ad-
ministrative data. Therefore, physicians and providers do not have to submit any addi-
tional data (Medicare Access and CHIP Reauthorization Act, 2015, w.s.). However, ob-
taining this data is very complex because it cannot be extracted from one source 
(Deloitte Report, 2017, p. 6). Usually, CMS also does not communicate the results to 
providers more than once a year, which can lead to invalid responses to the system, 
which means that changes cannot be made without the data. However, this issue has 
already been detected and addressed by simplifying the reporting requirements for the 
first year of MACRA.  
The third domain involves clinical practice improvement activities. These are difficult 
to identify because there is no data infrastructure yet to measure performance in this 
domain (Deloitte Report, 2017, p. 11).  
The meaningful use of EHR certified technology is the last domain. EHR certified tech-
nology is expensive, hence it is easier for larger providers to equip themselves with than 
it is for solo practitioners. More than 600 EHR manufacturers sell the technology to 
providers across the US health system (Deloitte Report, 2017, p. 5). Even though 60% 
of the provider market is supplied through 5 EHR companies, the large variety of sys-
tems and vendors make it complicated to synthesize and compare data by setting or 
provider. Consequently, there are many different and incompatible EHR systems in the 
American health care market.  
Many physicians reported that the MACRA performance documentation may distract 
them from actual patient care due to the excessive bureaucratic burden (Shinkman, 2016, 
w.s. and Shyrock, 2016, p. 2). CMS reacted to these objections by loosening the re-
strictions. Currently, providers can select between three options in order to avoid a neg-
ative payment adjustment. All these options introduce the participant to the new value-
based payment system to encourage conformity with the requirements of the system 
over time (Medicare Access and CHIP Reauthorization Act, 2015, w.s.). 
It is expected that MACRA will drive physicians to join larger organizations and net-
works to be part of APMs and their payment advantages, thus increasing participation 
in value based-payment agreements (Survey of US Health Care Executives, 2016, p. 7). 
However, the law might disrupt the relationships between health care systems, physi-
cians, and life science companies like medical device companies and pharmaceuticals, 
creating barriers. Nevertheless, these parties need to work together to overcome obsta-
cles in providing quality care. Therefore, alliances between health care systems and life 
science companies will be significant in order to evaluate which products work best on 
which type of patient to achieve better treatment outcomes and improve cost efficiency 
(Lohmann, Rippmann, 2014, pp. 127-131).  
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4 System partnerships 
Providers need to optimize and digitalize medical processes in order to secure quality 
and efficiency in the health care sector, an endeavor that is complicated and expensive. 
Often providers cannot afford these expensive innovations, so they simply try to save 
costs by dismissing staff. This in turn leads to poor quality care and eventually leads to 
negative payment adjustments (Lohmann/Rippmann, 2014, p. 122). Add something here 
about how system partnerships can avoid that scenario and how you will discuss the 
positive and negative aspects of these partnerships in this section. 
4.1 Positive aspects of a system partnership 
To be successful under MACRA, providers need to completely change the way they 
have been working (Deloitte Report, 2017, p. 1). One way to become successful is to 
establish a system partnership with a medical device company. Such a partnership means 
that the two entities have more than a common customer-vendor relationship; this im-
plies a full partnership where they develop and establish treatment solutions together 
(Siemens Healthineers, 2015, w.s.). A variety of partnerships exist, creating tailored so-
lutions for every possible cooperation between medical device companies and providers. 
On one hand, providers often need to invest in their digital infrastructure or innovate in 
general (Lohmann, Rippmann, 2014, pp. 122-131), but they often do not have the finan-
cial reserves to do so. On the other hand, Medical device companies are able to support 
these changes financially through multiple payment models which ease the payment for 
providers. Additionally, they can provide them with medical devices to clear the way 
for further innovation processes, given that they are in a system partnership. As a result, 
the provider can participate in the progress of medical technology without worrying 
about financial resources. 
The provider can further benefit from cooperation with a medical device company by 
using the company as a positive role model for modernization of health care (Lohmann, 
Rippmann, 2014, p. 126). Currently, medical device companies are global players who 
have to align to the market. Providers are protected by law and thus never had to adjust 
to the global market in the same way. However, now that the market is changing through 
MACRA, providers are forced to compete on a higher level. Medical device companies 
can encourage providers to take steps in the direction of digitalization. They can assist 
providers in terms of restructuring and reorganizing while also relieving the company 
financially and motivating the staff through quick wins in digitalization.  
Medical device companies can also teach staff how to optimally operate devices and 
technology, generating an efficiency gain (Lohmann, Rippmann, 2014, p. 128). Also, 
the companies have the expertise to analyze weak points in a process and subsequently 
System Partnerships between Medical Device Companies and Health Care Providers 
155 
help to optimize those. Together, the two partners have the opportunity to use the devel-
opment work of the medical device company to create change more swiftly than previ-
ously possible.  
If the providers and medical device company cooperate closely together, they are also 
able to establish clinical pathways together. Clinical pathways are the unitary way, 
agreed upon by all concerned parties, a provider treats patients with steady, proficient 
quality (Lohmann, Rippmann, 2014, pp. 122-131). It is determined to be the most effi-
cient way to treat a patient and is complex to develop. When the provider and all relevant 
employees along with the medical device company agree to devise a clinical pathway, 
it will be especially efficient.  
Sometimes medical device companies collaborate to facilitate product improvements 
(Siemens Healthineers, 2015, w.s.). There are various products that can be innovated 
and upgraded, such as Magnetic Resonance Imaging (MRI) and Computerized Axial 
Tomography (CAT) scans. A partnership with a provider allows scrutiny of workflows 
and improvement of the device accordingly. For example, Siemens Healthineers and 
Northwell Health have been collaborating since December 2016 as a research partner-
ship in order to improve the outcomes of Northwell’s Imaging Clinical Effectiveness 
and Outcomes Research Program (Business Wire, 2016, w.s.). According to their first 
published paper, 'Value of Advanced Imaging in Improving Health Outcomes and 
Healthcare Spending in Acute Stroke', they already discovered that during a stroke the 
best choice for an imaging exam, whether to use an CT or MRI, depends on the personal 
characteristics of the patient. With this finding, Siemens Healthineers and Northwell 
Health hope to illuminate new pathways to treat patients more effectively and influence 
health policy rulings to improve population health.  
4.2 Negative aspects of a system partnership 
There are some factors, however, which providers and medical device companies should 
bear in mind when considering a partnership. Both parties need to be completely honest 
about their intentions when establishing a working relationship (Lohmann, Rippmann, 
2014, p. 130). If there are any discrepancies it is highly likely that the cooperation will 
not work. Constant risk management is a necessity to detect possible inconsistencies 
early enough to rectify the situation. Also, credibility is an important matter. If the pro-
vider does not believe the intentions of the medical device company are genuine there 
is no basis to build on and thus it is likely that the partnership will not come about 
(KMU-, Krankenhausstudie 2000, 2000, pp. 94-100). 
Furthermore, not every medical device company is able to establish a system partner-
ship. There are special features needed for a partnership to occur. The structure of the 
company has to be more like a service company than a simple vendor (Lohmann, Ripp-
mann, 2014, p. 127). These service qualities are essential to be successful in such a 
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partnership due to the thorough preparations which are needed to determine if the two 
partners fit well together before founding the partnership. 
5 Discussion 
In the following part, the focus lies on the central question: to what extent can a system 
partnership between a provider and a medical device company can save costs and sim-
ultaneously improve the quality? 
First of all, it is apparent that there is a need for change in the health care market 
(Squires, Anderson, 2015, w.s.). MACRA expresses these needs and tries to take a step 
toward a better functioning health care market. To accomplish this, providers have to 
leave old pattern of fee-for-service logic. MACRA is a law propels providers into value-
based payment reform and therefore makes changes inevitable.  
The providers also have to digitalize. This might be expensive at first, however, as soon 
as the provider gets used to it expenses can be saved. In a partnership, the medical device 
company may help the provider to acclimate to new devices and new technology, allow-
ing providers to benefit from the profound knowledge of the device company. The med-
ical device company is then able to develop the products and sell them to the provider. 
Naturally, the company has more detailed insight into the product than the provider. 
This insight can be communicated to the provider and customized to the specific re-
quirements the provider requests. Both can benefit from economies of scale and the 
medical device company can profit from economies of scope as well. A medical device 
company usually has more than one provider with whom it collaborates. After the new 
technology is incorporated, the provider is highly likely to receive higher revenues under 
MACRA, under the condition that the medical device company provides EHR certified 
technology and the provider reports the performance categories correctly.  
Research partnerships, especially, can play an integral part in quality improvement. The 
medical device company and the provider work together to scrutinize topics which can 
contribute to excellent patient care provision. For example, imaging techniques can be 
enhanced and the evaluation of images can be simplified for physicians. Consequently, 
the rate of misinterpreted images might decrease and thus might lower the rate of incor-
rect diagnoses. There may then be more satisfied and correctly treated patients, which 
is an indicator for high quality as well as value in the health care market. If there are less 
wrong diagnoses, there are fewer follow-up treatments, which also would lead to de-
creasing costs. As a further result, quality would be improved as well by decreasing 
unnecessary care. Additionally, medical device companies can use collected data to im-
prove all their devices and develop new devices. Older technologies will be replaced 
through this process in the near future. Consequently, providers will be provided with 
better technologies and the medical device companies can market more products.  
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When the medical device company tackles the burden of inefficient processes by opti-
mizing them, both partners can focus on their core activities. It is particularly important 
for providers to focus on their core capacity to revise actual treatments. This is required 
to have a competitive edge against other providers (Lohmann, Rippmann, 2014, p. 129). 
If a provider has established clinical pathways together with a medical device company, 
both better concentrate on the maximal performance. The medical device company sup-
ports the provider to implement the provider’s ideas, expectations, and suggestions. To-
gether, they are able to achieve state-of-the-art medicine and improve the quality of 
treatments dramatically. Additionally, both can improve their images. Hence, the medi-
cal device company will gain more customers and the provider more patients. Both ben-
efit from an excellent status and thus can save costs through economies of scale, leading 
to a positive effect on their revenue as well. 
Physicians in a system partnership focus more on medical outcomes because their part-
ner releases them of incidental economic, technical, and organizational issues to a great 
extent. Also, nursing staff is disburdened from supplementary documentation obliga-
tions and other administrative tasks so they can concentrate more on patients. Through 
such a system partnership, resources are efficiently used and will be reimbursed to a 
greater extent by MACRA. 
Another notable point is that medical device companies can support providers by build-
ing up a good data infrastructure. It simplifies data collection and data transfer to fulfill 
MACRA reporting requirements, which is likely to result in higher payments. Also, to-
gether they can evaluate the data better to review the number of mistakes made by each 
physician and create competition by rewarding physicians who made the least mistakes. 
This will also increase the quality of care and is an effective incentive to save costs from 
unnecessary follow-up treatments. 
Additionally, if the provider receives all the required devices from the same medical 
device vendor, there is only one maintenance contract to negotiate. Consequently, the 
maintenance complexity is reduced and more standardization is achieved. Every device 
is similarly programmed and this leads to simplified usage for every physician. Now 
only one introduction from the medical device company is needed for the staff to explain 
how to use a device properly and in the best, fastest way. In general, standardization is 
essential for faster and more efficient working practice. Also, the reduced complexity of 
maintenance contracts saves time and resources. Fewer staff members are required to 
check the contracts with each individual device company and therefore costs are re-
duced.  
However, only a functioning system partnership offers the advantages listed above. If a 
system partnership does not achieve this there are severe disadvantages which must al-
ways be kept in mind. 
Elisabeth Ludwig 
158 
The many barriers to effective cooperation are seen as a negative aspect. Partners must 
compromise, a process which distracts the provider from focusing completely on provid-
ing health care. Also, medical device companies do not wish to cooperate with every 
provider. They mainly focus on larger health providers to get better outcomes. Smaller 
health providers do not have the scope the medical device companies want to reach with 
those partnerships. Additionally, the larger providers supervise a higher number of pa-
tients each day. If they can save costs through system partnerships, it will affect the 
health care economy more than if the medical device companies would only cooperate 
with smaller providers. Furthermore, larger providers have a higher negotiation level 
than smaller ones. They can achieve better conditions for the system partnership due to 
their size. More medical devices and technologies are needed in larger organizations and 
it is a greater challenge for the medical device company. Therefore, more costs can be 
avoided by the providers due to volume discount. However, the medical device company 
has a secure customer through the system partnership, who relies on its products and to 
whom it can sell more as an economic benefit despite the volume discount. 
A major aspect of the partnership is the dependency between the provider and medical 
device company. Once a partnership is established, the provider is dependent on the 
medical device company. The provider needs to believe in the good intentions of the 
medical device company (KMU-, Krankenhausstudie 2000, 2000, pp. 94-100) and try 
to keep the possible dependencies as minimal as possible. This can be accomplished 
through customer-vendor relationships with other medical device companies. Along the 
same lines, the medical device company is prompted to reveal all its intentions so it is 
evident that the company does not want to exploit the provider. If such abuse took place, 
it would first lead to significantly higher costs for the provider and the system partner-
ship would finally end in a collapse. 
Nevertheless, the advantages of correctly aligned system partnerships between two par-
ties outweigh the risks of a partnership not properly functioning. Even though it is ex-
pensive at first, innovation is necessary. Through this process, quality can be signifi-
cantly increased and costs decreased due to modification of health care systems in the 
US through various system partnerships.  
6  Conclusion 
The health care market is a fast-changing market. MACRA takes a step in a new direc-
tion which has significant influence on how providers function. The need for change had 
been obvious before the law passed through Congress. MACRA now helps the health 
care market adjust faster to the new circumstances it faces. Providers are now required 
to change within the next couple of years. They have four years to align with the new 
payment models and become quality- and value-based providers. System partnerships 
between providers and medical device companies are a model which will support those 
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changes and help both parties perform at their best. Though smaller providers will not 
benefit as much from system partnerships now, they are expected be attractive for med-
ical device companies as well in a few years. 
System partnerships facilitate the repositioning providers to focus on their core compe-
tencies in order to improve medical outcomes. The medical device companies take bur-
dens from providers and support them with technological knowledge and innovations. 
Clinical effectiveness and economics can significantly be improved through these part-
nerships as well, creating another benefit for both participants.  
Already established partnerships demonstrate the huge advantages both sides have ex-
perienced from their system partnership. These also show the possible variety of part-
nerships. Every system partnership differs and the medical device company has to adjust 
to each provider. This process leads to creative and innovative solutions which exem-
plify how system partnerships benefit providers, medical device companies, and the 
health system as a whole, especially in the future. Therefore, this concept of system 
partnerships has to be further developed in order to minimize the risks and focus on the 
advantages.  
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Regulatory Processes & Innovation Cycles in Times of  
Digitalization – a Contradiction? 
Peter Konrad 
Digitalization - without a doubt - is the main driver of innovation nowadays. This 
phenomenon takes place in almost every business, even within the medical device 
industry digital development is an important driving force. Digitalization allows a 
broad range of people to create their own mobile applications, as demonstrated by 
the enormous number of digital products available for mobile devices. While the 
simplified creation of digital products accelerates innovation in the medical device 
industry, regulatory processes remain the same yet seem to be necessary to provide 
a safe market entry. This work examines the influence of digital innovation on med-
ical devices and compares the regulatory processes in the US and Germany. There-
fore, a theoretical background of innovation and regulation theory is given. Subse-
quently, the regulatory systems of medical devices in the US and Germany are an-
alyzed regarding their fit for mobile applications. After describing problems arising 
due to long and inappropriate regulation systems, recommendations are given by a 
fictive regulatory system on how regulatory processes can be adjusted to accommo-
date mobile medical applications.  
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1 Introduction 
Innovative developments within healthcare industry are often regarded as both a boon 
and bane at the same time. On one hand, making progress in medical devices offers huge 
potential: Processes may be simplified and optimized, providers better connected, and 
patient care improved. On the other hand, technological progress is blamed as a main 
driver for the continuous increase in healthcare costs (Sorenson et al., 2013). A substan-
tial role within innovation in healthcare is played by digitalization. The range of benefits 
of digitalization for the healthcare industry and health systems can still hardly be imag-
ined, though it is evident that digital products have had a huge impact (Malvey and 
Slovensky, 2014, p. 1). This rapid change to digitalization leads to several challenges: 
The subordinate problem deals with a still missing coherent terminology for digital, in-
novative products in healthcare (Albrecht and Jan, 2016, pp. 48–52). Of greater im-
portance is the creation of an appropriate regulatory system, which allows fast access to 
the market but still considers and eliminates potential threats (Kramer et al., 2012, 
p. 853). Due to health systems often being strictly regulated, beneficial circumstances 
for creating innovative products are scarce. Nevertheless, the number of digital products 
seems to grow without any limits while the political and regulatory frameworks around 
the globe struggle to keep pace (Bierbaum and Bierbaum, 2017, pp. 255–256; Boulos et 
al., 2014, p. 1; Roh and Kim, 2017). There is no doubt that regulation of medical devices 
is a mandatory part within every health system to secure patients’ health. Regulatory 
processes must fit adequately to the fast cycles of innovation and follow the rapid 
changes initiated by digitalization as well as the confusing number of digital products 
which claim to be part of the healthcare system. 
This work examines the problems within the medical device industry due to rigid and 
long regulatory processes in addition to the dynamic innovation cycles within the indus-
try. Because the meaning of digitalization for innovation in healthcare is still to be de-
termined this work will just focus on digital products within the medical device industry. 
A theoretical framework about regulation and innovation forms the basis for this topic. 
Afterwards, the application of regulatory processes on digital medical devices is inves-
tigated. Corresponding to the topic of the book, the focus is on these processes in the US 
and Germany. An evaluation of the suitability of the current situation and potential sug-
gestions for improvement closes this essay. 
2 Innovation and regulation – a theoretical background  
2.1 Theory of regulation and the principal-agent phenomenon 
The act of regulating market entry and distribution of medical devices within a health 
system has the intention of protecting people from undesirable effects on their health 
status (Cheng, 2003, pp. 3–8). This is based on a very fundamental understanding of 
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regulation: The interaction of normative objects and private interests demands govern-
mental action, which is represented through politics (Baron, 2007, p. 1,349). Regulation 
is commonly separated into economic regulation, social regulation and administrative 
regulation. While economic regulation is used for improving the performance of mar-
kets (e.g. through restrictions, standards, market entry conditions, etc.), social regulation 
relates to the protection of public health and well-being. Finally, administrative regula-
tion determines governmental actions in private and public sectors, e.g. taxes and 
healthcare administration (OECD, n.a.).   
Within markets, those regulatory interventions are required because of asymmetric in-
formation, a main part within the principal-agent theory. This phenomenon occurs when 
there are parties contracting with each other which are suffering an unequal level of 
information and individual action cannot be observed. As a consequence, this leads to 
moral hazard, which prohibits “first best” solutions (Holmstrom, 1979, p. 74). In the 
case of asymmetric information, regulation serves as mediator to create equal conditions 
between the principal and agent and to eliminate economically inefficient behavior 
(Baron, 2007, p. 1,349). Regarding regulation of medical devices, asymmetric infor-
mation can be observed in different scenarios: the manufacturer of a medical device 
(both physical and digital) has a strong advantage in information compared to custom-
ers; customers may be patients acquiring the product directly from the manufacturer or 
distributor and uses it for himself; or the customer is represented by a care provider, who 
acquires the medical device for commercial use and applies the medical device for pa-
tient treatment. The user in the last two cases is unable to assess the benefit of a medical 
device in advance, as is common in health economics (Zweifel and Manning, 2000, 
pp. 412–413). Furthermore, the manufacturer has an incentive to maximize his profit. A 
corresponding minimization of the costs to achieve greater profits in this situation could 
lead to a reduction of efforts to protect the interests of consumers. This legitimatizes  
governmental regulation to reduce economic costs and guarantee patient safety (Cheng, 
2003, pp. 7–8). Regarding medical devices affecting peoples’ health, the role of govern-
mental regulation is mainly to introduce and adopt a minimum standard of quality.  
There are several theoretical mechanisms through which asymmetric information can be 
solved by governmental regulation (Baron, 2007). In a concrete setting with a regulatory 
framework, the manufacturer of the medical device would have to pass a predefined and 
comparable standard, which allows the users to trust the product is at least a certain level 
of quality. Attention should be paid to changing circumstances, though. Regulatory pro-
cesses may be adequate for a certain range or type of products, but changes and drifts 
over time may influence the industry and demand an adoption of new regulatory frame-
work.    
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2.2 Theory of innovation and the innovation process  
The term “innovation” is widespread and used in several contexts with different mean-
ings (Baregheh et al., 2009). For a better understanding, there should be a common def-
inition of innovation: following the Sociologist Everett M. Rogers and his pioneering 
book “Diffusion of Innovations” innovation should be understood as something that dis-
tinguishes itself through a certain novel characteristic (Rogers, 2003, p. 12). This can be 
expressed through new processes, products, or changes in organization. The aim inno-
vation strives for - from a company’s point of view - is either to reduce unit costs and/or 
enlarge demand within the market (Sengupta, 2014, p. 1). Therefore, innovation is also 
seen as a possible way to create competitive advantage (Porter, 1990, p. 74).  
Innovation is often separated into different subtypes. We will just focus on few which 
are relevant to the medical device industry and digitalization:  
- One subtype is technology-based innovation. This term sums up all product in-
novation, process innovation, investments of the industry in research and devel-
opment, and the transmission of technology (Sengupta, 2014, p. 1).  
- Another separation into subtypes involves endogenous and exogenous innova-
tion. Endogenous innovation develops from the incentives of the market. Inno-
vation in this case is most often created by being the first company with a new 
technology and earning a monopolistic standing within the industry, e.g. 
through patent protection. Exogenous innovation describes a form of innovation 
which develops through a background outside the industry, e.g. academic re-
search (Sengupta, 2014, pp. 1–5).  
- Finally, there should be separation between incremental and radical/disruptive 
innovation. While the first means to make small changes piece by piece on an 
already existing product, the latter describes a complete substitution of an exist-
ing product (Stewart, 2011, p. 2). 
These “types” of innovation take place in an innovation process. One of the most com-
mon interpretations is from Andrew van de Ven (1999), who distinguishes between a 
linear and a cyclical model. The main difference between these models is that there are 
straightforward, defined tasks within the linear model and a more blurry, interdependent, 
and repeating process within the latter. Additionally, the cyclical model makes it diffi-
cult to comprehend which aspects are influencing which development. In comparison to 
the linear model, a cycle of the innovation process is defined by the obligatory fact that 
it must repeat itself (Figure 10.1). 
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Figure 1: Innovation cycle in the medical device industry  
 
Source: Own representation based on Van de Ven, 1999 and Mostardt, Ochs, et al., n.a. 
If we consider the previous information about the different subtypes and characteristics, 
innovation within the medical device industry by digital products can be categorized as 
follows: The first aspect of innovation arises through digitalization, which represents a 
divergent technology. Therefore, we see technology-based types of innovation. Second, 
mainly endogenous innovation can be observed. This is a result of the incentives of the 
healthcare market and its demand for innovative solutions. Third, digital products rep-
resent disruptive innovation. Those products do not only improve but also substitute 
existing products on the market. All this technology-based, endogenous, and disruptive 
innovation in the medical device industry happens within a cycle of innovation that cre-
ates incremental progress. This means that this new area in the medical device industry 
is improving through its changes. All these special factors lead to a special demand for 
regulation of the products created. 
This leads us to how innovation is adopted by the users: innovation - digitalization in 
particular - can hardly be described without diffusion. Diffusion is the process of com-
municating an innovation through a social system (Rogers, 2003, p. 10). Rogers distin-
guishes between different types of adopters, according to their innovativeness. This fac-
tor determines the rate of adoption of an innovation, i.e. how fast does an innovation 
establish itself within a system (Rogers, 2003, pp. 22–23). Additionally, innovation 
must be separated from invention: while innovation means a change in the producing 
systems of manufacturers, invention describes a shift within the technical opportunities 
themselves (Brozen, 1951, p. 239). Innovation itself always creates uncertainty, which 
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depends on the user’s possibility to evaluate the risks. Because the risks of medical prod-
ucts can hardly be assessed by the users - according to the principal-agent theory - it is 
the duty of regulatory procedures to reduce those risks for the patients. The specific 
aspects of health systems, e.g. the reimbursement system and the number of different 
actors, influence the diffusion of innovation. In consequence, the economic success of a 
medical app depends on the rate of diffusion, which in turn benefits from low uncertainty 
and short regulatory processes. Regulation therefore can have huge impact on diffusion 
of medical device innovation.  
2.3  The mutual impact of regulation and innovation 
The governmental approach of implementing regulatory processes in markets represents 
an interference with the liberal market environment. These actions are mandatory as a 
result of market failure provoked by asymmetric information as mentioned above (Aker-
lof, 1970; Samuelson, 1984). Consequently, those diverse conditions have several posi-
tive and negative effects on innovation cycles.  
On the one hand, different regulatory actions enhance the circumstances for innovation 
in markets. Regulation can ensure an appropriate level of competitiveness and openness 
among businesses. This is a main condition to promote innovation in an industry because 
a certain level of competitiveness sets incentives to achieve a competitive advantage 
(OECD, n.a., p. 12). Therefore, companies have to reach several requirements which 
can only be fulfilled by creating product or process innovations (Blind, 2016, p. 3). In 
contrast to this indirect way of promoting innovation, the straight approach would be 
realized by handing out intellectual property rights. This form of regulation is explicitly 
dedicated to enhancing innovation by giving patents to create a monopolistic situation 
as a reward (Blind, 2016, p. 3). 
On the other hand, regulation can lead to massive impediments for innovation. The reg-
ulatory burden on the companies requires financial resources and time which could oth-
erwise be invested in innovative approaches. This hits small companies trying to focus 
on their innovative initiatives especially hard (Stewart, 2011, p. 2). Regulation might 
also restrict research efforts, the possibility of using different technologies, and the tech-
nology diffusion (OECD, n.a., p. 12). Furthermore, competition can be hindered and 
market entry can be complicated. This leads to a delay in supply or even a cessation of 
production(Blind, 2016, pp. 8–10). Especially within the medical device industry, the 
interaction between regulation of and innovation in market entry plays a huge role: how 
is it possible to ensure patients have access to the newest innovations in a fast way but 
also make sure that safety is not jeopardized (WHO, 2010, p. 14)? 
The relationship between regulation and innovation seems to be one-sided because reg-
ulation has huge impact on innovation. Despite this, it can also be mutual and digitali-
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zation is a very suitable example. The development of digital products created new sec-
tions within many businesses, if not a business itself. Following Rogers (2003), innova-
tion leads to uncertainties about how to treat new products. Consequently, this innova-
tive development encourages the creation of new regulatory mechanisms (Bierbaum and 
Bierbaum, 2017, p. 249).  
3 Regulatory processes as a hurdle for innovation? Data from the U.S. and 
Germany 
3.1  The ‘mobile medical device’ – an example of innovation 
When renowned Harvard professor Clayton M. Christensen stated back in 2000 that 
healthcare could be “saved” by disruptive innovation, he would not have known that 
digitalization will maybe make this happen (Christensen et al., 2000). The introduction 
of digital opportunities created several new but blurry business fields in healthcare, e.g. 
mobileHealth (mHealth), telehealth and eHealth (Malvey and Slovensky, 2014). Ac-
cordingly, the range of digital medical devices is very inconsistent and does not improve 
with growing technical opportunities (Hudes, 2017, p. 1). For consistency in this work, 
a common understanding of what is meant with the term “medical device” in the digital 
spheres should be determined. First, the focus is exclusively on digital products. There 
is no doubt that innovation in the medical device industry happens in many ways, but 
digitalization has an outstanding position in the present time. Also, the innovation cycles 
of digital products differ heavily from physical products, creating several challenges for 
regulation.  
Second, a standard definition of “medical device” should be adopted by the US Food 
and Drug Administration (FDA) and the Bundesinstitut für Arzneimittel und Mediz-
inprodukte (BfArM). These institutions are responsible for approval procedures for 
medical devices in the US and Germany. Accordingly, this essay will focus on the reg-
ulatory processes of mobile medical applications and will exclude health applications 
(programs with only preventive purpose), telemedicine, and any kind of health infor-
mation systems (BfArM, 2015; FDA, 2017b). The investigated programs are used by 
patients or professional users. mobile medical apps are software programs running on 
mobile devices, which fall into the category of medical devices in the US and Germany 
(BfArM, 2015; FDA, 2017c). This will be further be specified in the following sections. 
3.2 Regulatory processes and innovation cycles in the US 
The FDA first published a guideline for mobile medical applications in 2013 and up-
dated this due to dynamic development in 2015. This guideline states that a mobile med-
ical app must fall under section 201(h) of the Federal Food, Drug, and Cosmetic Act 
(FD&C Act) (FDA, 2015, p. 7). This states the app has to be an accessory to a regulated 
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medical device or has to convert from a mobile platform into a regulated medical device 
(FDA, 2017c). The section 201(h) also gives a description of which criteria have to be 
met to be declared as medical device: a medical device has to affect body functions or 
be involved in “the diagnosis of disease or other conditions, or in the cure, mitigation, 
treatment, or prevention of disease”(FDA, 2015, p. 7). The application of this definition 
represents the first level of regulation. If the product does not meet this description, there 
will not be any regulatory process. As soon as the intended use of the digital product 
meets the definition, the same regulatory processes used for physical medical devices 
are applied (FDA, 2017c). The process starts with the classification of the mobile med-
ical device into three classes of risk. With a higher risk class, the severity of regulatory 
requirements increases. The medical device is allocated to one of the risk classes by a 
classification number, which belongs to the area of application on a human body (FDA, 
2014a). No matter which class a medical device is part of, there are general controls like 
being manufactured under a quality assurance program, fit for the intended use,  labeled 
adequately, and registered as well as listed by the FDA (FDA, 2014b). Class I is the 
most common for mobile apps and represents devices with low risk for the user which 
must only fulfill general controls in most cases. Medical devices with moderate risk 
ranked as Class II must pass a Premarket Notification 510(k) in addition (FDA, 2014a). 
This process should demonstrate to the FDA that the medical device is safe and effective 
by comparing it with an already established device on the market. After the 510(k) is 
found successful by the FDA, the product can be introduced immediately on the condi-
tion that there might be inspections at any time by the FDA (FDA, 2016). For high risk 
devices (Class III), a Premarket Approval is mandatory. This includes  scientific, regu-
latory documentation that demonstrates safety and effectiveness and is often supported 
by clinical studies (FDA, 2017d). After passing those regulatory processes the mobile 
medical device can be introduced to the US market (Kramer et al., 2012). 
The time-consuming parts within the regulatory process of the FDA are the Premarket 
Notification 510(k) and the Premarket Approval for risk classes II and III. For the 
510(k), the FDA sets itself a time frame of 90 days from the receipt of the 510(k) to 
come to a decision. If 100 days are exceeded, clarifying communication will take place 
(FDA, 2017e). In the case of the more strictly handled Premarket Approval for Class III 
devices, the time frame is extended to 180 days. The FDA confesses that the process 
may be lengthen if necessary (FDA, 2017d). In practice, the length of both regulatory 
processes take much longer: an investigation of all 510(k)-processes between 2012 and 
2016 shows an average of 177 days in 2016 instead of the proclaimed 90 days (Emergo 
Group, 2017, p. 5). Not even 20% of all devices are cleared within the proposed timeline 
(Emergo Group, 2017, p. 7). The same situation can be examined for the Premarket Ap-
proval process for class III medical devices. Data varies between 290 and up to 518 days 
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as average instead of 180 days (AOK-Bundesverband, 2013; Makower et al., 2010; Wal-
ter et al., 2016). Figure 10.2 summarizes the path of a digital product through the regu-
latory processes of the US. 
 
Figure 2: Regulatory process of a Mobile Medical Device in the US 
  
 
Meanwhile, innovation in the medical device industry is accelerating and the number of 
digital products is growing at an annual rate of 25 percent (Cortez et al., 2014, p. 372; 
FDA, 2017a). A survey under manufacturers carried out, that the most important drivers 
to gain competitive advantage are product innovation and reduction of time-to-market 
(PA Consulting, 2016, p. 12). Yet the time-to-market for medical devices takes three to 
seven years from conception to completing the regulatory processes (Fargen et al., 
2013). From the start of communication with the FDA to approval, it takes an average 
of one to two and a half years (Makower et al., 2010, p. 6; Rising and Moscovitch, 2015). 
This development provokes reaction from the regulatory institutions. To keep the num-
ber of mobile medical applications under control, the FDA sets very strict definitions of 
what is regulated and which products are not. Table 10.1 shows a selection of different 
regulations concerning mobile medical devices. Class III devices were not represented 
in the given examples of the FDA. A large portion of mobile apps which are per defini-
tion a medical device is excluded from regulatory processes because they pose low risk 
to consumer safety. For these low risk products there is no list with concrete details, 
only different examples (FDA, 2015, pp. 15–18). The broad exclusion of regulated mo-
bile medical apps suggests an overload of the regulatory capacity. Furthermore, the FDA 
presents a list of apps which may be a medical device (FDA, 2015, pp. 23–26). The FDA 
also does not make clear how to deal with updates. It is simply stated that “minor, iter-
ative product changes” do not require a re-evaluation of the product (FDA, 2017c). This 
underlines the uncertainty the institution when handling innovative products. 
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Table 1: Examples of FDA regulations for Mobile Medical Devices 
Device 
Name 
Applicant Clearance 
Date 
Regulation Descrip-
tion 
Risk 
Class 
JiveX 
VISUS TECHNOL-
OGY TRANSFER 
GMBH 
9/16/2016 
Picture archiving and com-
munications system 
Class II 
Lumify Ul-
trasound 
System 
Philips Healthcare 10/3/2016 
Ultrasonic pulsed doppler 
imaging system 
Class II 
(If a manufacturer's device falls into a generic 
category of exempted class I devices as de-
fined, there is no explicit regulation) 
 (e.g.) Calculator/data pro-
cessing module for clinical 
use 
Class I 
Source: FDA 2015. 
3.3 Regulatory processes and innovation cycles in Germany 
In Germany, most of the responsibility for defining products as medical devices and 
regulating market entry is transferred to the European Union. These European laws must 
be implemented into national law. Therefore, all European regulations are compulsory 
for the German system.  
As in the US, the first aspect for commercial distribution is the definition of the product. 
The German definition set in the Medizinproduktegesetz (MPG) follows the guideline 
93/42/EWG of the European Union (also called Medical Device Directive; MDD). The 
decisive factor for a mobile app being declared as medical device is – similar to the FDA 
– the intended use. If the device should be used for diagnosis, prevention, supervision, 
or cure of sickness or injury, to change a physiological process, or for contraception the 
MDD is applied. Comparable to the FDA, a risk classification for these medical devices 
is used. Applications are separated into Class I with low risk (with Is for sterile and Im 
for measuring), Classes IIa and IIb are for middle and increased risk products, respec-
tively, and Class III is for high risk devices. Figure 10.3 represents the process in Ger-
many. The classification is regulated under the MDD, which defines 18 rules regarding 
health risks (BfArM, 2015). According to these rules, most mobile medical devices are 
ranked Class I  and sometimes IIa or IIb (BfArM, 2015; Bierbaum and Bierbaum, 2017, 
p. 255). The MDD further classifies mobile medical devices as active medical devices 
which are dependent on an external power source and often ranked within higher risk 
classes (BfArM, 2015). If medical apps are changed or expanded by updates, there is no 
clear way to deal with the change. In cases of a tremendous impact on users health, the 
responsible authority has to be informed (Richtlinie 93/42/EWG des Rates. Europäisches 
Parlament und Rat, 1993).  
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Figure 3: Regulatory process of a Mobile Medical Device in Germany 
 
 
The aim of the regulatory process is the CE-sign, which shows the safety and effective-
ness and also allows medical devices to be distributed within the European Single Mar-
ket. Depending on the risk classification, the product must pass different assessments. 
Class I devices can be assessed by the manufacturer themselves and no inspection body 
is needed (e.g. TÜV; Technischer Überwachungsverein). For all other classes, an in-
spection body must be involved and a declaration of conformity must be provided 
(BfArM, 2015). The declaration of conformity depends on the risk classification and is 
determined by the regulations of the European Union. The requirements of approval 
procedures rise to correspond with higher risk classes. These can include risk manage-
ment, technical documentation up to clinical studies, and cost-benefit-analysis within 
the MDD (BMG, 2010). In contrast to the US, where the state-owned FDA does the 
assessment by 510(k) or Premarket Approval, the risk classification and the declaration 
of conformity is done by the manufacturer itself. Just the certification is performed by a 
chosen inspection body according to appendix I of the MDD (BMG, 2010). Germany is 
in a decentralized and less arranged setting compared to the more centralized and trans-
parent one in the US (Kramer et al., 2012, pp. 850–851). 
As in the US, the regulatory processes play the leading role on the way to the market. In 
contrast, the time-to-market is reduced due to decentralized regulation: empirical data 
shows that the CE-certificate is assigned 36 months earlier in Germany than in the US 
for devices with Premarket Approval (Hwang et al., 2016, p. 4).Yet, the whole process 
is still estimated to be between four to six years (Neumann et al., 2016, p. 50). In both 
countries, the approval for low- and moderate-risk devices seems quite similar, where 
most mobile medical apps are concerned (Kramer et al., 2012, p. 852). Nevertheless, 
with a maximum release cycle of less than one year (in comparison to more than three 
Peter Konrad 
174 
years for normal medical devices), time-to-market increases and represents a loss of 
potential due to regulatory processes for innovative digital products (Knöpple et al., 
2016, p. 13). 
4 Possibilities for a harmonious interaction between regulation and inno-
vation in healthcare 
After looking at American and German medical device regulation, both have common-
alties and differences. The risk classification systems are obligatory and seem to be quite 
similar, while the degree of centralization as well was the length of regulatory processes 
differs (Kramer et al., 2012, p. 850) Theory also provides a necessary component of 
economic and social regulation to maintain fair market conditions and secure population 
health. Yet this has partly negative effects on innovation and diffusion of innovation due 
to long regulatory processes. Since innovation cycles are much shorter for mobile med-
ical apps, the application of the same regulatory processes as for physical devices seems 
questionable. Regarding the huge number of medical apps, a separate regulatory process 
would be more appropriate. For a better alignment, such a process is fictively proposed 
hereinafter: 
For manufacturers of mobile medical apps, it is important to get a fast and comprehen-
sive overview of the regulatory requirements. Therefore, a clear definition of a digital 
medical product must be found. The confusing mixture of terms like eHealth, mHealth, 
etc. prohibits a clear understanding and impedes the dialogue. The definition should be 
determined by concrete criteria and not the intended use or blurry examples. After an 
adequate definition and separation from apps with just preventive character, a classifi-
cation must take place. The used risk classifications seem to be proven, but the results 
are biased due to the mixture with normal medical devices. A system tailored for digital 
products is necessary because the risks of digital products can hardly be compared to 
risks of physical devices. Lewis & Wyatt (2014) e.g. separate between inherent (those 
within an app) and contextual risks (which occur through use). A three-stage classifica-
tion may maintain: Class I includes apps that contain or collect data. Within class II are 
apps that give support to the doctor or patient for diagnosis or therapy based on data. 
Class III would contain apps with data based recommendations for diagnosis or therapy 
that “substitute” care providers  (Knöpple et al., 2016, pp. 22–25; Neumann et al., 2016, 
p. 25). This classification may be executed by a decision tree or similar tool. Of decisive 
importance is the consideration of updates. The development of digital products often 
happens through an iterative process and in cooperation with the final user. Furthermore, 
algorithms may be used, which evolve with increasing application (Neumann et al., 
2016, pp. 32–35). This must be considered within the regulatory process and demands 
a reporting system. This hypothetical regulatory process is depicted in figure 10.4. 
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No approval procedure should be prescribed for class I devices because these would not 
intervene in treatment. For classes II and III, a procedure similar to that used for drugs 
can be conceivable: due to the iterative development process of apps, it may be tested 
step-by-step by raising sample sizes until a market maturity can be attested to (Neumann 
et al., 2016, pp. 32–35). This process may also lead to an upgrade in risk classes for 
medical apps. Accordingly, updates must be reported to the competent authority within 
a post-market surveillance system. If this authority should be centralized or decentral-
ized is hard to answer. Since a decentralized system can accomplish regulatory processes 
obviously faster, it seems to be more suitable for medical apps to enable an appropriate 
chance for diffusion (for further inspiration how regulatory processes might be adopted 
to medical apps see Boulos et al., 2014; Lewis and Wyatt, 2014; Neumann et al., 2016). 
 
Figure 4: Hypothetical regulatory process for Mobile Medical Devices 
 
 
It remains unclear how such a risk classification system is appropriate for learning algo-
rithms and how to evaluate the storing of personal data. As such, this example of an 
autonomous regulation for medical apps might go too far for now, but it may give ideas 
for future improvements to regulatory processes.  
5 Conclusion  
Innovation in healthcare calls for changes in the rigid systems of the US, Germany, and 
many other countries. The barriers to creating medical devices decline due to the oppor-
tunities presented by digitalization. Strongly altered structures are the consequence and 
governments must adapt their regulatory processes. Internationally changes are occur-
ring: The European Parliament approved a new Medical Device Regulation in April 
2017 with a transitional period of three years. Therein, medical apps earn greater im-
portance, but the regulatory processes will not be simplified, quite the contrary. The old 
classification system remains but new wording ranks software risks often higher than 
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before, which leads to longer regulatory processes. This means much more burden on 
most, often young, innovative companies, which might fail due to this regulation. In-
stead, a regulatory system that encourages innovative products by enabling an adequate 
speed of the process would be a better way to promote and enable innovation in the 
medical device industry.  
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The Role of Digital Health Care Startups 
Florian Rinsche 
Digital health has become a real buzz word in recent discussions about transforming 
the healthcare system. One driver for digitization of healthcare are startups. Startups 
are newly emerging companies with a new business model that identifies a certain 
problem and tries to fix it. This essay sheds light on the role of digital health startups 
with respect to the healthcare system. Digital health startups can be found in all 
areas and all degrees of digitization: from digital presentation of analogue content 
to deep learning with processing of and reaction to incoming information. When 
comparing the U.S. with Germany, the economic ecosystem of the U.S. is much 
more attractive for digitization as well as for startups. Nevertheless, the German 
startup-scene is catching up. As digitization in healthcare is a relatively new trend, 
it will change the art of providing health care. To foster innovation in healthcare 
through digital health startups some regulation must be changed. 
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1 Introduction 
Digital health is a real buzz word recently and does not merely depend on the startup 
scene. Opportunities and, above all, risks of the technology are currently being discussed 
intensively. Almost every company in healthcare is developing its own strategy to dig-
itize their services. Digital enterprises, on the other side, enter the healthcare market-
place to bring their services to the healthcare context. A third source of digitization are 
startups. Independent of healthcare or not, startups have a somewhat different philoso-
phy than big established companies which involves identifying small problems in life 
and trying to find solutions. 
For some, digital health startups are an inspiration; for others, they appear to be a threat. 
Most of the health care enterprises view digital health startups as a chance to foster their 
own digital transformation- either through partnership or through mergers and acquisi-
tion. 
The founders of digital health startups are different in many respects, but what they do 
have in common is a clear vision. Together, they bring the conventional and fragmented 
healthcare to the 21st century. The patient of the future is digitally proficient, independ-
ent, and mobile- so he expects the same from his healthcare provider. 
One example is the app mySugr. The founder of mySugr developed the idea after real-
izing he is regularly confronted with irregular daily routines and a lot of travel through 
his work as a consultant (Lindekamp and Lücker, 2014). This schedule presents a real 
challenge for good diabetes management: he struggles with continuously varying blood 
glucose, insulin, and carbohydrate levels (Westermann, 2017). To fix the problem, he 
developed a data driven app that helps him - and other users - to remember to use his 
insulin syringe and calculate the right doses for every situation. mySugr takes advantage 
of the current trend where patients are pivoting away from getting their health infor-
mation from physicians toward relying on what Google or other online portals can de-
liver to the masses about health. As a medical device, mySugr went through the whole 
regulatory process to prove that it is founded on a real medical basis with supporting 
studies. 
Besides the startups, even big players in health care want to invest in the area of digital 
health. One way is to digitize their own business model to boost efficiency and develop 
the business model further. Others choose to develop a value driven program around 
their original product. Yet another way is to build completely new business models that 
would not be feasible without big data and accompanying analytics to utilize the infor-
mation to a greater extent than previously possible. 
This essay tries to shed light on the role of digital health startups with respect to the 
health care system. The significance will be demonstrated in terms of monetary value as 
well as in terms of potential further development, where the latter will be more important 
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than current monetary values. Thereafter the future trends of the digital transformation 
and what should be done to enable growth will be analyzed with a summary and con-
cluding remarks will be presented at the end of the essay. 
2 Digital Transformation in Health Care 
One of the most important sectors of almost every national economy is the healthcare 
system, with a share of the total economic performance of around 10 to 12 percent in 
Europe and up to 18 percent in the United States. As a result, any transformation of the 
healthcare system will be important for the entire economy of a country. 
In many cases, the words “digitization” and “startups” are said in one breath. Neverthe-
less, both terms have their own meaning. According to Robehmed (2013), associate ed-
itor at Forbes, a startup company is defined as a newly emerging company with an in-
novative business model that solves a problem and has the aim to grow or achieve a high 
business value.  
While the term “startup company” was relatively easy to define, the term “digitization” 
or “digital transformation” is not as easy. Digitization can be understood most simply as 
the conversion or convergence of analogue products, services, processes, and business 
models to a digital environment. A Study of the Bertelsmann Stiftung (2016) states dig-
ital health is a “cooperative or interactive application of information and communication 
technology to improve healthcare and the public health”.  
In terms of the digital transformation of healthcare, there are 5 definable degrees of dig-
ital transformation. First, digitization can be seen in the sense of an automatization. An-
alogue content is presented or reported in a digital way, e.g. information on a homepage, 
with information stored on data carriers instead of paper. Bilateral communication at 
this level does not exist between sender and receiver. In the second degree, there is com-
munication between sender and receiver and a bilateral interaction. In this stage, two or 
more individuals communicate with each other via email or other messaging tools. The 
third degree is defined by the digital processing of data that are entered manually or 
digitally. Forth, objects of closed and open systems communicate with each other, e.g. 
the anesthesia machine takes patient information from the electronic health record 
(EHR), uses the data to calculate the right dose, and transfers the information back to 
the EHR. In the fifth degree, what is known as deep learning exists, i.e. learning algo-
rithms that process incoming information react to the data and evaluate the results. If 
new patterns emerge, these will be considered in future processes. Technology of all of 
these degrees is currently used in healthcare. 
The digital transformation of the healthcare system is driven by three different sources. 
As Elton and O’Riordan (2016, p. 137) quote, there are digital companies that step into 
the healthcare industry (“Digital Gone Healthcare”), there are healthcare enterprises that 
discover the digital space (“Healthcare Gone Digital”), and the third, final source of the 
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digital transformation is the startups that seek to solve problems with a new digital busi-
ness model independent of huge companies.  
Whereas most of the “Digital Gone Healthcare” Companies focus on business-to-con-
sumer (B2C) business models, the “Healthcare Gone Digital” Companies have a 
stronger focus on the business-to-business (B2B) sector. The startups, however, are not 
limited to either model. Figure 11.1 shows the typical points of contact for each of the 
three sources of the digital transformation in healthcare. 
 
Figure 1: Points of Contact of Digital Health Companies along the Healthcare Value Chain 
 
 
In comparison to other industries, experts attest to a lower level of digitization in 
healthcare systems. Especially within the media, finance, and communication industries, 
the digital transformation has happened very quickly.  
In the future, digital applications in healthcare will become more important. The grow-
ing demand for healthcare services will be a major driver of digital health all over the 
world, especially in ageing societies like Germany. It is expected that by 2060 more than 
one third of the entire population of Germany will be 65 years or older. The demand for 
healthcare services is expected to rise due to the increased proportion of elderly people 
(Statistisches Bundesamt, 2015). The number of care dependents is estimated to be 
around 3.25 to 4 million people till 2060.  
The ageing population of Germany is expected to have a positive effect on the adoption 
of digitization within the healthcare system. While providers are slowly adopting digit-
ization, most Germans are open to modern technologies. More and more elderly people 
are increasingly accustomed to using digital products in everyday life, so they want to 
use it for healthcare issues as well. The prevalent myth about digital healthcare was that 
only younger generations are receptive to it, and thus, digitized healthcare systems 
would not reach the core stakeholders of the health system. However, patients from all 
age groups are more than willing to use digital healthcare services and the number con-
tinues to grow.  
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3  Digital Health Startups in Germany and the US 
The ecosystem of the US is much more attractive to founders in the digital community, 
which extends to a more attractive digital health community as well. Digitization is often 
discussed in a compelling, positive way in the US, whereas in Europe the concerns about 
digital technologies predominate conversation. Nevertheless, regarding Germany, the 
startup-scene is catching up. The Crunchbase database shows more than 530 digital 
startup companies in health care in Germany, and the numbers are rising with a gigantic 
growth potential. 
It is estimated that the digital health market in the USA is about six times larger than in 
Germany. In the first quarter of 2016, over $1.8 billion were raised in venture capital 
funds for digital health startups (Stoakes, 2016). This is just one expression of a cultural 
difference between the two countries. Whereas German physicians perceive risk for pa-
tients in digital applications, American doctors understand the need to adapt innovations 
to make further progress in medical development (Westermann, 2017).  
When the potential of healthcare startups is high, their setbacks are as well. The main 
challenge for digital health startups remains in their business model: who will pay for 
the service. The people of Germany, or in whole Europe, are used to healthcare services 
being paid by their insurance, so their willingness to pay an additional amount of money 
is limited. While the structures of systems like the NHS are more beneficial to imple-
ment innovations on a large scale, the Germany Statutory Health Insurance (SHI)-sys-
tem with currently approximately 110 different SHI-companies is a bit more difficult. 
The system of many smaller insurances in Germany can be beneficial since it creates an 
opportunity for different collaboration and competition, but the real challenge is for dig-
ital health to become part of the standard care of all SHIs. Up to this date there is no 
start up to tackle this issue in the first healthcare market.  
Therefore, a lot of digital health startups enter the second healthcare market. In this part 
of the market, the startups operate in the consumer-oriented B2C area. So, for Germany, 
approximately half of all healthcare startups deal with monitoring or checking the cur-
rent health status of a patient. More cost-savings are expected in therapy, diagnosis, and 
prevention than in the current application of the technology. 
In healthcare, regulation is a large barrier for (new) enterprises entering the healthcare 
market. There is a dilemma between sophisticated regulation (FDA 510k approval13 in 
the U.S. and the CE-declaration of conformity in the EU14) designed to protect patients 
                                              
13 In the U.S., the process of approval for medical devices is governed by Article 510k of the Food, 
Drug and Cosmetic Act (FD&C). The procedure is administered by the Food and Drug Administration 
(FDA). 
14 With the CE-declaration of conformity, the manufacturer declares that ist product satisfies the spe-
cial requirements for medical devices. The acronym „CE“ is an abbreviation for „Conformité 
Eropéenne“, the french term for „European Conformity“. 
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and the desire of the medical technology industries to have short innovation cycles to 
reduce the minimum time it takes to get to the market. Thus, if the goal of the startup is 
to enter the first healthcare market, it will be meaningful to consider the requirements 
of the respective regulatory framework from the very beginning. Relevant topics in this 
context are data protection, data security, and regulatory affairs. If the startup fits the 
strict regulatory requirements of Europe, it will be no additional challenge to meet the 
requirements in the US. For regulation of medical devices this dynamic is the other way 
around. Europe has a less strict regulatory framework than the US, leading some medical 
technology companies to prefer launching their product first in Europe before moving 
to the US market (Westermann, 2017). 
The healthcare systems of the US and Germany are very different in many respects. 
Nevertheless, they struggle with the same problems with similar goals: financing the 
rising demand for care at reasonable or lower costs, enhancing the overall quality of the 
system, and increasing patient satisfaction. At this point, many digital startups come in 
to try solving existing problems that are not addressed incumbent companies within the 
industry. Startups may have disruptive solutions that begin in small niches, maybe at a 
lower quality in some dimensions, which press forward in more and more markets with 
increasing usability. 
The main topics under this category are fitness and self-tracking applications. The suc-
cessful startups in the German healthcare market are Clue, mySugr (Austria), Klara, 
Memorado, and Sonormed. Self-Tracking, which means the digital recording of body-
related data, are also a trend in Germany. 57% of the population is using digital health 
applications, mainly mobile apps and 12% of the population is using wearables. People 
are looking for information regarding a healthy lifestyle as well as tracking their fitness 
and health data. Wearables and fitness/health trackers are overcoming initial skepticism 
about the technology and even reaching out of the fitness area. This expands to not only 
handling chronic conditions, but demand is also growing in all areas of individual life-
styles. 
4 Future Trends of Digital Health 
So far there is hardly any data on the actual use of digital technologies in healthcare, 
either in Germany or in the US. Also, it is unclear how they assess the risks of using 
these technologies. Currently, this period is characterized by a huge increase in the effi-
ciency of information and communication technologies in general and in healthcare. 
Technology from other sectors and industries has already started to enter the healthcare 
market. As one example, the internet will integrate digital health into everyday life and 
act as a facilitator of change in the industry. 
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Digital health is expected to set the pace of development and deployment of new medical 
applications and will transform markets all over the world. This technology will facili-
tate increased access to healthcare services. As White & Case concluded from their sur-
vey, over 90% of companies say that digital health will have a tremendous influence 
within their overall business strategy. These companies are also willing to increase their 
investments in digital health. 
According to Bauer (2017), there are 4 trends in the scene of healthcare startups. First, 
startups are engaging in artificial intelligence (AI), machine learning, telemedicine 2.0 
(improved versions of existing telemedicine), and virtual reality (VR). Other trends -to 
complement the list– are the inclusion of data analytics, genomics/sequencing, digital 
medical devices, and population health management in modern technologies. This list 
is neither mutually exclusive nor collectively exhaustive. For example, artificial intelli-
gence and genomics/sequencing are both based on data analytics. 
Big data seems to be the most essential element of digital health and plays a crucial role 
in data-based decision making. In combination with data analytics, researchers and doc-
tors can enhance their understanding of diseases on the one hand and patient behavior 
on the other hand. With this understanding, patients might get the right therapy faster 
than they would today. As more than half of American citizens struggle with a chronic 
disease (Centers of Disease Control and Prevention, 2016), a better understanding of 
patient behavior can improve population health management by taking more environ-
mental factors and individual behaviors into account. 
The massive amount of data collected will be used to improve the healthcare provided. 
Based on big data and data analytics, artificial intelligence and machine learning would 
be able to influence diagnosis and therapy of patients. One prominent example of this 
topic is the IBM Watson. In health care, this supercomputer is filled with countless med-
ical studies and clinical data which act as the point of origin. To serve patients, the spe-
cific history of a patient is input into the IBM Watson so the supercomputer can specif-
ically assist the doctor in diagnosis and therapy decisions. With the clinical studies in 
combination with patient histories, the IBM Watson learns and recommends diagnosis 
and therapy options based on the information provided. This information will be con-
sidered in similar cases in the future and will support the individual physician in every-
day clinical life. 
When focusing on hospitals, big data enables the application of value-driven health care. 
A progress complete with transparency, accountability, and economic efficiency is ex-
pected to foster the change of a system from volume to value-driven healthcare. Data 
analytics may give the doctor short-term or long-term feedback of his decisions and even 
allow for high and improving quality to be recognized and rewarded. 
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In the field of medical devices and virtual reality, robotic surgery is one of the key ap-
plications. This technology may enable surgeons to perform minimally invasive proce-
dures that are now complicated in a more precise and controlled way than what can be 
achieved today with conventional surgery. In combination with continuous imaging 
technology and virtual reality, the surgeon will be able to better see what is going on 
inside the body. The main disadvantage is that surgical robots are currently very expen-
sive so that they are mainly deployed in high-end state-of-the-art clinics within rich 
countries. 
5 Concluding Remarks 
To enable the digitization of the healthcare system, healthcare actors should demonstrate 
a basic openness to innovative solutions. Considering this, there is still a need to protect 
the fundamental rights of the humans which might be adversely affected through digiti-
zation. To address this, Germany and the European Union have worked out a Charter of 
Digital Fundamental Rights of the European Union that formulated essential rights in 
response to ongoing digitization (Digital Charter, 2016). The aim of this document is to 
guide digital change in a positive direction and to establish an essential framework of 
conditions. 
Data protection and data security are important issues, especially within the healthcare 
system. Nevertheless, this should not lead to widespread refusal to use healthcare data 
for scientific purposes or hinder the improvement of the healthcare system in the context 
of data analytics. To ensure the aims of protecting and securing data are met, the regu-
lators should define standards and terms of use. Also, a unified legislation for each coun-
try, at the least, should be created so that there is more transparency regarding these 
issues. 
An interesting finding of the Bertelsmann Stiftung (2016) is that general population is 
more open to digital health applications than healthcare providers. This is observed 
through the rising demand within the second healthcare market. It is expected that this 
will lead to a boost within the first healthcare market. For providers, it is not enough to 
digitize existing products. Innovative solutions must be developed with innovative ap-
proaches to caring for the patient. Maybe the healthcare industry can learn from other 
industries, like the fintechs, as both healthcare and banking deal with credence goods. 
To understand why a focus on digital healthcare startups is important, the automotive 
industry should be examined. Two recent topics in the automotive industry are electric 
mobility and autonomous driving. Both themes were innovated and made popular by 
startups, which did not originate from the existing automobile industry. The name Tesla 
is closely linked to the electromobility, and Google is one of the pioneers when it comes 
to autonomous driving. Both concepts have increased in demand so much that almost 
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all established manufacturers have now put these topics on their own research and pro-
duction agendas. 
This essay demonstrated that the regulatory framework for healthcare enterprises in gen-
eral, and startups in particular, acts as one barrier to entry into the market. Becoming a 
standard part of care takes a long time in Germany and the US. The process is expensive, 
complex, and lacks transparency. It will be necessary to equalize the regulatory require-
ments for healthcare technologies between the countries, at least within Europe, to 
simply the processes in a transparent way with binding deadlines and clear responsibil-
ities. 
Digitization in healthcare is a relatively new trend. It will change the art of providing 
healthcare. Within this trend, digital health startups will asset the pace of development 
to surpass the technology available through incumbent companies. Startups may be one 
puzzle piece to achieving the triple aim of healthcare: better quality and better patient 
experience at lower costs (Berwick et al 2008). In addition to their meaning within the 
healthcare system, startups are important regarding economic and employment growth. 
In conclusion, to achieve digitization of healthcare and improve care in the US and Ger-
many, regulations must be changed to promote innovation from digital healthcare 
startups and other companies taking steps to digitize the health system.  
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As healthcare continues to see both vertical and horizontal system integration, sys-
tems struggle to handle large aggregates of patient data. Big Data has aided in re-
ducing costs and increasing profits, in understanding patient risk stratification, and 
helping to determine appropriate interventions. More recently, widespread dissatis-
faction with overall healthcare costs and suboptimal quality has led to healthcare 
leaders searching for new strategies to improve. Big Data not only affords physi-
cians an epidemiological insight necessary to implement widespread change, but 
also uses retrospective insight, pattern recognition, and predictive power to offer 
direct and indirect interventions, often coupled with devices or preexisting inter-
ventions. Despite some challenges in addressing patient privacy, the paradigm shift 
from singularly managed patients and data to Big Data systems is underway. Big 
Data methodologies construe the provider as an agent within a larger community or 
population organism, one that must adapt and change to suit the needs of those it 
serves. It allows for the provision of better care, in terms of the care itself provided 
and the logic of its distribution. In the right hands, if Big Data is the face of 
healthcare’s future, it will be a humanitarian one.  
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1 Big Data: From ‘Me’ to ‘We’ 
As healthcare expenditures in the United States continue to rise to levels well above the 
national inflation rate, there is a continued interest and obligation to shift towards strat-
egies and innovations that contain costs and further improve quality and outcomes. 
Though the United States spends almost twice the OECD average on healthcare spend-
ing (in USD per capita), national quality and outcome benchmarks continue to place 
well below those of less developed countries. For a country that often fashions itself as 
a world-best provider of healthcare, the growing chasm between healthcare expenditures 
and outcomes has led to the prioritization of reforms and new initiatives aimed at miti-
gating this discrepancy. As medical record keeping and documentation moves towards 
electronic platforms, large datasets are available for computational analysis, often re-
vealing patterns, trends, and associations on the individual and group level. In recent 
years, ‘Big Data’ has been a trending topic for many in the healthcare industry, allowing 
systems to utilize technological advances and opportunities in the hopes of providing 
better care, while lowering costs in the process.  
The consideration of Big Data in studying population health only began about 200 years 
ago (Siemens Healthineers, 2015). In tracking the cholera epidemic throughout London, 
John Snow’s map helped to dispel the miasma theory and locate the source of the out-
break. In in the brief span of time thereafter, there has been much improvement in trend-
ing and forecasting, largely due to technology. The application of epidemiological pur-
poses has gradually undergone a paradigm shift from individual tracking to tracking for 
population health benefits, resulting in technologies and device adaptation to allow for 
both of these activities during data collection. From a financial perspective, Big Data 
has allowed systems to identify opportunities to improve profits and reduce overhead 
(Bresnick, 2017). Electronic Medical Records (EMRs), for example, have allowed phy-
sicians and health systems to collect large quantities of data and patient information, 
which can then be used for risk stratification, to forecast patient trends, and to identify 
possible interventions.  
Considering both perspectives, Big Data has fostered an innovative methodology for 
systems: data gleaned from the individual are used to attain better understanding of the 
overall population -- and vice versa. On the one hand, Big Data is often used in the 
service of heavily-personalized medical care pathways as part of a strategy to help guide 
patient care throughout a patient’s care encounter; said strategies fall under the umbrella 
of what is commonly deemed 'population health management'. On the other, aggregated 
data is used to study disease trends for populations and to tailor community-based inter-
ventions and strategies, which may then contribute to improved population health 
through decreases in patient morbidity and mortality. Furthermore, countries with aging 
populations can use data to try and find far-reaching solutions to manage patients with 
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high disease burden and chronic care issues (Bresnick, 2017). But with such widespread 
opportunities for health improvement come manifold challenges in the spheres of im-
plementation and regulation, especially as pertaining to patient privacy.  
2 Transition to Big Data: Why Now? 
Widespread public dissatisfaction with overall health care costs and soaring premiums 
has led to wide-spread dissatisfaction with current reimbursement schemas. The shift 
from fee-for-service (FFS) models to value-based models of care has resulted in new 
ways to quantify success in disease management at both the individual and system level, 
contain costs, and enable equal access to and quality of care. This shift, initiated by the 
Affordable Care Act (ACA), also precipitated a shift in reimbursement methodologies 
toward an emphasis on patient outcomes, which in turn has resulted in many systems 
embracing and accepting Big Data as part of their fabric and foundation (McDonald, 
2017). Value-based reimbursement schemas, such as that targeting a reduction in 30-
day hospital readmissions, have necessitated systems to manage large swaths of patient 
data, to find trends and opportunities for improvement (Koufi, Malamateniou and 
Vassilacopoulos, 2015)(OFIs). Better understanding of upstream social and clinical con-
tributors to hospital readmission allows physicians and hospital administrators to in-
crease communication and coordination through the system; with multiple departments 
working on the same patient and tracking the same information, better care is expected 
to result from increased diligence towards patient communication, compliance, and 
oversight (Groves et al., 2013). 
Bundled payment programs offer another point of intervention for Big Data. Though 
recent administrations have further delayed widespread implementation of this cost con-
tainment strategy, most systems have implemented bundled payments in cardiology and 
orthopedics that help track outcomes and costs through the entire episode of patient care. 
Concurrent with bundled payments, multiple interventions, physicians, and services are 
tracked and tied to quality and improvement, offering further opportunities to improve 
care usage data. However, manipulation of datasets requires additional expertise and 
education, and an efficient data analytics/ information technology (IT) team remains key 
to ensuring that new payment systems are able to be implemented successfully 
(McDonald, 2017).   
Though Big Data is far from a new phenomenon for companies and strategists, the 
healthcare industry represents a large opportunity for its integration and application. Pa-
tient management and patient-centric approaches have been part of the evolutionary 
trends that healthcare in the United States has recently experienced, and the efficacy of 
these approaches stands to increase from the simultaneous adoption of Big Data strategy. 
The shift toward evidence-based medicine has caused physicians to tailor approaches 
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and interventions based on scientifically-verified results that have shown a special de-
gree of promise among patient populations (Bresnick, 2017). Big Data has allowed evi-
dence-based medicine to be collected at a systemic (and additionally, a national) level. 
As systems collect vast amounts of patient information, data may be easily manipulated 
by algorithms to identify trends, successful interventions, and cross-check strategies 
with additional comorbidities. For physicians practicing in regions of the country that 
experience high disease-burden with multiple chronic conditions (ex., rural expanses, 
many CEAC-classified counties, the Deep South), such trending allows them to track 
large groups of patients and see how different interventions influence results and quality 
(Wood, 2017). 
The overutilization of costly technologies and procedures can drive up hospital and sys-
tem spending. Global clinical decision support system markets are expected to rapidly 
rise in the coming years to help address this and other clinical inefficiencies. Such sup-
port systems can aid physicians during triaging, diagnosing, and treatment, which would 
further reduce costs and overutilization of the system. Per reporting by MarketsandMar-
kets, these global support systems are estimated to surpass $550 million by 2018, at a 
compound annual growth rate close to 10% between 2013 and 2018 (Siemens 
Healthineers, 2015). The United States is the foremost user of such systems to date, with 
over 3500 petabytes of stored data within these. Europe follows with about 2500 
petabytes, and then -- a distant third -- Japan with 400 petabytes. As countries continue 
to shift to EMRs and computerized systems with greater integrative potential, Big Data 
will be more available to them, leading to expected increases in petabytes stored. Re-
ducing costs is hypothesized as the main driver of this increased uptake, though im-
proved quality and care outcomes, aging populations, and rising disease incidence also 
play important roles in the uptake.   
3 Current Uses of Big Data in Device Sector 
The increased utilization of medical apps and smartphone technology has presented a 
new opportunity for patient tracking and Big Data management. In 2016, mobile health 
raised $1.3 billion between 622 completed deals, constituting the largest component of 
total healthcare IT virtual care (VC) funding (Mukherjee, 2017). Increased utilization of 
smartphones in emerging markets solidifies their place in future markets. Public senti-
ment is arguably in line with the data: some research has even indicated that over two-
thirds of Americans have shown favor for digital health over physical (Elias, 2015). As 
wireless technology plays an ever-larger role in the day-to-day lifestyle of a working 
American (i.e., forty-hour workweeks, heavy childcare and supplemental domestic work 
burdens), prioritizing convenience and ease-of-access will lead more systems to focus 
on tech-based platforms for patient interactions. Health smartphone apps currently have 
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the highest number of downloads of any category of application (Elias, 2015). Consum-
erization will further drive physicians to adapt a new, tech-friendly practice, at risk of 
network leakage to other practices and physicians should they fail to adapt. Regardless, 
this technological integration of medical information into the hands of patients and con-
sumers will only continue to drive innovation. A concurrent trend is unfolding in wear-
able devices; serving as a bellwether for this new trend, FDA Commissioner Scott 
Gottlieb has recently written of a 'Digital Health Innovation Plan' that would allow third-
parties to easily and rapidly certify new products that are not as ‘high risk’ as devices 
(Gottlieb, 2017). It would be expected that Big Data and patient tracking/monitoring 
apps (Fitbit, etc.) will continue to expand offerings on the market (Ventola, 2014). 
As a physician’s tools for diagnosis shift from stethoscope to smartphone, and the doc-
tor’s office waiting room shifts to the patient’s living room, other non-patient facing 
areas of medicine are also utilizing virtual platforms. One promising current technology, 
teleradiology, allows for the storage and transmission of radiological images. This Big 
Data trend comes as a way to ease the access issues radiologists and other physicians 
experience when trying to compare images, interpret images, and use images as part of 
evidence-based medicine. Picture Archiving and Communication systems (PACS) is 
just one example of an IT system used currently (Benjamin, Aradi and Shreiber, 2010). 
Teleradiology and PACS allow for improved clinical results (final reports that contain 
useful information) and business results (in scenarios of improved speed of result turn-
over, patient care, etc.). SuperPACS—a system that allows radiology group serving mul-
tiple sites having disparate PACS, research information systems (RIS), and reporting 
platforms, to view these sites as virtually one site and use one desktop (Benjamin, Aradi 
and Shreiber, 2010)—help improve global functionality of the radiological sector. Min-
imizing the burden on local sites and increasing the global nature of the images and 
information helps to standardize the practice and better identify workflow issues and 
opportunities for improvement. Additionally, implementation of such systems allows 
for global access for all referring physicians. Using SuperPACS portals, physicians are 
able to access information and have a central location and folder for their patients. This 
sort of communications technology has been reported to be cost efficient, increases re-
mote access to data, and is a logical solution to manage multiple files across multiple 
locations as the United States continues to see mergers and acquisitions throughout the 
healthcare and hospital industry (Groves et al., 2013). Unlike other technologies and 
innovations in radiology, this particular example and application places radiologists as 
some of the main stakeholders in application, increasing buy-in.  
4 Further Reforms and Opportunities in Big Data 
Applications and use cases or opens up the potential for interventions and opportunities. 
The ability to aggregate patient data has been present since the introduction of EMRs, 
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though the brunt of the healthcare industry’s capacity to analyze and manipulate these 
data has only come into play the past couple of decades. As technologies continue to 
improve and the capability of Big Data extraction expands, healthcare will see furthered 
developments involving Big Data and healthcare IT. A McKinsey analysis listed four 
categories that most, if not all, healthcare-related Big Data encompasses (Kayyali, Knott 
and Van Kuiken, 2013). As healthcare IT continues to expand, and technology increases 
consumerization, we may expect to see further varieties of Big Data.  
4.1 Retrospective Insight 
Prior to more recent years, initial applications of Big Data have focused on retrospective 
insight via retrospective data analysis. Applications and technologies were equipped to 
take large sums of data and analyze them for researchers. Previously -- and, by most, 
currently -- patient safety was studied in retrospect: clinical events were identified after 
being flagged for issues, and then analyzed to identify opportunities for improvement 
(Weinger et al., 2003)(OFIs). Reducing medical errors and safety concerns is a common 
goal of systems, and ties into many reimbursement schemas. Big Data, when applied 
retrospectively, is simply one of the parts to the pathway to reduce medical errors. Data 
must be extracted from flagged patient files and stratified to identify breakdown and 
issues in the workflow. Usually in-house committees study these and find common flaws 
that can be disseminated to medical staff in an effort to reduce future instances of work-
flow breakdown. While this approach has been the common norm for most system struc-
tures and data reporting, real-time monitoring and flagging of misuse or issues would 
likely increase safety and quality outcomes in healthcare systems.  
4.2 Predictive Power 
Pattern recognition artificial intelligence has been proposed as one of the more promis-
ing innovations for the future of radiology. Though this does not require radiologist 
stakeholders, the technology could vastly improve the efficiency and accuracy of imag-
ing. However, research is varied and inconclusive at this stage. The issue of contention 
is that, though pattern recognition can provide great promise, it requires a pseudo-cus-
tomization that makes it difficult to implement quickly across systems. In a study (Woo 
and Kim, 2017), utilization and application of US, CT, MRI technologies was shown to 
have led to an increase in the frequency of small renal masses being detected. This re-
sults in more renal cell carcinoma and benign tumor diagnosis, but no one pattern was 
found to be sufficient; rather, multiple imaging patterns should have been considered in 
tandem to then begin to narrow down remarkable images and possibly note malignancy. 
Should several imaging patterns be integrated and an algorithm created, then there could 
be a potential for widespread use of pattern recognition, hopefully leading in turn to 
faster image interpretation with less error. Though initial investments in technology 
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would be quite costly, the return on investment would be more than enough to recoup 
startup costs, as systems could reduce the amount of budget allocated to overhead costs 
(specifically: personnel) in the department. Currently, Houston Methodist Hospital em-
ploys AI technology that interprets breast x-rays 30 times faster than physicians, and 
which diagnoses with 99% accuracy (Patel et al., 2017). Though there is a fear that cur-
rent pattern recognition and the incorporation of AI will eradicate jobs among radiolo-
gists, the coexistence of human and machine is an inevitable phenomenon as automation 
increases and most studies indicate that AI is unlikely to replace radiologists 
(Krittanawong, 2017). To compensate for any possible disruption, radiologists could 
continue to subspecialize, and focus on interventions and a more technical application 
of skills, ones not yet able to be imitated by digital counterparts. 
Simultaneously, predictive power can also be applied to help detect and prevent further 
fraud, waste, and abuse. Systems use patient bills and records to analyze trends and de-
tect anomalies such as overutilization of services, discrepancy of treatment spanning 
several hospitals within a system and lack of coordination around diagnoses, and pre-
scription filling issues. For example, in implementing Big Data, the Centers for Medi-
care and Medicaid Services (CMS) prevented more than $210.7 million in healthcare 
fraud in a year (McDonald, 2017). Similarly, after transitioning to a predictive modeling 
environment, UnitedHealthCare generated a 2200% ROI after developing methodology 
to identify inaccurate claims (McDonald, 2017).  
4.3 Data Management: Population Health 
Big Data’s role in population health is not a novel application; however, its potential 
applications are great and can have a larger impact than present-day. Big Data is able to 
help providers assess and manage the risk of the populations they serve. Disease trend-
ing can allow practitioners to prioritize and strategize initiatives that are most far-reach-
ing for their populations. Community clinics, coalitions, and health fairs are becoming 
more common as health systems try to increase market share, and provide improved care 
for their patients and catchment areas.  
4.4 Direct Intervention 
Diabetes Mellitus (DM) I and II monitors, and continuous feedback loops, have been 
enabled by the application of real-time Big Data. In constantly relaying information back 
to a physician or device manufacturer, trends can be analyzed, using target values to 
indicate when insulin injections are automatically needed (Ventola, 2014). Technologies 
such as these alleviate the disease burden on the patient, allowing them to potentially 
live life with less expenditure of effort. In the case of DM patients, continuous feedback 
devices alleviate the need for the patient to rely on timekeeping values and self-injec-
tions. For younger patients (DM I), and those with anxiety and aversion to injections 
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(DM I or II), continuous feedback devices do the work for the patient and only require 
routine checkups with the physician and device manufacturer. Large aggregations of 
patient data also allow physicians to not only study individual disease trends, but also 
study trends within the patient population in general (Ventola, 2014). This enables them 
to improve practices and workflow processes. This technology is more cost-efficient 
than traditional insulin injections and physician visits. Additionally, continuous im-
provement would drastically decrease ED and physician visits as a result of unmanaged 
diabetes. Reduction in unnecessary admissions could further help drive down healthcare 
expenditures.  
Wearables, those less invasive than the continuous feedback insulin regulators, also 
show promise and hope in using patient data in order to help improve patient outcomes 
in a less invasive approach. Project DETECTED, an “intelligent bra”, is a wearable that 
is able to detect breast cancer with greater acuity than a mammography, while also re-
ducing a patient to unnecessary exposure (Ferenstein, 2012). Temperature sensors that 
screen breast tissue are able to track, record, analyze, and identify inconsistencies. These 
offer an invaluable alternative to mammographies, which have recently been found by 
multiple studies to be less accurate in detection of abnormalities in women with dense 
breast tissue. As over 40% of women currently have dense breast tissue, the inaccuracy 
leads to unnecessary biopsies and a furthering of costly technologies and surgeries. As 
systems try to consolidate costs, devices such as these offer the possibility for major cost 
savings and convenience for providers and patients.  
5 Implications for Healthcare & Big Data 
Going forward, the biggest challenge to the use of Big Data will likely be the integration 
of Big Data during the paradigm shift from FFS to value-based care. Value-based care, 
as aforementioned, is organically a more patient-centric approach. As episodes of care 
are redefined and value-based models are implemented, there will be a necessity to up-
grade reporting systems, claims processing, and process automation. Redefining these 
will lead to patient-centric improvements and outcomes as physicians, nurses, managers, 
and other healthcare employees will be encouraged to communicate and work together 
more closely. The alignment of patient and provider incentives, in addition with updated 
technology that could lead to cost transparency, will help to alleviate the current clinical 
nuance that plagues the system.  
Alleviating the clinical nuance between provider and patient will help to transform cur-
rent systems from low-value to high-value services. Current models, by contrast, pit the 
provider and patient against one another and the incentives for patients may not fit into 
standards and benchmarks set for physicians -- and vice versa. 
Patient privacy is one of the top concerns when considering the implications Big Data 
may have on a system. In light of the summer 2017 cyber-attack on England’s National 
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Health Service (NHS), additional protections and firewalls should be mandated for Big 
Data sets, especially those stored in cloud-based platforms (Gordon, Fairhall and 
Landman, 2017). Unfortunately, studies have cited low organizational vigilance, inade-
quate staffing and training, and insufficient technology investment as enablers for the 
susceptibility to healthcare data attacks. With more than 50% of hospitals reporting at 
least one ransomware attack in the past 12 months, increased budgetary allocations to-
wards intensive training and IT upgrading is an absolute necessity of health systems 
(Gordon, Fairhall and Landman, 2017). Inquiries into the cyberattacks indicated that, 
while providers had been warned about possible NHS attacks, several computer and 
processors were outdated and unable to access and download the firewalls necessary to 
prevent the ransomware attacks. While ‘Big Data methodologies’ greatly facilitate col-
lection and analysis of data, the pressure to stay abreast of security developments in the 
IT landscape poses a severe, essential challenge, given that the penalty for failing to do 
so can be no less than total data exposure (Harsh, Patil and Seshadri, no date).   
6 Conclusion 
Healthcare’s greatest challenge in the era of Big Data will be the necessity of providers 
to stay updated to change processes, especially with respect to informational security. 
Continual education and training will need to be added as security updates and techno-
logical advances become common-norm of healthcare practices. In particular, Big Data's 
storage on cloud-based applications requires a market level of protection. The Health 
Information Technology for Economic and Clinical Health (HITECH) Act was enacted 
in 2009 to extend HIPAA’s requirements to all parties that have access to protected 
health information (PHI) (‘Big Data and Health Disparities -Zhang et al., 2017), but in 
light of recent provider data breaches, more remains to be done in this area. 
As current payment reforms help to alleviate the divide between patient and provider, 
there will be a new clash—an exaggerated one—between providers and other stakehold-
ers. Owners or manufacturers of imaging technologies may use Big Data to identify 
underserved patients and disease areas. While possible to be construed as an attempt to 
provide overall improvement to population health, this initiative could exacerbate 
overutilization of healthcare, leading to an increase in provider costs. 
Such phenomena are the growing pains of paradigm shifts. Reconceiving the way pro-
viders think about the provision of care necessitates similar shifts in methodologies, 
workflows, even technologies. And this particular adjustment, this motion from 'Me' to 
'We', is one to be embraced, both for its cost-saving potential and for its intrinsic philos-
ophy of holism. Big Data methodologies construe the provider as an agent within a 
larger community or population organism, one that must adapt and change to suit the 
needs of those it serves. It allows for the provision of better care, in terms of the care 
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itself provided and the logic of its distribution. In the right hands, if Big Data is the face 
of healthcare's future, it will be a humanitarian one.  
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Big Data: A Panacea to the Health Care System’s Challenges? 
Valmir Hajdari 
In the last two decades, “Big Data,” the analytics of enormous amounts of data files, 
has had an exponentially growing impact on the economy. Software solutions are 
being heavily researched, although so far, both technological and scientific ad-
vances are not developed enough to create programs able to accommodate the nec-
essary sample size and thus, truly reliable information. There are countless possible 
applications for “Big Data” analyses, especially in industries that heavily rely on 
statistical data sets, such as the health care sector. Due to the current lack of software 
solutions capable of coping with the large data sets, today’s analysis and usage of 
“Big Data” is limited. Nonetheless, today’s software is still able to sort through 
unstructured patient data much faster than any manual process could. The results of 
first programs in the US have shown great potential in solving problems in health 
care. These improved financial savings, as well as being able to take preventive 
measures concerning certain diseases, through to the data analysis of a whole soci-
ety, and even saving lives by accelerating diagnostic procedures. Although there are 
certain concerns about privacy and security, this paper shows that in the future “Big 
Data” analysis will tackle numerous heath care related problems and increase the 
efficiency and efficacy of public health. 
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1 Big Data: Could the Use of Big Data help to solve problems of the Health 
care? 
The first use of the term “Big Data” is documented in a 1997 paper by NASA scientists. 
They described an issue which concerned the problem of the visualization of large data 
sets (Cox, 1997, p. 235). “Big data” as it is understood today, is defined as large elec-
tronic records which are so large and complex that they are almost impossible to analyze 
with conventional software programs (Kayyali, 2014, p. 2). A report from 2012, which 
was presented to the US Congress, defines “Big Data” as: "large quantities of high-
speed, complex, and variable data that require advanced techniques and technologies to 
facilitate the capture, storage, distribution, management and analysis of data" (IHTT, 
2014). The data management tools developed so far are inadequately suited for manag-
ing these records (Frost & Sullivan, 2015). “Big Data” is not only unique because of the 
volume, but also because of its variety and velocity (Frost & Sullivan, 2015).  
 
Looking at health care, we can see that the health care system historically has collected 
and stored a very large amount of data (Kayyali, 2014, p. 5). The numerous records and 
measurements of patient and hospital information can be defined as “Big Data”. It in-
cludes data such as medical imaging, clinical decisions, doctor's letters, laboratory tests, 
prescription and insurance data, as well as other patient records. However, some patient- 
specific pieces of information, such as social media contributions on social networks, 
can also be part of Big Data (Bian et al., 2012, p. 26). A study published by McKinsey 
sees health care as one of the five sectors with the greatest potential for “Big Data” 
applications (Kayyali, 2014, p. 2). Compared to the past when the data was mostly avail-
able in printed form, the trend nowadays is heading further towards the digitization of 
these existing data sets. Numerous healthcare challenges (demographic changes, co-
morbidities, etc.) and the rising cost of healthcare have led many researchers to believe 
the vast amount of data is the solution to many problems in health care. “Big Data” can 
be used to support clinical decision making, disease monitoring of a patient, or to im-
prove public health (Fernandes et al., 2012, pp. 38-42).  
 
Previously published reports show the potential uses of health data. According to one 
report, in 2011 alone, a quantity of 150 exabytes of health-related data were stored in 
the US.  Due to the advancing digitalization and technological approaches, the amount 
of data is expected to rise to yottabytes and far beyond this in the foreseeable future 
(IHTT, 2014). For the healthcare industry, the very large amount of data provides nu-
merous opportunities to improve the status quo of health care. An algorithm that would 
be able to understand all this data and connect them in the right order could potentially 
lead to lower costs in health care, and therefore improve public health. The use of “Big 
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Data” in health care thus holds many significant advantages available (Ikanov, 2014, p. 
4-7). 
 
This essay will examine if the use of “Big Data” could help to solve problems of the 
health care system. It provides an overview of data analysis in the health care sector. It 
is shown what benefits of Big Data could have for the health care. Afterwards, the char-
acteristic properties of “Big Data” are described in more detail, followed by an architec-
tural framework of big data analytics for healthcare and some examples of “Big Data” 
in current use. 
2 Big Data analytics in Healthcare 
Data analysis refers to the examination of data sets which is intended to draw a conclu-
sion from the displayed data (Ikanov, 2014, pp. 4-7). Data analytics is used in all busi-
ness areas. For example, it may be used to help determine the favorite car color of the 
population for the respective year, or how the new electronic product launch was 
adopted on the market. In costly emergency care, data analysis can help select the most 
efficient treatment and preserve resources. Additionally, data analysis can also provide 
improvements in preventive care, including predictions of population-related diseases 
and preparations for preventive treatment (Ohlhorst, 2012). “Big Data” can also be used 
to provide prognoses for specific epidemiological developments or ensure that special-
ists are already preparing for a case of flu before the outbreak of a flu epidemic. Medical 
research, especially, can benefit greatly from “Big Data”. The ability to collect all data 
from a particular case and then filter it according to specific results helps to draw the 
right medical conclusions about a disease (Deross et al., 2011, pp. 52-67). 
 
Due to the new possibilities such as the Big Data, medical research and the rising cost 
pressure in medical treatment, the health care sector has had to redefine the reimburse-
ment models. The trend of reimbursement models has gone from the fee-for-service 
variant to diagnosis-related case groups with flat-rate reimbursement rates. In addition, 
models such as the “pay-for-performance” are gaining more and more interest from the 
cost carriers. The “pay for performance” model is primarily about achieving a certain 
treatment outcome and, in the best case, surpassing this result (Burghard, 2014). The 
better the treatment outcome at the end of a medical intervention, the higher the service 
provider is compensated for his or her services. However, the additional financial profit 
should not be the only reason for the implementation of “Big Data.” Improvement of 
treatment quality as well as treatment result are reason enough for the implementation 
of “Big data” analyses. (Lavelle, 2011, pp. 23-25). 
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3 The characteristics of Big Data – Volume, Variety, Velocity 
“Big Data” is defined by three main features: volume, velocity, variety. Over time, 
health-related data is still being created and collected continuously, with a vast amount 
of data coming together. Although this technical progress has some negative effects, the 
positive developments and improvements far outweigh the costs. Advances in data man-
agement, especially in the context of the visual mix and cloud computing, allow for more 
effective data collection, storage and evaluation (Feldman et al., 2011). The health-re-
lated data can now be accumulated in real-time and at a very high rate. This ever-in-
creasing data represent new challenges. With the increased volume and the change in 
the variety of old, accumulated and new data, new algorithms for retrieving, analyzing 
and comparing the data are necessary in order to arrive at a result-oriented treatment 
decision. 
 
Previously, the majority of health data was statistically comparable files in paper form, 
such as radiographs and medical reports. Nowadays, a large part of the health data con-
sists of real-time data from patients, which could be analyzed in real-time (Feldman et 
al., 2011). For example, a particular algorithm could use the data of the operating room 
monitor in real time to suggest a specific treatment recommendation or a particular med-
ication. The analysis of real-time data may in some cases make the difference between 
life and death (Ikanov, 2014, pp. 4-7). An example of this could be automatic defibril-
lators which read the analyses the patient’s heart rhythm and suggest treatment. 
 
Through the future use of programs that analyze health data in real time, service provid-
ers would be able to reduce mortality and morbidity of the patients with proper and 
quickly-implemented treatments, and possibly even prevent whole disease outbreaks. 
An example of this real time data analysis in healthcare in current use is the monitoring 
of newborns via real time streaming in some Intensive Care Units (ICU), allowing the 
interception of life threatening infections (IHTT, 2014). The possibility to analyze and 
evaluate all the collected data of an individual patient would greatly improve the health 
of the individual but also of the society (Feldman et al., 2011). 
 
3.1 Structured, Unstructured and semi-structured Data 
Not only the amount, but also the nature of health data has changed over time. Therefore, 
future algorithms and analysis methods will have to adapt to new job and economic 
environmental conditions in order to counteract the speed, the volume and the diversity 
of the data being collected. In fact, the health data are more of a multimedia format and 
are often unstructured. The high number of structured, unstructured and semi-structured 
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data provides the health sector with interesting challenges that must be solved in order 
to ensure a functioning analysis of health data (Feldman et al., 2011). 
 
Structured data is used to describe data that is easy to query, store, retrieve or even ana-
lyze. In addition, structured as well as semi-structured data contain electronic recordings 
of the instruments and other digital examination data. Further, all the data converted 
from paper form into electronic data are also added to this group of data. Unstructured 
data is the common form of data that arise during the care of the patient. These include 
hand-written notes of care, prescriptions, examination images (MRI, CT), etc. Nowa-
days, there are also many ways to gather data about one’s own health (Manyika et al., 
2011). There are smart watches and fitness machines which, if desired, that are capable 
of recording vital functions and many other health data. Also, on social media platforms, 
many tools are offered to check out one’s own constitution, such as track measuring 
devices. However, the evaluation of this data is far from being as efficient as desired. 
An actual synthesis of all data to ensure an evidence-based result is not currently possi-
ble. Therefore, to make an interpretable result from this data, it requires more efficient 
programming capable of evaluation of all collected data, as well as the ability to perform 
an automatic conversion of unstructured as well as structured data (Kesh et al,. 2007, 
pp. 39-57). 
 
Consequently, it is stated that the positive potential of “Big Data” lies in the merging of 
all possible data types. The synthesis of data can help individual patients, as well as an 
entire population. Today, the large amounts of data support scientific research and de-
velopment of new processes or pharmaceuticals (Manyika et al., 2011). Enhanced data 
synthesis could assist the development and approval of improved medicines at cheaper 
prices and in a faster time period. Also, the prescription of the best possible therapeutic 
option could be made easier and more effective by the use of “Big Data” (Feldman et 
al., 2011). “Big Data's” potential to improve efficacy and decease cost is very high 
throughout healthcare and can lead to the resolution of many current challenges. The 
scarcity of resources and the consequences of the demographic changes could be miti-
gated by “Big Data”. 
 
3.2 The fourth characteristic of Big Data – Veracity 
Beside the three stated characteristics of “Big Data,” volume, variety and velocity, 
scholars have introduced a fourth characteristic feature called veracity. It describes the 
flawlessness and credibility of “Big Data” sets, as well as their analysis and results. 
Genuine matching data, especially in health care, is of immense importance (Fernandes 
et al., 2012, pp. 38-42). Genuine means that the data must be correct and true, and that 
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the records must be complete. Any decision based on false evidence, in the worst case 
can decide between life and death. In particular, the unstructured data, which usually 
arise during the care of the patient, must be checked for their veracity, as this data and 
its analysis is often very difficult and can produce incorrect results. An example of un-
structured data causing poor veracity is the handwriting of a doctor, which can be diffi-
cult to read and difficult to interpret, resulting in an end point error. This can lead to a 
false prescription of medicine or worse, even death. (Feldman et al., 2011). 
 
Veracity is a characteristic which not only is required in health care, but also covers all 
economic sectors, especially on the payers' side. In many treatment cases the reimburse-
ment of a large amount of money is necessary and therefore the correctness of all data 
is a prerequisite (including the correct patient, hospital, DRG code, money amount, treat-
ments, and prescriptions) (Fernandes et al., 2012, pp. 38-42). In order to achieve accu-
rate yearly results, it is extremely important that all relevant data correspond correctly 
to the event. 
4 Architectural Framework for Big Data analytics 
The conceptual framework for a “Big Data” analysis project is very similar to the widely 
available health information systems or other analysis programs (Fernandes et al., 2012, 
pp. 38-42). The basic difference lies in the processing execution. Because analysis of 
“Big Data” is to be done with very large data sets, the processing of this data is divided 
into several sections. This method is not simple due to the high volume of data. In addi-
tion to the large size, the variety of data is also a reason to divide the data (Deross et al., 
2011, pp. 52-67). The processing of such large data sets is a recent development. With 
the processing of “Big Data,” various service providers hope to be able to make better 
informed health-related decisions, and thereby save resources. The algorithms and mod-
els for processing “Big Data” are very similar to the existing analysis tools. The user 
interfaces used to edit “Big Data”, on the other hand, differ completely from the tradi-
tional data analysis programs. This is, on one hand, due to the volume and the variety of 
the data, and on the other hand to the diversity of results displayed. The conventional 
data analysis tools are generally very user-friendly and transparent. Data analysis tools 
for “Big Data”, conversely, are very complex, require a great deal of skill in the evalu-
ation and visualization of the results, and they are also highly program-intensive. The 
complexity of the programs results from the high complexity of the data sets (Capgem-
ini, 2013, p. 4). The content of “Big Data” in healthcare can come from internal or ex-
ternal sources. The internal sources are the electronic patient records, clinical reports on 
treatment and diagnosis, and computerized physician order entry, etc. Data from exter-
nal sources can come from pharmacies, insurances, labs, etc., and are available in dif-
ferent formats from different locations (Lavelle, 2011, pp. 20-32). 
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In the first step, the data must be pooled before processing. The data is still raw at this 
time and must be processed or transformed into system-compatible formats in the next 
step (Kesh et al., 2007, pp. 39-57). The data can also remain in the raw form and can be 
processed by commands. Another possibility to edit “Big Data” is the so called “data 
warehouse.” With a data warehouse, data from different sources are aggregated and 
adapted for processing. After extracting, transforming and uploading the data, these are 
cleaned up and prepared for analysis. Depending on whether the data is structured or 
unstructured, several data records can also be entered into the data analysis programs 
for processing (Ikanov, 2014, p. 5). 
 
In the next step, when creating a conceptual framework, further decisions must be made 
regarding individually relevant functions. It is, for example, necessary to decide which 
possibilities for editing or inputting information must be available. It must also be de-
cided on possible transmission functions to other carriers or devices. Of course, deci-
sions on the tool selection for processing the data records are still required. 
 
An existing platform for data processing of “Big Data” is offered by the freely accessible 
Hadoop program. This platform has the possibility to edit very large records by distrib-
uting the records to different servers which work parallel to the solution of the problem. 
Finally, the results of all servers are integrated into one (Deross et al., 2011, pp. 52-67). 
Hadoop has great potential for the processing of large data sets and thus allows compa-
nies more alternatives. However, the operation of Hadoop can be very difficult as there 
are limited professional staff who are able to use this program. Furthermore, the software 
is difficult to install, maintain, and configure and qualified employees are rare and very 
costly. Nonetheless, the program is a first step in the right direction to solving future 
challenges in health care via “Big Data” analysis. 
5 Applications of Big Data in health care 
Several “Big Data” applications are already in use today. These programs have mainly 
been implemented to either achieve advanced cost efficiency or to streamline medical 
processes and treatments. In one example, IBM reported the usage of a software tool by 
an unnamed, large healthcare provider that collects and analyses unstructured data sets 
such as physicians notes and reports. Through this process, the data is available quicker 
which reduces the time sorting through documents and thus saving cost (IBM, 2014). 
 
A different approach is being taken by the Columbia University Medical Center. Their 
“Big Data” program aims to analyze data files of patients with brain injuries. Correla-
tions that signify serious complications can be diagnosed up to 48 hours faster than by 
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a manual sorting processes (IBM, 2014). Furthermore “Big Data” programs can have 
unforeseen positive effects as well. While creating a “Big Data” set, the US insurance 
company, Kaiser Permanente, found adverse effects concerning a drug used to treat 
rheumatic pain which has since been withdrawn from the market. A similar process was 
used to classify groups of persons with increased risks of developing diabetes. “Big 
Data” software can therefore not only be used to tackle economic issues, but also to 
further scientific medical discoveries as well (IHTT, 2014). 
5.1 The Data Revolution 
Nowadays, a large data revolution is in progress, especially in the health care sector. 
There are many different reasons for this, but above all, this is happening due to the 
strong increase in the availability of information. Over the past decades, many pharma-
ceutical companies have gathered years of research and development data into medical 
databases. Suppliers and payers have also participated in the digitalization process by 
introducing an electronic patient records, among other things. Gradually, the US federal 
government and other public interest representatives have opened their medical infor-
mation in the form of data for research purposes. This includes data from clinical trials 
or patient-related information. 
 
In the case of “Big Data,” cost-policy considerations are also the most powerful drivers 
in the demand for big data solutions. After a steady increase over the past 20 years, US 
health spending has risen to 16.4 percent of GDP (OECD, 2014, p. 219). This value 
corresponds to nearly $600 billion more than the benchmark for a country of the size 
and wealth of the USA. In order to counter the resource shortage, many payers like 
Medicare and Medicaid have changed their remuneration system from fee-for- service 
model, which rewards the service provider, to high-volume risk sharing agreements that 
prioritize results. The changes in remuneration have had an impact on pharmaceutical 
companies, as their medication needs to demonstrate evidence-based benefits. With this 
new competitive environment, health care professionals have a strong interest in reduc-
ing the cost of health care spending through “Big Data” applications (Kayyali, 2014, p. 
3). 
5.2 Data protection 
The use of Big Data in health care requires special data protection guidelines and laws 
due to the very sensitive information contained in health care data. The current coalition 
agreement of the Federal Government in Germany already contains keywords such as 
"opportunities for digitization," "telemedicine," "data protection," "e-care" and "elec-
tronic health card." The introduction of the e-health law by the Ministry of Health has 
A Panacea to the Health Care System’s Challenges? 
217 
integrated a roadmap for the introduction of a digital infrastructure with very high secu-
rity standards (Koalitionsvertrag, 2014, pp. 137-144). Furthermore, for the evaluation 
of health data, a high level of data protection is required in order to obtain public ac-
ceptance for the use of Big Data. For example, the start of the big-data project "care 
data" of the Health and Social Care Information Center (HSCIC) in Great Britain had to 
be postponed because the confidentiality of the health data to be evaluated, the cancel-
lation in the event of a contradiction from a patient, and the limitation of the data eval-
uation could not be guaranteed. In addition, the data could also have been used and 
abused for police and commercial purposes (Striegler, 2014). 
 
Without a public conversation about Big Data and technical and legal solutions regard-
ing data protection, etc., there will be no acceptance for Big Data in society overall or 
in health care, specifically. Ensuring a high level of acceptance and ensuring a high level 
of security when using Big Data are two tasks to fulfill. 
5.3 Advantages of Big Data for health care 
Due to the digitization and the effective use of large data, health care organizations have 
been able to gain significant advantages (Burghard, 2014). Among other things, diseases 
can be recognized and treated in earlier stages than before. In addition, numerous ques-
tions which have not been answered so far can be solved by the use of “Big Data.” 
Certain developments or results may be predicted and estimated by the analysis of col-
lected data (e.g., Length of stay) and therefore, be better controlled. Potentially medi-
cally-unsuitable interventions also can be canceled in advance due to extended data anal-
ysis which can provide information about possible complications (including bleeding, 
clotting, rejection) or the possible risk of infection of a patient (Burghard, 2014). Ac-
cording to McKinsey's business consultancy, “Big Data” and the use of data analysis 
could save up to $300 billion a year in US health care. Two-thirds of $300 billion would 
be generated by an eight percent decrease in the current health issues because of a re-
duction in health expenditures. In addition, according to McKinsey, $165 billion could 
be saved in the field of clinical operations, and $108 billion could be saved in in the field 
of research and development (Manyika et al., 2011). In principle, McKinsey states that 
the use of “Big Data” can reduce the waste in healthcare and, in addition, it can improve 
efficient treatment of patients. For example, “Big Data” makes it possible to perform a 
precise comparison between different treatment methods at a clinical operations level, 
thus providing a response to more cost-effective treatment methods. Additionally, more 
effective treatment methods can be converted into treatment guidelines with a better 
result in the treatment of the patient. The use of “Big Data” has a positive impact on the 
patient and the care provider. 
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“Big Data” could also be used in research & development. By using different algorithms 
and statistical methods, the different clinical studies can be carried out more precisely 
and more effectively. For example, the choice of the trial design or the determination of 
the participants in a study opens possibilities for more suitable practice through data 
analysis, since all relevant details are included. Furthermore, the subsequent analysis of 
the clinical trial is detailed by an algorithm and thus ensures the unwanted effects of an 
intervention can be quickly recognized (Manyika et al., 2011). 
 
Important long-term changes can be also generated in public health. Through the use of 
an algorithm, real-time data can perform the monitoring of certain diseases, thereby al-
lowing for a better understanding of the causes and spread of these diseases. In addition, 
the results obtained can be used to improve public health. Intervention of a possible 
influenza wave or epidemic may also be made quicker by the analysis of health data and 
thus protects larger population groups (Manyika et al., 2011). The use of all accessible 
data also makes the development of interventions or required vaccines faster. The large 
amounts of data can also be used to determine the needs of patients. This can be used to 
ensure that the services offered to the patient are increased in a more efficacious manner. 
A highly developed public health sector can ultimately lead to improved evidence-based 
medicine (IBM, 2014). By combining data from different areas (clinical data, opera-
tional data and financial data), the most efficient treatment and better care can be imple-
mented. The use of “Big Data” and the corresponding data analysis, therefore, has fi-
nancial and qualitative improvements in health care for the stakeholders as well as the 
patients. 
6 Conclusion 
A usable and effective data processing platform that makes it possible to use “Big Data” 
must include the necessary tools for data analysis if it is to improve both efficiency and 
clinical outcomes of the health care system. Important factors in such a platform include 
the user-friendliness of the program, the ability to manipulate the data, the security of 
the private data, as well as the scalability of the system (Bollier, 2010). In addition, real-
time data analysis allows for a quick reaction and important intervention, which is a 
critical prerequisite for healthcare-associated analysis programs. Similarly, the gap be-
tween data collection and data processing should be closed. In addition, special man-
agement questions about ownership and governance of and rules surrounding data must 
also be taken into account. The fact that health data is often not standardized should also 
be addressed when creating a big data analysis program (IHTT, 2014). 
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The analysis of large data records, called “Big Data,” has the ability to improve the 
health economy. “The use of Big Data” has the propensity to change the ways of think-
ing in the health care system by using new technologies and taking into account large 
data sets. On the one hand, the new findings may reveal new treatment alternatives, and 
on the other hand, “Big Data” can reduce the consumption of resources and improve the 
financial efficiency in health care. Therefore, it is only a question of time as to when 
“Big Data” will used, via appropriate programs, for the benefit of the health care sector. 
Furthermore, of course, all the issues mentioned above must be addressed. Privacy, in 
particular, should be taken into account. The violation of privacy would mean a serious 
loss of public trust in “Big Data” and therefore in healthcare. This could delay the entire 
implementation of data processing with “Big Data” or prevent it completely. 
 
In general, the use of “Big Data” can help solve numerous health-related  problems. 
Advantages of such applications range from furthering cost savings, or being able to 
take population based preventive measures, to even saving lives by accelerating diag-
nostic procedures. Furthermore, precisely planned treatments can be used to avoid wast-
ing resources and double testing. Predictions of different scenarios, such as influenza 
epidemics, are also made more possible by analysis of “Big Data.” For “Big Data” anal-
ysis to be advantageous and not misleading, the data sets must be large and extensive 
enough. This leads to concerns about both privacy and security.  
Nonetheless, a widespread availability of “Big Data” software solutions could tackle 
these issues while solving problems in all areas of the health care system.  
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The Public Health System in Germany and the U.S. 
 – a Comparison 
Verena Schiefelbein 
The main goal of public health is to prevent disease and to promote health. To reach 
this aim, it is important not only to focus on health education, but also implement 
policies. Although the American and German public health systems are structured 
in a similar manner (federal, state, and local-components), the American system is 
unique in that it is particularly fragmented, with many people uninsured and health 
care costs which are exceptionally high. Prevention is one of the most important 
aspects of public health as it not only includes measures that reduce risk factors and 
lower the probability of acquiring a disease, it also stops the progression of a disease 
or reduces the consequences of the condition once it has occurred. In order to best 
prevent disease, one must consider the risk factors that cause diseases. This paper 
focuses on three risks factors: tobacco consumption, alcohol consumption, and obe-
sity. While Germany is burdened with a high prevalence of tobacco and alcohol 
consumption among adults, the United States faces a serious issue regarding the 
prevalence of obesity. Both countries have introduced various measures to reduce 
the prevalence of the risk factors. By curtailing the pervasiveness of risk factors, 
diseases and chronical diseases, especially, can be prevented thus minimizing health 
care costs resulting from medical treatment of such conditions. 
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1 Introduction 
Today, multiple factors affect health. Besides environmental influences and the conse-
quences of climate change, nutrition and individual lifestyle are also important determi-
nants that may increase the occurrence of diseases. There are two different types of dis-
eases: communicable diseases (like Ebola and HIV/AIDS) and non-communicable dis-
eases (such as diabetes, multiple sclerosis, coronary heart disease, and cancer). In addi-
tion to the type of disease, the diverse risk factors are relevant and influence the state of 
health. Today, many diseases (heart diseases) have epidemiological dimensions and are 
widespread in populations across the world (Nationale Akademie der Wissenschaften 
Leopoldina et al., 2015, p. 3). 
Epidemiology describes the health status of a population and determines the factors 
causing disease, their processes, and intervention options. It examines the distribution 
of outcomes, which are mainly the number of diseases and deaths, as well as risk factors 
in a population (Egger and Razum, 2014, pp. 23-24). Over the last century, infectious 
diseases have been treated more effectively and efficiently due to better and newer med-
ications. Current issues in public health are a result of the growing prevalence of chronic 
diseases and their risk factors, population aging, and widening social inequalities (Ger-
linger et al., 2012, p.764). Public health is unique in concentrating not only on the health 
of individuals, but also on the health of society as a whole (Nationale Akademie der 
Wissenschaften Leopoldina et al., 2015, p. 3). 
The following paper gives a general overview of the German and American public 
health systems. To begin, it is important to understand how public health is defined and 
what aspects are included as they will influence the practice of public health institutions. 
Additionally, an explanation will be provided on how the public health systems in Ger-
many and the United States (U.S.) are organized. Following this, the difference between 
Germany and the U.S. regarding three main risk factors considered in this essay (tobacco 
consumption, alcohol consumption, and obesity), will be analyzed. Once these aspects 
are considered a conclusion will be provided. 
2 Introduction to the public health systems of Germany and the U.S. 
2.1 Definition of public health 
Public health is an expansive, multidisciplinary subject including multidimensional 
fields such as the promotion of good health or the prevention of non-infectious diseases 
(Ashton, 1988, p. 232; Committee for the Study of the future of Public Health Division 
of Health Care Services (Committee), 1988, p. 7). Besides the prevention of diseases, 
public health is comprised of sectors such as environmental health, nutrition, food and 
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drug control, sanitation, immunization, traffic laws, firearm control, and health educa-
tion (Tulchinsky and Varavikova, 2014, p. 536). 
Winslow, who was responsible for encouraging public health at the beginning of the 20th 
century, defines public health in the following way: “Public health is the science and the 
art of preventing disease, prolonging life, and promoting physical health and efficiency 
through organized community efforts […]“ (Winslow, 1920, p. 30). 
Public health should be focused on a clean and healthy environment. This implies pro-
tecting the public from pathogens such as waterborne disease (e.g. cholera) that are 
spread through unsanitary environments and cause illness. The control of community 
infections that are spread through direct contact from one individual to another is also 
important. Typical communicable infections which can be monitored and prevented are 
pneumonia and influenza. It is even more important to educate and support individuals 
in practicing daily personal hygiene so they remain healthy. Lastly, the organization of 
health care services for early diagnosis and preventive treatments as well as the devel-
opment of the social machinery are vital to public health programs as well as through 
them public health can be improved too (Winslow, 1920, pp. 24-27). 
One of the main aspects of public health is prevention. This includes measures to hinder 
the occurrence and spread of diseases. Prevention aims to reduce risk factors, lower the 
probability of getting a disease, stop the progress of disease and lessen consequences 
from illness or injury (Walter et al., 2012, p. 196; world health organization, 1984, p. 
17). As one of public health’s most important tasks, it is necessary to implement a com-
prehensive approach including education and the establishment of safety structures to 
carry out prevention effectively (Cohen and Swift, 1999, p. 204). 
In 1983 Larry Cohen, who has been an advocate for public health since 1972, founded 
the spectrum of prevention. He established this system since he believed that prevention 
was not fully understood by most people and only seen as an educational practice and 
not as complex process. The tool improves the approach to injury prevention and en-
courages practitioners to implement various initiatives. Cohen placed the main emphasis 
on influencing policy and legislation (Cohen and Swift, 1999, p. 203). In the following 
section the six levels of Cohen’s spectrum of prevention will be explained (Cohen and 
Swift, 1999, pp. 204-206). 
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Figure 1: The spectrum of prevention 
 
Source: Own graphic based on Cohen, L. and Swift, S. (1999), The spectrum of prevention: developing 
a comprehensive approach to injury prevention, in: Injury Prevention, Vol. 5, No. 3, p. 203. 
1) Strengthening individual knowledge and skills 
On this level, the focus lies on the transfer of knowledge and skills from physicians, 
human service professionals, and non-professional workers trained in health or wellness 
to individuals in order to increase their understanding and capacity for self-prevention. 
2) Promoting community education 
Community education should reach a broad range of people, a large group or the whole 
population, and communicate information to improve health. Mass media campaigns 
are used because they have a further reach than other methods and attract more people. 
Through mass media, individuals become increasingly aware of public health issues and 
understand the necessity of finding solutions on a societal level and their responsibility 
to be part of the solution. If communities are able to use media strategically, this can 
also attract the attention of legislators who have the power to advocate for policy change. 
This process is called media advocacy and it is a key part of keeping a community edu-
cated. 
3) Educating providers 
Since providers are responsible for transfering their knowledge to the general public, it 
is necessary that they also improve their understanding of prevention to transmit the best 
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information that is currently available. This can be accomplished through continuing 
education for health providers. 
4) Fostering coalitions and networks 
Coalitions, formed by several participants in the public health system, are crucial to 
achieve vital public health goals. Only by working together is it possible to ensure suc-
cess, reduce expenses, and increase the credibility of the participants. Coalitions have a 
greater impact to achieve a community effort than any individual could have. 
5) Changing organizational practices 
Key organizations in Germany and the U.S. for health are law enforcement agencies, 
health departments, and schools. Through examining their practices this can affect the 
health and safety of the greater community. If these institutions change their internal 
organization (e.g. regulations and norms) this influences the behavior, the health, and 
the safety of their members. Changes in legislation often initiate a change in organiza-
tional practice as well. 
6) Influencing policy and legislation 
The enactment of a law is most important because it has the broadest influence and 
ability to improve health outcomes. Laws may already exist, but in order to make a law 
more effective, changes or adaptions might need to be made. 
2.2 Organization of the public health systems 
The Centers for Disease Control and Prevention (CDC) generally defines a public health 
system as “all public, private, and voluntary entities that contribute to the delivery of 
essential public health services within a jurisdiction” (CDC, 2013). 
Public health’s mission is to guarantee conditions in which people can live a sustainably 
healthy life. The aim is to achieve an organized community effort which transmits 
knowledge about how diseases can be prevented and addressed to public agencies, pri-
vate organizations, and individuals (Committee, 1988, p. 7). Public health participants 
are the government, nongovernmental organizations (NGO), and community groups 
(Schneider, 2017, p. 25). 
There are three core functions of public health agencies at all levels: assessment, policy 
development, and assurance. Each public health agency is obligated to collect, analyze, 
and release community health data (assessment). The aim is to develop public health 
policies within their jurisdiction to protect the interest of the public. Lastly, they must 
also assure that all necessary services are provided and accessible for everyone (Com-
mittee, 1988, pp. 7-8). 
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Structure of the public health system in the U.S. 
When discussing the U.S. health care system, it is necessary to touch on the legal pre-
conditions, which are the basis of the system. Public health is under the purview of the 
states because it is not specifically delegated to the federal government. Therefore, the 
responsibility is reserved by the states (Schneider, 2017, p. 26). The public health system 
in America is divided into several parts. There are governmental public health agencies 
at the federal, state, and local level, which carry the majority of responsibilities, but there 
is also an active exchange with private-sector organizations and NGOs (like health care 
providers, insurers, charities, and other groups) that concentrate on education, lobbying, 
and research in public health (Salinsky, 2010, p. 5; Schneider, 2017, p. 36). The follow-
ing section will focus on governmental public health agencies at all levels. 
On a federal level, the Department of Health and Human Services (HHS) is responsible 
for public health activities. Tasks of the federal government include establishing nation-
wide health objectives, supporting knowledge development, and providing funds and 
technical assistance to states. HHS is separated into three major agencies: The Centers 
for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and 
the Food and Drug Administration (FDA).The CDC, also known as the epidemiologic 
agency for the nation, fights disease no matter how it occurred and supports communi-
ties and individuals to do so as well. Its aim is to increase the health security of the 
nation. The health protection agency provides and analyzes huge amounts of health in-
formation, tracks disease to find out where disease occurs and how to prevent it, and 
brings knowledge to every individual with the mission to protect the citizens against 
health threats and to respond to them when they arise (CDC, 2014b).The NIH carries 
out and supports biomedical research and is one of the largest research institutions in 
the world. The FDA is the organization that evaluates all new drugs entering the market, 
helps to bring new innovations on the market that improve public health, and provides 
science-based information to individuals to use drugs in a proper way. The FDA protects 
the public health as it ensures the safety, efficacy and security of drugs, but also biolog-
ical products, and medical devices. It further regulates the distribution and manufactur-
ing of tobacco products to reduce tobacco use by children and young adults (Schneider, 
2017, pp. 32-35; FDA, 2017). 
State’s public health agencies are responsible for fulfilling the states task to protect 
health, safety, and the general welfare of the population (Schneider, 2017, p. 30). Due 
to this responsibility, state are the primary authority for public health in the U.S. (Sa-
linsky, 2010, p. 7). States are autonomous and authoritarian in providing population-
based and personal health services through statutes (Lister, 2005, p. 11). Each state has 
an established state health agency, which assumes governmental public health activities. 
The state public health systems as a whole are very fragmented because each state has a 
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high degree of flexibility in choosing how to structure its syytem (Salinsky, 2010, p. 8). 
State health department activities are mainly funded by state taxes, federal grants, and 
fee-for-service payment structures (Schneider, 2017, pp. 30, 32).  
At a local level, the extent to which public health agencies have authority is limited by 
state policy, but local policymakers have the flexibility to determine which activities are 
provided and how they are provided (Salinsky, 2010, p. 15). Public health organizations 
differ among states because size, powers, and funds vary. In general, every county must 
establish a health department that serves cities as well as rural areas. These organizations 
are responsible for the day-to-day public health matters, such as the surveillance of local 
health problems and assuring that high-quality services are available in their community. 
In addition, local health departments are also responsible for tending to the health and 
well-being of underserved, less privileged persons. Aside from governmental funding, 
local health departments are typically financed by local property taxes, sales taxes, and 
fees for provided health services, but this varies from state to state (Schneider, 2017, pp. 
29-30; Committee, 1988, p. 9). 
Local and state health agencies are strongly connected. State health agencies delegate 
responsibility to local health agencies, but the authority given differs and depends on 
the chosen structure (centralized, decentralized, and hybrid approach). Within a central-
ized approach the control and responsibility for health care services rests with the state 
health agencies, whereas within a decentralized approach total responsibility for public 
health services provided in a specific jurisdiction is delegated to local agencies. Within 
a hybrid approach state and local health agencies both provide services and share re-
sponsibility (Lister, 2005, p. 11). State and local health agency activities are shown in 
the table below. 
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Figure 2: State and local health agency activities 
 
Source: Own graphic based on Salinsky, E. (2010), Governmental Public Health: An overview of state 
and local public health agencies, No. 77, Washington DC, pp. 11-16. 
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as prevention, which deals with health promotion and legal issues of prevention or dis-
ease control. Also, general healthcare activities are overseen by the ministry including 
information and health education as well as early detection and prevention of diseases. 
Since public health is a widespread field, as previously mentioned, there are various 
other federal ministries that tackle public health issues like the Federal Ministry of Ed-
ucation and Research, which is responsible for educating the population, or the Federal 
Ministry of Labour and Social Affairs which is responsible for rehabilitation. A federal 
institution with resemblance to the American CDC is the Robert-Koch-Institut (RKI). 
Its task as a federal institution for infectious diseases and non-communicable diseases is 
to identify, prevent, and combat these diseases. It is also responsible for the Federal 
Health Monitoring System (Walter et al., 2012, pp. 273-275). 
Besides federal ministries and institutions, health insurance companies play an im-
portant role as it is their statutory mandate to promote, recover, or improve the health of 
their policy holders by offering information, consultation, and services. With statutory 
health insurance reformation in 1989 measures of the health promotion and disease pre-
vention were established for the first time in the healthcare system. In §§20-24i in the 
German Social Security Code, Book V (SGB V) the main services of health insurance 
companies are recorded to include services for the prevention of diseases, workplace 
health promotion, the prevention of work-related risk factors, promotion of self-help, 
and services during pregnancy and motherhood. Different program offering for preven-
tion and health promotion are a substantial part of health insurance competition and lead 
to two positives effects. On the one hand, people who want to stay healthy are attracted 
to join the health insurance and on the other hand already insured people stay healthier 
and therefore costs stay at lower level, because the insurance risk pool is better. It can 
be said that promotion and prevention programs are an adjusting screw on the health 
insurance market, which means that they are an important decisive criterion regarding 
the decision making of individuals to join an insurance agency (Walter et al., 2012, pp. 
279-280). 
Although legislation for health prevention is the responsibility of the federal govern-
ment, states also have a main task regarding health prevention due to constitution. On a 
state level, ministries with a special department for health are responsible for the imple-
mentation of laws and control of public healthcare. The Conference of Health Ministers 
and the Association of the State Board of Health coordinate activities of national minis-
tries on the federal level. Tasks of state ministries vary and include financially support-
ing State Associations, National Offices, and State Working Groups for health. They are 
established in nearly every German State and have the aim of coordinating, promoting, 
and cooperating within health education and health promotion on a state level to improve 
the health of the population. Practical examples are information events, work groups or 
training programs (Walter et al., 2012, p. 281). 
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With facilities very accessible to and in direct contact with citizens, prevention and 
health promotion play an important role on local level. Health departments are particu-
larly relevant as they are represented in every district and have the legal responsibility 
to prevent disease and promote the health of the population. Their tasks include com-
bating communicable diseases, providing vaccines, offering consultancies for different 
patient groups, and performing check-ups for children. Services for early detection of 
disease were introduced in 1971 and nowadays include prenatal care, cancer-screening, 
and screenings for an early detection of heart-diseases, kidney diseases, and diabetes. 
Although medical consultation is effective, it has only a marginal importance. Other 
facilities that act on a local level and in direct contact to the citizens are schools, sports 
clubs, pharmacies, welfare centers, and churches. All of them have the same task: to 
give health information, health education, and health care provision (Walter et al., 2012, 
pp. 281-285). 
A special governmental institution in the public health system is the public health ser-
vices (Öffentlicher Gesundheitsdienst=ÖGD), located at the local level, which can be 
associated with a service-orientated administrative structure. Its main tasks are to create 
conditions in which people can be healthy, to promote public health needs as an impar-
tial player, to act practical, and to protect the human dignity of every individual. The 
ÖGD is sometimes called the third pillar of the healthcare system besides ambulatory 
and stationary medical treatment. Although its percentage of total healthcare expendi-
tures is lower than one percent, this institution has a great importance for the quality of 
life and the life expectancy which have both increased. Services the ÖGD provides are 
essentially health protection (reducing infection and improving hygiene), health promo-
tion and prevention (strengthening of resources and boosting health-related opportuni-
ties), and healthcare management (developing the healthcare system and improving 
quality). The ÖGD is regulated differently by every state legislation and therefore has a 
heterogeneous profile (Wildner et al., 2016, pp. 289-292). 
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Figure 3: Institutions at all levels in the German public health system 
 
Source: Own graphic based on Walter, U., Schwartz, F. W. and Plaumann, M. (2012), Prävention: In-
stitutionen und Strukturen, in: Schwartz, F. W., Walter, U., Siegrist, J., Kolip, P., Leidl, R., Dierks, M. 
L., Busse, R. and Schneider, N. (Ed.), Public Health: Gesundheit und Gesundheitswesen, third edition, 
Urban&Fischer, München, p. 272. 
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3 Risk factors 
According to the World Health Organization (WHO), a risk factor is “any attribute, 
characteristic or exposure of an individual that increases the likelihood of developing a 
disease or injury” (WHO, 2017). Through health promotion and prevention, the proba-
bility of risk factors occurring and subsequently resulting in disease can be reduced 
(OECD, 2015a). The effectiveness of the preventive action is proven by a decrease in 
the prevalence of a disease (Egger and Razum, 2014, pp. 23-24). 
The number of possible risk factors is high and includes a large variety of risks from 
high blood pressure, tobacco use, alcohol use, high blood glucose, high cholesterol, and 
high body mass index to physical inactivity and low fruit and vegetable intake. These 
factors can increase the risk for chronic diseases like heart disease, diabetes, and cancer 
and risk factors affect all income groups of all countries. Unsafe sex, alcohol use, pol-
luted water, poor sanitation, and low hygiene affect the population in different ways, 
sometimes causing serious issues, especially in low-income countries, for example 
Ebola in many African countries (WHO, 2009, p.v; Tulchinsky and Varavikova, 2014, 
p. 243). This paper focuses on the three risk factors mentioned in the OECD report from 
2015: smoking, alcohol consumption, and obesity. 
3.1 Tobacco use in Germany and the U.S. 
Tobacco use affects nearly all organs of the body and causes cardiovascular diseases, 
several types of cancers, and pulmonary diseases (OECD, 2015a). In Germany, 28.7% 
of the adult population smoked in 2015, with 26.1% of women and 32.2% of men smok-
ing cigarettes (Piontek et al., 2017, p. 43). It is notice-able that as age increases the 
number of regular smokers grows, especially for men. Furthermore, the percentage of 
smokers decreases as social status increases (Pötschke-Langer et al., 2015, pp.39, 44-
45). In particular, the highest proportion of smokers among both genders is between the 
ages of 18 and 44 years (Robert-Koch-Institut, 2014, p. 113). The tobacco-based health 
expenditure in Germany totaled € 79.09 billion in 2015, of that amount € 25.41 billion 
(7.4% of total health care expenditures) could be attributed to direct costs for treatment, 
care, rehabilitation, and costs for secondhand smoke victims. Indirect costs that bur-
dened the economy amounted to two-thirds of tobacco expenditure (€ 53.68 billion) 
through the loss of resources such as death, permanent disability, care, and unemploy-
ment of potential workers (Pötschke-Langer et al., 2015, pp. 66-67). 
In the United States, 15.1% of adults smoked cigarettes in 2015, with more men (16.7%) 
than women (13.6%) having smoked. Most of the smokers were between the ages of 25 
and 44 years. Moreover, the prevalence of cigarette smoking is higher in people with 
lower education or if they live below the federal poverty level (Jamal et al., 2016, pp. 
1,207-1,208). The annual costs for lost productivity attributable to death from cigarette 
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smoking amounted to $150.7 billion in 2009 (U.S. Department of Health and Human 
Services, 2014, p.671). Annual health care spending on tobacco-related conditions in 
2010 amounted to $170 billion, which was 8.7% of the total health care expenditures 
(Xu et al., 2015, p. 326). The economic costs for smoking and exposure to secondhand 
smoke amount to around $300 billion annually. 
When comparing the direct health care costs in both countries regarding smoking, the 
percentage of total health care expenditures is 1.3% higher in the U.S. than in Germany, 
although there are twice as many smokers in Germany. 
3.2 Alcohol consumption in Germany and the U.S. 
Alcohol use causes diverse illnesses such as liver cirrhosis, strokes, and several cancers, 
but it also leads to accidents, injuries, and violence (OECD, 2015a). In 2015 the 30-day 
prevalence of any alcohol consumption among adults amounted to 72.5% in Germany. 
77.1% male persons and 67.8% female persons consumed alcohol over a month time 
period. 21.4% of the population practices risky consumption, meaning that on average 
more than 12 grams of pure alcohol are consumed daily for women and more than 24 
grams for men, whereby more men than women practiced it (Piontek et al., 2017, pp. 
67-68). The most at risk consumers are between 18 and 29 years old. Women from the 
age of 30 onwards and from a higher social and educational status are at a higher risk of 
harmful alcohol consumption than women with a lower social and educational status 
(Robert-Koch-Institut, 2014, p. 117). Another alarming aspect of alcohol consumption 
is binge drinking. This is defined as the consumption of at least five alcoholic drinks a 
day. 46.5% of males and 21.6% of females were identified as binge drinkers in the 30-
day prevalence. Binge drinking is especially pronounced within the 18 to 24-year-old 
range (Piontek et al., 2017, p. 69). Economic costs were quantified to total € 39.30 bil-
lion in 2015. Indirect costs amounted to € 30.15 billion, whereas direct costs totaled € 
9.15 billion, which account for 2.7% of total health care expenditures (Effertz, 2015, p. 
315). 
In America, excessive alcohol use consists of binge drinking, heavy drinking, alcohol 
consumption by pregnant women, and alcohol use by people younger than 21 years. In 
contrast to Germany, binge drinking in the U.S. means consuming more than five alco-
holic drinks for men and four or more drinks for women on one occasion. Heavy drink-
ing is defined as consuming eight or more drinks per week for women and 15 or more 
drinks per week for men (National Center for Chronic Disease Prevention and Health 
Promotion, 2016). In 2015, the 30-day alcohol consumption prevalence among adults in 
the U.S. was 56%, whereby 61.3% men and 51.1% women consumed alcohol (Center 
for Behavioral Health Statistics and Quality (CBHSQ), 2016, p. 939). The 30-day binge 
drinking prevalence in 2015 among adults was 26.9%, with more men binge drinking 
than women. Persons aged 26 to 29 participated most in binge drinking. 7% practiced 
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heavy alcohol use, where men consumed twice as much as women. In the U.S., full-time 
employed people and people with a college degree are more at risk for excessive alcohol 
consumption than unemployed people with a lower educational status (CBHSQ, 2016, 
pp. 893, 949). The excessive drinking costs amounted to $249 billion in 2010. 72% of 
the total costs are related to losses in workplace productivity and 11% are related to 
direct health care expenses. The other 17 % made up criminal justice expenses, motor 
vehicles crash costs, and property damage (CDC, 2017). 
Comparing Germany and the U.S., the prevalence of adults consuming alcohol is 15% 
higher in Germany, but the proportional part of directly related costs on total health care 
expenditures in the U.S. is 8.3% higher than in Germany. 
3.3 Obesity in Germany and the U.S. 
Overweight and obese adults and children are at a very high risk of developing many 
diverse diseases such as hypertension, high cholesterol, diabetes, cardiovascular dis-
eases, respiratory problems (asthma), and musculoskeletal diseases like arthritis 
(OECD, 2015a). Obesity is an abnormal or excessive fat accumulation that is measured 
with the body mass index (BMI)1. A BMI higher or equal to 25 is defined as being 
overweight, whereas obesity is having a BMI higher than or equal to a BMI of 30 (World 
Health Organization, 2016). 
According to OECD measures, in 2013 the obesity prevalence among adults in Germany 
was 23.6% (OECD, 2015a). In 2012, 67.1% of men and 53.0% of women between the 
ages of 18 and 79 years were overweight. The prevalence of obese people amounts to 
23.3% of males and 23.9% of females. The percentage of overweight men is higher than 
the percentage of overweight women, whereas the percentage of obese people is roughly 
equal in both genders. The number of overweight women increases continuously with 
increasing age, whereas men have a peak at around 30 to 39 years of age, with the num-
ber of overweight men nearly doubling in between these ages. Women with a high social 
and educational status have a lower prevalence of being overweight or obese than 
women with a lower social status (Mensink et al., 2013, pp. 791-792). In 2015, € 63.04 
billion were spent on obesity related costs. Direct costs including sickness benefit, care, 
and accident costs amount to € 29.39 billion (6.8% of total health care expenditures) and 
indirect costs (€ 33.65 billion) covered productivity losses and premature mortality (Ef-
fertz, 2015, p. 316). 
In the United States, 35.3% adults suffered from obesity in 2013 (OECD, 2015a). By 
2014, the percentage was already over 37%. Women had a higher prevalence of obesity 
(40.4%) compared with men (35%). Middle-aged individuals of both genders, men and 
women between the ages of 40 to 59, were especially affected by obesity (Flegal et al., 
                                              
1 BMI = person’s weight in kilograms / square of his height in meters [kg/m2] 
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2016, p. 2,287). In total, 70.7% American adults were overweight or obese (National 
Center for Health Statistics, 2016, p. 200). The obesity prevalence among men is quite 
similar on all income levels with the tendency to be higher for people at higher income 
levels or with higher educational status. Women earning more or having a college degree 
have a lower prevalence of being obese (Ogden et al., 2010, pp. 1-3). According to 
Finkelstein, the estimated national medical care costs for obesity-related illnesses 
amounted to $147 billion in 2008, which made up 9.1% of national health expenditures 
(Finkelstein et al., 2009, p. 828). Total annual economic costs amounted to $215 billion 
(Hammond and Levine, 2010, p. 294). 
The rate of obesity in America is more than 10% higher than in Germany and as a result, 
the percentage of direct healthcare costs related to total health care expenditure is higher 
in the U.S. 
4 Comparison 
In general, the risk factors that occur are similar in Germany and the U.S., but the prev-
alence and costs to both countries vary. For example, the prevalence rates for tobacco 
and alcohol use are much lower in the U.S. in comparison to Germany, yet they spend 
more money due to these risk factors (as a percentage of total health care expenditure). 
With regards to obesity, the U.S. has a higher prevalence rate and also spends more on 
this issue. The question that arises out of these results is: Why does the U.S. spend so 
much money on health care despite limited gains? 
Health care expenditures as a share of the GDP amounted to 16.4% in the U.S. and 
11.0% in Germany in 2013 (OECD, 2015a, p. 169). The U.S. has worse health outcomes 
for every condition, except for cancer, when compared to most other developed coun-
tries (OECD, 2015a, pp. 45-64). So, the American society is paying more and getting 
less. The reasons for high health care costs can be attributed to high administrative costs 
due to a lack of coordinated care in a multi-player system. Higher prices for treatments 
and pharmaceuticals in addition to investment in new technology increases costs as well. 
The fact that Americans consume more in the form of treatment, diagnostic tests, pre-
scription drugs and pharmaceuticals than any other developed country also attributes to 
their significant health expenditures (Cutler, 2013). In addition, Americans pay doctors 
more than most other countries do (Yglesias, 2013). 
Looking at the organizational structures, both have basically equal elements as both 
countries have entities at the federal, state, and local level with different jurisdictions for 
each segment. However, the American public health care system is more fragmented 
and therefore contributes to higher health care costs in addition to many of the other 
factors already mentioned above. The risk factors Americans are exposed to are mainly 
responsible for many chronic diseases (diabetes, cancer or heart disease), which are then 
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the main drivers of high health care expenditures (Sturm, 2002, p. 245). Therefore, it is 
important to introduce effective preventative measures to contain costs. 
The key reasons that the U.S. succeeded in reducing the prevalence of smoking was 
because their public health policies not only prohibited smoking in indoor public and 
private workplaces, but also increased the tobacco product excise taxes while imple-
menting mass-media campaigns (CDC, 2014a, p. 133). In comparison, Germany has not 
implemented any measures over the last seven years aiming to reduce consumption and 
they are the only country to allow unlimited outdoor advertisement (Deutsches 
Krebsforschungszentrum, 2017). It is worth mentioning that Germany already imple-
mented a law successfully years ago. The Non-Smoker Protection Law was established 
in 2007 and includes a smoking ban in public institutions of government, sport, and 
education institutions as well as a ban in children and youth facilities as well as in res-
taurant and eateries. 
The U.S. was able to decrease the alcoholism and dangerous drinking probability by 
reducing commercial and social access as well as economic availability ((Hingson et al., 
2006, p. 739). This was achieved by setting the minimum legal drinking age to 21 and 
by prohibiting the consumption of alcohol in public places (Voas and Fell, 2011, p. 225). 
In addition, the U.S. introduced further strategies, for example, a school-based program 
to strengthen adolescents’ ability to avoid peer pressure and resist alcohol consumption. 
Extracurricular activities also reduce alcohol use and so does family involvement 
(Komro and Toomey, 2002, pp. 5-14). Germany sets their focus instead on awareness 
and information campaigns, for example “Kenn dein Limit”. 
With regards to obesity, the U.S. has not been as successful. Causes for obesity in Amer-
ica are countless. However, physical inactivity, consumption of high-calorie foods, high 
stress, and a low-income drastically increase the probability of becoming obese (Uni-
versity of Maryland Medical Center, 2015). Germany guarantees a better work-life-bal-
ance, allowing more time for sports and other activities which decrease the risk for be-
coming overweight or obese (OECD, 2015b). 
The U.S. introduced good strategies for reducing alcohol and tobacco consumption, but 
still has higher health care expenditures. Looking at prevention expenditures as a share 
of total health expenditures in 2014, Germany spends 3.1% and the U.S. 2.9% (OECD, 
2016, p. 134). Higher health care expenditures are not attributable to higher investments 
in preventative strategies, but to faults in the organizational structure of the health care 
system. In comparison to Germany, who spent far less, America does not work in an as 
cost-effective manner. 
5 Conclusion 
Implementing policies to address public health issues is not always easy. This is partic-
ularly a concern in the U.S. To succeed, a problem must be recognized, a solution must 
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be available, and the political conditions must be right to implement a health policy 
through an open policy window. In the U.S., the bipartisan structure and disagreements 
in the Congress often impede the development of new policies (Kingdon, 1993, pp. 41-
43). In addition, politicians want to achieve short term solutions to get re-elected. There-
fore, big public health solutions that are needed to solve pressing public health issues 
are rare. It is important to focus on upstream measures as they are more effective than 
downstream measures. Upstream measures take place on a macro policy level and seek 
to diminish the cause of the cause, whereas downstream measures act on an individual 
level and seek to change the effects of the cause (National Collaborating Centre for De-
terminants of Health, 2014, p. 3). U.S. politicians prefer to focus on downstream 
measures as opposed to upstream measures because their implementation is easier, 
faster, and typically costs less (Rutter et al., 2017, p. 61). It is important to consider the 
imbalance of the U.S. health care system in comparison with the German system when 
looking at policy solutions and interventions for public health issues. Despite the short-
comings that any health care system may have, the public health agencies in the U.S. 
and Germany, ultimately serve to reduce the prevalence of risk factors in society. As a 
result of this reduction, these systems prevent diseases and improve the health status of 
individuals and reduce health care expenditures, even when combating complex risk 
factors such as tobacco, alcohol and obesity (Maciosek et al., 2010, p. 1,656).  
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Serving the City of Detroit – The Detroit Health Department 
Jenny Reinold and Simone Leeb 
The Detroit Health Department is an institution with a diverse set of responsibilities. 
It offers a wide range of services and programs to secure and to maintain Detroiters 
health and well-being, especially for those people who are not able to take care of 
themselves. The upheaval in the Detroit automobile industry caused unemploy-
ment, decreasing habitants and fiscal problems. In the consequence amongst other 
things, the investments in the Health Department have been reduced, which led to 
downsizing and ending health services and programs. Subsequently, Detroit had to 
struggle with socioeconomic problems and public health. With its key role in po-
pulations health, the Health Department is a central contact point for people living 
in the Detroit Area. In order to maintain the resurfacing strength of Detroit’s Health 
Department and to make it even better it is necessary to collaborate with different 
sectors and other Departments for a mutual exchange and to generate money for the 
Health Department with funding partnerships. 
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1 Introduction 
The Detroit Health Department provides public health services and partners with neigh-
borhood and community stakeholders to improve the health and the quality of life of the 
people in the Detroit metropolitan area (CITY OF DETROIT, 2001A - 2017, 2001A - 2017).  
To get a general idea of the health programs in Detroit and to understand further im-
provement in community health needs, this paper initially outlines the history of Detroit. 
The second chapter will give an overview of how the determinants of health are influ-
encing Detroit´s health services and which steps the department has implemented to face 
the problems that result from poor health. Finally, there is a discussion of how the health 
department could improve Detroiter’s health based on the determinants of health and 
what future challenges they might address. 
2 Theoretical Principles 
2.1 Detroit History 
To get a better understanding of what the Detroit Health Department is and the work 
that they do, it is necessary to get an overview about Detroit’s history. Detroit originally 
was the “motor-city.” The factories produced passenger vehicles, weapons, and equip-
ment for the U.S. military in the twentieth century. It was a thriving time for Detroit in 
the automobile industry and manufacturing (LOUGHEED, 2014, p. A325). Even today, 
the space reflects how it was laid out is based on cars. The city initially was built over a 
large area because it was assumed that everyone would have a car. Therefore, no major 
subway-system was built in the city, and this continues to have a big impact on the city’s 
infrastructure and how people think of health. (KHALDUN, J.S., 2017) 
Back in 1950, Detroit’s population peaked at more than 1.8 million (U.S. CENSUS BU-
REAU, 2005, p. 1) but as the car industry collapsed, the people left as well. The conse-
quence was a decreasing tax-base and decreasing habitants. Today, the population is 
only a third of its original size. From 2000 (with a population number of 951,270) to 
2010, the population dropped by 25 percent to 713,777. Detroit’s population has been 
declining for more than 60 years. (WORLD POPULATION VIEW, 2017)  
In the following diagram, you can see the populations’ development in the past decades. 
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Figure 1: Detroit’s Population from 1820 to2015 
  
Source: Authors’ own presentation, data from WORLD POPULATION VIEW, 2017. 
Because of the rough economic situation, Detroit had to struggle with socioeconomic 
problems. Due to economic decline, people moved away. On the one hand, people lost 
their jobs and now were looking for better job opportunities. On the other hand, the 
housing vacancy in the city caused a drop in the property-values. (WORLD POPULATION 
VIEW, 2017; LOUGHEED, 2014, p. A325). 
The fiscal problems of Detroit were substantial enough to cause nearly the largest mu-
nicipal bankruptcy in U.S. history. In 2013, it also affected the health department. 
(DAVEY, M. 2014, p. A21). All these factors contributed to public health issues and 
crime. Therefore, there are a lot of areas in Detroit today which are vacant and are de-
clining instead of growing.  
The Detroit Health Department plays a major role in public health. In the next chapter, 
you will find important keynotes about the Health Department before the department’s 
programs will be introduced. 
2.2  Detroit Health Department 
The first recorded actions taken by the city in developing an environmental health pro-
gram were in 1827 (Molner, J.G. and Getting, V.A., 1955, p. 855). After the implemen-
tation of public health services in Detroit, the department of health was able to extend 
its services not only to face one problem but to implement several programs at a time. 
Today the department follows the vision, “A healthier Detroit and healthier Detroiter.” 
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Therefore, it tries to improve the health and quality of life of the citizens through pro-
grams, policy promotion and partnerships in neighborhood and around the city (Molner, 
J.G. and Getting,V.A., 1955; Khaldun, J.S., 2016). 
As a consequence of the bankruptcy – in the end of 2011 the City of Detroit had $12 
billion debts in long-term liabilities – the public health services were privatized in 2012. 
This step was a result of the declining population of the City of Detroit and the accom-
panying decrease of fiscal revenues. Outsourcing the health department to a public in-
stitute saved the city money. Instead of receiving money from the city, the institute 
would be funded with government and foundation grants. Health services like immun-
izations and tuberculosis treatment were turned over to the Institute for Population 
Health in order to prevent closing any clinics. (Bouffard, K., 2014; Huffpost, 2012)  
Since the city is currently getting out of the bankruptcy, it is starting to regain responsi-
bility for some of the services. In Fall 2014, the health services also returned to the 
Detroit Health Department (R. Pool and K. Stratton, 2015; Bouffard, K., 2014). With 
the new start after returning all health services to the department, a new health depart-
ment director was announced. Dr. Abdul El-Sayed is committed to reconstruct the pro-
grams of the health department and public health services by reducing the disparities 
(The Detroit News, 2015). 
Detroit Health Department services include amongst others: 
 Environmental Health and Safety 
 HIV/AIDS Program 
 Immunizations 
 Lead Prevention 
 Maternal Child Health 
 Office of Public Health Emergency Preparedness 
 Vision Screening 
 Women, Infants, and Children (WIC) Program (City of Detroit, 2001b - 2017) 
2.3 Facing Problems / Determinants of Health 
Health and diseases result from a complex interplay of several effects. Health-related 
behaviors, as well as access and quality of health care, have an enormous impact on 
health status. Socioeconomic factors, especially, are important not only for an individ-
ual’s health but also for the health of the whole population.  
The following illustration shows different determinants which all contribute signifi-
cantly to how healthfully we live.  
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Figure 2: Social Determinants of Health 
 
Source: Authors’ own presentation, data from SENTERFITT, J.W.  ET AL., 2013, p. 2. 
Personal surroundings, education, neighborhood safety, employment, income, infra-
structure and the environment are components that all belong to the social and economic, 
known as socioeconomic, factors of health (SENTERFITT, J.W., ET AL., 2013, p. 2). 
Detroit in particular is facing issues related to these determinants of health. As shown in 
2.1, after the huge economic breakdown, a lot of inhabitants lost their employment and 
left the city. Because of the declining population, some areas of Detroit nowadays are 
like a ghost town which contributes to a high rate of crime.  
Today Detroit is one of the metro areas with the highest rate of concentrated poverty in 
the U.S (KNEEBONE, E. AND HOLMES, N. 2016). A high rate of poverty entails a lot of 
challenges. NEIGHBORHOODSCOUT found that, compared to other cities, Detroit has one 
of the highest crime rates in America. (NEIGHBORHOODSCOUT, 2017) 39.8% of the res-
idents are below the poverty line and almost 60% of the children grow up in poverty. 
79% of the residents in Detroit are African-American. According to KHALDUN, life in 
Detroit is rough especially for them. They still have disadvantages compared to white 
residents and are also not free in the choice of areas in which they can live. Moreover, 
about 20% of the residents are uneducated, don’t have education qualifications and 
barely have a possibility to enhance their chance of obtaining a better job and life. The 
rate of unintended teen-pregnancy is higher in Detroit than in other cities and areas. Six 
percent of the women between 15 to 19 years gave birth during past year (CENSUS RE-
PORTER, 2015 AND KHALDUN, J.S., 2017). 
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Beside these socioeconomic factors also the infrastructure in the Detroit area has an 
impact on the individual’s health status. In 2011, nearly one in four households in De-
troit had no access to a vehicle (DATA DRIVEN DETROIT, 2012, p. 10). A well-organized 
public transportation system is crucial for these people. But currently, transportation 
services in Detroit are infrequent, not on time, and are thus, unreliable. Beside this the 
system is facing problems with the regional connections, which makes it almost impos-
sible for some people to reach their jobs and even grocery stores (REGIONAL TRANSIT 
AUTHORITY OF SOUTHEAST MICHIGAN, 2016, p. 2). 
Moreover, SHANNON ET AL. found that the grocery stores, which provide healthy food 
are mostly located in white neighborhoods. This fact makes it even harder for people 
living in impoverished neighborhoods to buy healthy food and thus has a direct impact 
on their health status (ZENK ET AL., 2005, p. 664). The environmental exposures in De-
troit are another issue for residents. Asthma is one of the most common chronic disease 
of childhood in the world. Due to the proximity of industrial pollutant and the interstate 
motorways a high number of children in Detroit are struggling with asthma (KEELER ET 
AL., 2002, pp. 176.-179). Another example for the unhealthy environmental conditions 
is the Flint Water Crisis. It started in 2014 when the drinking water supply in nearby 
Flint, MI was switched from Lake Huron to the Flint-River to save money. About four 
weeks later over 100,000 residents were exposed to high levels of lead in the drinking 
water due to the insufficient water treatment. It turned out that elevated blood lead levels 
found in children in Flint are associated with the Flint drinking Water Crisis (HANNA-
ATTISHA ET AL., 2016, p. 283). 
3 Interventions 
The Detroit Health Department tries not to create programs only focused on individuals. 
It tries to create a public health infrastructure and support this in consideration of the 
determinants of health and the issues of Detroit. According to KHALDUN, creating 
healthy conditions where people are able to live a healthy life is the definition of public 
health (KHALDUN, J.S., 2017, p. 17). The Detroit Health Department pursues the princi-
ple “health across the lifespan”, divided into “healthier beginnings,” healthier child-
hoods,” as well as ”healthier lives” (KHALDUN, J.S., 2017, p. 18). The health department 
offers different programs for every stage of life as well as for “healthier places” (DE-
TROIT HEALTH DEPARTMENT, 2017A). The following chapters will explain some elected 
programs.  
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3.1 Healthier Beginnings 
Hearing and Vision Screening 
The Hearing and Vision Screening Program addresses children of Detroit between three 
and ten years (DETROIT HEALTH DEPARTMENT, 2017A). Hearing and vision screenings 
are essential in order to prevent speech or cognitive disorders and to support the child’s 
development. The screenings are free of charge and take place at school (MICHIGAN 
DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2017). The screenings are an im-
portant intervention, because 15% of children show abnormalities regarding the hearing 
and vision screening. 
Maternal-Child-Health 
Within the framework of the program a variety of services is offered to young mothers, 
for example (DETROIT HEALTH DEPARTMENT, 2017A): 
 Dental care 
 Car Seat Safety (help with the correct seat and safety measures) 
 Safe Sleep (ABCs´: Alone in the childrens’ bed, on their Backs, in a safe Crib, 
in a Smoke-free room) 
 Activity Program 
 Baby Hotline for individual help 
Sentinel Flu Surveillance Network 
The Michigan Health Department is part of the U.S. Outpatient Influenza-like Illness 
Surveillance Network (ILINet), a cooperation between the Centers for Disease Control 
and Prevention (CDC), health departments and the State of Michigan (MICHIGAN DE-
PARTMENT OF HEALTH AND HUMAN SERVICES, 2017B). Some elected medical providers 
in contact with patients with influenza are so-called “sentinel physicians.” Sentinel phy-
sicians report the number of patients with Influenza-like illness (ILI).  
These patients are divided into five different age groups: 
 0 - 4 years  
 5 - 24 years 
 25 - 49 years 
 50 - 64 years 
 65+ years 
Moreover, sentinel physicians collect some respiratory specimens of a certain amount 
of patients with ILI for respiratory virus panel testing.  
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3.2 Healthier Childhoods 
Lead Safe Detroit 
To face the challenges among children younger than six with elevated blood levels the 
Detroit Health Department developed a coalition named “Lead Safe Detroit”. City de-
partments work with community partners to coordinate childhood lead prevention and 
removal in the city. The program is about prevention and education. They eliminate the 
lead from the houses to decrease the risk to exposure the children. Nurses visit homes 
with children affected by lead. The nurses support the families and work with them to 
improve the compliance by educating how to prevent from lead exposure.  
The health department also conducts water testing in schools, preschools, and homes to 
guarantee a health environment. Another part of the program is the environmental stand-
ards for lead. For this initiative the Detroit Building Authority and the Detroit Health 
Department are working together to locate potential lead exposures and to eliminate 
them for children (CITY OF DETROIT, 2001C - 2017). 
Women Infants and Children Program (WIC) 
The “Women Infants and Children Program” (WIC) embraces determinants of nutrition 
for children under the age of five (DETROIT HEALTH DEPARTMENT, 2017A). The pro-
gram aims to establish a good health status for children by considering important issues 
of nutrition as well as breastfeeding. Furthermore, the program aims to educate young 
mothers about important nutrition facts, because this is an important part of health pre-
vention (COHEN & SWIFT, 1999, p. 203). 
 
Sister Friends Detroit 
The volunteer community “Sister Friends Detroit” aims to help mothers of Detroit to 
establish a healthier live for themselves and their children (SISTER FRIENDS, 2017).  
Background of the establishment of Sister Friends Detroit is the fact that the mortality 
rate of Black babies is at twice the mortality rate of other babies in Detroit. The reason 
for that is that mothers are often exposed to high risk factors such as stress or no access 
to prenatal medical care which can have negative effects on pregnancy. 
Sister Friends Detroit follows the following principles: 
 Taking care of each member 
 Creation of a culture of care 
 Support for pregnant mothers as well as young mothers with newborn babies 
Sister Friends Detroit tries to find the right programs for pregnant mothers to get the 
help they need in order to guarantee a normal course of pregnancy. Moreover, the goal 
is to establish a growing community where the members help each other. 
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3.3  Healthier Lives 
HIV/ AIDS program 
There exist two programs helping people with Human Immunodeficiency Virus (HIV)/ 
Acquired Immune Deficiency Syndrome (AIDS). The Ryan White Program gives ad-
vice for medical issues. The Detroit Health Department cooperates with the Sexually 
Transmitted Diseases Clinic, which offers a wide range of services to people with HIV/ 
AIDS, for instance (CITY OF DETROIT, 2017A): 
 Screening, testing and treatment 
 Pre-Exposure Prophylaxis (PrEP): Pre-oral medication 
 Post-Exposure Prophylaxis (PEP): Medication after an exposure 
 Condoms free of charge 
The Housing Opportunities for Persons with AIDS program helps with concerns about 
appropriate accommodations (DETROIT HEALTH DEPARTMENT, 2017A). Both programs 
even help in cases of uninsured people infected with HIV.  
3.4 Healthier Places 
Environmental Health and Safety 
The program embraces environmental health issues, for instance checkups of institutions 
of child care or public swimming facilities (DETROIT HEALTH DEPARTMENT, 2017A). 
The program aims to protect the inhabitants of Detroit from health-damaging effects. 
Furthermore, the program deals with expressions of dissatisfaction from the population 
about certain institutions.  
Related to the Environmental Health and Safety program are the institutions of the Med-
ical Marijuana Caregiver Centers (MMCC). MMCC are health care centers, which were 
established and opened after the Michigan Medical Marijuana Act of 2008. The centers 
distribute marihuana prescribed by physicians and offer consultations to the population 
(CITY OF DETROIT, 2017B). MMCC are exposed to between four and nine inspections 
during the beginning of a new business. Later, inspections are conducted every three 
months in order to maintain high quality and health standards.  
 
Food Safety 
The Food Safety Program’s goal is the protection of the population from health-endan-
gering foodstuff (DETROIT HEALTH DEPARTMENT, 2017A). For that reason, there are 
special checkups for food establishments. In this context, the Detroit Health Department 
points out, that the offer of any favor to the inspectors are expressly prohibited.  
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Another task of the program is the education of the inhabitants about food and how to 
prevent illnesses of food. In addition, the Department of Food Safety supports new food 
startups how to achieve the necessary licenses to open their businesses. 
 
Public Health Emergency Preparedness 
The Office of Public Health Emergency Preparedness coordinates tasks in the case of a 
public health emergency (DETROIT HEALTH DEPARTMENT, 2017A). The definition of a 
public health emergency is an event, which exposes a high amount of people to a health 
risk, such as tornadoes, extreme heat, or flood (Michigan Prepares, 2017). The conse-
quence can be epidemic (US DEPARTMENT OF HEALTH AND HUMAN SERVICES, 2017). 
Public Health Emergency Preparedness consists of different tasks: 
 Comprehensive emergency planning: plans are written, how to save the popula-
tion in case of public health emergency 
 Emergency training and exercises: training of the Detroit Health Department 
stuff 
 Coordination with local, state and federal partners: close collaboration with the 
police and fire department of Detroit, the American Red Cross, etc. 
 Community engagement: consideration of different ethnic groups’ needs, spe-
cial needs of older residents etc.  
4 Future Challenges and Conclusion 
Public health of Detroit still faces the problem of being underfinanced. For instance in 
2009, the Detroit Health Department budget was $96.8 million compared to $28 million 
in 2016 (PAREKH & UDOW-PHILIPPS, 2016). There was a considerable increase of city 
investments in public health from $1.6 million per capita in 2015 to $11.1 million per 
capita in 2017 (KHALDUN, J.S., 2017, P. 16; PAREKH & UDOW-PHILIPPS, 2016). 
In comparison to the state’s statistics, Detroit shows an overall bad public health out-
come. The infant mortality rate in Detroit was 13.6% compared to 6.8% of Michigan, 
and the Diabetes rate in Detroit, with a percentage of 14.6, was also significantly higher 
than the diabetes rate in Michigan with a percentage of 10.4. 
The reasons for these results are due to socioeconomic, economic as well as educational 
factors. In recent years, there was a great economic development in Detroit. Neverthe-
less, a high amount of Detroit’s residents still live under poor conditions. The Detroit 
Health Department has achieved a lot of improvements in recent years, but there is still 
a lot of work to do. According to PAREKH & UDOW-PHILIPPS there must be more col-
laborations and partnerships between the different sectors. Partnerships, especially with 
potential funding partners, are essential to generate more money for the Detroit Health 
Department (PAREKH & UDOW-PHILIPPS, 2016). 
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Additionally, other city departments have to strengthen the Detroit Health Department 
and there has to be a continuous mutual exchange between them. Also, public schools 
should intensify their efforts in health programs for young people, because a low edu-
cation level is related to a poor health status. Only if these obstacles are overcome in the 
future will the public health outcome of Detroit will improve significantly.  
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Serving the City of Detroit – The Henry Ford Health System 
Arne Birkner 
The Henry Ford Health System (HFHS) is one of the largest comprehensive, inte-
grated health systems in the United States. Since its foundation in 1915, the system 
has been regionally rooted in the City of Detroit and the Detroit metropolitan area. 
Detroit itself faces huge challenges. The decrease of the manufacturing sector 
caused a large decrease in population and employment. The HFHS serves the city 
not only as a high-quality healthcare provider, but plays other roles as well. As one 
of the largest employers, the HFHS has been a stable economic and social factor for 
many years. Reduced investments in the cityscape and in community health are 
affecting long-term support in Detroit´s future. The social and economic importance 
of HFHS for the Detroit metropolitan area creates a relationship between the HFHS 
and the City of Detroit that ensures mutual dependency and cooperation.  
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1 Introduction 
The Henry Ford Health System (HFHS) is one of the nation’s oldest and largest com-
prehensive, integrated health systems in the U.S. With the mission “to improve human 
life through excellence in the science and art of health care and healing”, HFHS is 
providing a wide range of health care services in the Detroit metropolitan area (Henry 
Ford Health System, 2016). The non-profit organization is one of the key contributors 
to economic and social life in Detroit. While looking at Detroit’s structural challenges, 
this paper is intended to analyze the medical, social, and economic significance and 
contribution of HFHS to the Detroit metropolitan area. Thus, particular attention is paid 
to the regional focus and educational programs of the HFHS. Based on the discussion 
and analysis of key aspects, the paper draws a conclusion about the role of the HFHS 
supporting the structural change of the City of Detroit. 
2 The Henry Ford Health System 
The Henry Ford Health System is a non-profit corporation committed to improving 
health and well-being of the Michigan community. Headquartered in Detroit, it provides 
healthcare and medical services, especially in south-western Detroit. Founded in 1915 
by auto-pioneer Henry Ford, it has become one of the nation’s leading and largest com-
prehensive, integrated health systems. The Henry Ford Health System also provides 
health insurance as well as a research and education program for its medical staff. The 
system is made up of seven Henry Ford hospitals, the Henry Ford Medical Group with 
37 Medical Centers, Community Care Services, the HFHS health insurance service, and 
the Henry Ford Accountable Care Organization (HFACO) (Henry Ford Health System, 
2016). 
Through its mission, the HFHS strives to achieve the goal of “transforming lives and 
communities through health and wellness – one person at a time” (Henry Ford Health 
System, 2016). The HFHS, therefore, pursues continuously improving “patient-cen-
tered, integrated, equitable, high quality, safe, and efficient health care”. Health at HFHS 
is based on innovative clinical excellence, medical education, and research. With the 
goal of optimizing health and well-being for all patients while maintaining equal quality 
of care, the system uses its experience and leverages the synergy effects of the organi-
zation. HFHS is pursuing a holistic approach in health care, while focusing their efforts 
on the individual person. Therefore, the HFHS aims to achieve the optimal result and 
treatment for single patients, customers, and employees (Hawkins et al., 2013, pp. 16-
17).  
The Henry Ford hospital system is comprised of four acute medical-surgical and two 
behavioral hospitals. The Henry Ford Hospital in Detroit is considered the HFHS flag-
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ship. The 877-bed tertiary care hospital and level 1 trauma center includes its own edu-
cation and research complex. It is recognized for clinical excellence and innovation in 
the fields of cardiology and cardiovascular surgery, neurology and neurosurgery, ortho-
pedics and sports medicine, organ transplants, and treatment for cancer care (Henry Ford 
Health System, 2015a). 
 
Figure 1: The Henry Ford Health System Hospitals 
 
Source: Author’s own representation based on Henry Ford Health System, 2016 
The HFHS health insurance service, the Health Alliance Plan (HAP), has 675,000 en-
rolled members. The HAP is a non-profit health plan that provides Group Insured Com-
mercial, Individual, Medicare, Medicaid, self-funded and Network Leasing product 
lines (Henry Ford Health System, 2016). In 2016, Health Plus of Michigan joined the 
HAP, making it one of the largest health insurers in the State of Michigan. Because of 
the merger, synergies in product and service areas, as well as provider networks resulted 
in increasing revenues, and the system as a whole was supported in its strive to achieve 
its vision (Health Alliance Plan of Michigan, 2017, and Henry Ford Health System, 
2016). 
In 2016, the HFHS established the Henry Ford Accountable Care Organization. With 
the combination of the expertise of more than 1,000 physicians, its hospitals, clinics and 
medical centers, the HFHS pursues this path in order to achieve healthier outcomes, 
while reducing patients’ burden and the costs of care (Henry Ford Health System, n.d.a). 
Besides its health and insurance services, the HFHS includes a research and education 
program. This program provides innovative physician training programs, which helps 
HFHS to initiate and collaborate in the field of medical research. The academic medical 
center of HFHS includes 200 medical specialists and 80 research scientists working on 
more than 2,000 research projects. The program continuously provides medical educa-
tion and training opportunities for more than 80,000 physicians, nurses, and allied health 
professionals to date.  
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The Henry Ford Medical Group was founded in 1915 and stands out as one of the na-
tion´s largest medical groups. It includes more than 1,200 physicians specialized in over 
40 practice methods throughout the 37 Henry Ford medical centers in the Detroit sub-
urbs of Wayne, Oakland, and Macomb Counties.  
In order to support innovation across the HFHS and in the metropolitan area of Detroit, 
HFHS founded the Henry Ford Innovation Institute in 2011. The establishment of the 
institute was supported by many founding partners with expertise in the fields of medi-
cine, science, technology, product design, and education, such as the Wayne State Uni-
versity College and the College for Creative Studies in Detroit. The Innovation Institute 
develops medical products, devices, and therapies in multidisciplinary collaborations in 
order to improve patient outcomes and cost effectiveness. In so doing, the Henry Ford 
Innovation Institute holds multiple license agreements, and received more than one mil-
lion dollars in license revenue alone in 2015 (Hawkins et al., 2013, p. 17, and Henry 
Ford Health System, 2015b, p. 19). 
A valuable asset of the HFHS is its diversity. HFHS has employees with many cultural 
backgrounds, is proud of its diversity and strives to ensure diversity in all of its health 
system areas. Using the diversity in its employees from over 60 countries, HFHS devel-
ops and studies ways to affect the health of its patients and the population in the Detroit 
metropolitan area. HFHS has been awarded several times for this commitment to diver-
sity (Henry Ford Health System, 2016). 
3 The City of Detroit 
Detroit is a city in the Mid-Western U.S. with a population of around 680,000, and is 
the most populous city in the state of Michigan. Detroit has been historically shaped by 
and heavily dependent on the automobile industry since the industrial revolution. It is, 
therefore, known as a predominantly working-class city (Bentley et al., 2016, p. 785). 
Like other formerly industrial shrinking cities, Detroit continues to face a perpetual de-
cline in population (Adhya, 2017, p. 3). From the 1970’s to the present, its population 
has been reduced by more than half (Bentley et al., 2016, p. 789). 
While there is a noticeable decline in American manufacturing jobs due to aspects of 
globalization and increasing automation since the 1970s, Detroit is also facing several 
structural challenges. Because of the loss of employment opportunities, the working 
class shrank, and the city’s overall population decreased. Furthermore, the real estate 
market declined, the tax base was undermined and city services suffered (Bentley et al., 
2016, p. 785-786). Detroit´s problems with a decreasing population have further been 
accentuated by the global economic crisis beginning in 2008. The collapse of the real 
estate and financial market had violent effects on Detroit´s economy (Adhya, 2017, p. 
4). The bankruptcy, especially, of two of Detroit´s three big automotive companies in 
2009, General Motors and Chrysler, had huge effects on the local labor market situation. 
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As a result, the population experienced another heavy reduction. The related continuous 
loss of population and taxes reached its climax with the bankruptcy of the City of Detroit 
in 2013. 
 
Figure 2: Population of Detroit between 1990 - 2016 
 
Source: Author’s own representation based on United States Census Bureau, n.d.a 
Today, poverty, unemployment, and housing vacancies are a globally recognized char-
acteristic of the City of Detroit. The median household income in Detroit is less than 
half of the average income across the United States. A very high poverty rate of more 
than 40 percent illustrates the unfavorable social situation in Detroit. Furthermore, a 
below average level of education (measured at a high school graduation or higher) and 
a low rate of people with health insurance are characteristics of the socioeconomic situ-
ation of the Detroit metropolitan area (Figure 16.3). To illustrate the low population 
density, an example is provided. The total area of Detroit is larger than the accumulative 
area of Manhattan, Washington D.C., and San Francisco. However, the population of 
these three regions is about 470 percent higher than in Detroit (author’s own calculation 
based on United States Census Bureau QuickFacts). The poor economic and social sit-
uation has serious implications for investments in the future of Detroit and is deteriorat-
ing the quality of life for its communities. 
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Figure 3: Comparative socioeconomic parameters 
 
Source: Author’s own representation based on United States Census Bureau, n.d.b, and United States 
Census Bureau n.d.c 
4 Medical Importance of HFHS 
Serving a market area of 4.5 million people in Southeast Michigan (Hawkins et al., 2013, 
p. 6), the HFHS records about 130,000 visits to the emergency departments, 3.77 million 
outpatient visits, and about 100,000 hospital admissions annually. The HFHS performed 
75.000 surgical procedures and recognized 22,500 new patients in 2015 (Henry Ford 
Health System, 2016). Given these figures, HFHS is one of the most important hospitals 
in the region. 
Overall, the seven Henry Ford hospitals, providing close to 2,500 beds in the Detroit 
metropolitan area, enjoy an excellent reputation. In the prestigious U.S. ranking of the 
regional hospitals in Detroit and the surrounding area of 25 miles, the HFHS was twice 
ranked, along with the Henry Ford Hospital Detroit and the Henry Ford Macomb Hos-
pital, at ninth. With sole regard to the City of Detroit, the two clinics are even in second 
place (Figure 16.4). 
 
Figure 4: Best regional hospitals in Detroit up to 25 miles surrounding 
 
Source: Author’s own representation based on U.S. News, n.d. 
  USA Detroit
Median Household income $ 53,889 $ 25,764
Educational Attainment 86.7 % 78.3 %
Poverty Rate 13.5 % 40.3 %
Persons without health insurance 13.0 % 16.7 %
# Hospital City
1 University of Michigan Hospitals and Health Centers Ann Arbor
2 Beaumont Hospital-Royal Oak Royal Oak
3 Harper University Hospital Detroit
4 Beaumont Hospital-Troy Troy
5 Genesys Regional Medical Center Grand Blanc
6 St. Joseph Mercy Ann Arbor Hospital Ypsilanti
7 Beaumont Hospital-Dearborn Dearborn
8 Providence Hospital Southfield
9 Beaumont Hospital-Grosse Pointe Grosse Pointe
9 Henry Ford Hospital Detroit
9 Henry Ford Macomb Hospital Clinton Township
9 St. John Hospital and Medical Center Detroit
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The eight Centers of Excellence of the HFHS have received acclaim and have gained an 
excellent international reputation for their clinical medical services. Along with the In-
novative Institute, the HFHS Centers of Excellence are the Heart and Vascular Institute, 
the Josephine Cancer Institute, the Neuroscience Institute, Orthopedic Surgery, Trans-
plant Institute, Vattikuti Urology Institute, and the Behavioral Health. Three of these 
institutions stand out as the most remarkable. The Josephine Cancer Center, one of the 
largest cancer centers in Michigan, has a global catchment area and provides cancer 
therapy for all clinical pictures. The Vattikuti Urology Institute performed the first ro-
botic surgery, which has become medical standard. Finally, the Behavioral Health treat-
ment has received multiple awards and provides inter-alia services in inpatient and out-
patient medical services. 
5 Social Commitment and Community Health 
As one of the largest companies in Detroit, HFHS is also committed to social responsi-
bility and efforts to improve community health in Detroit. The goals of HFHS are pro-
moting the health of the Michigan population, as well as the health of its employees.  
In order to achieve these goals, HFHS has several Community and Health, Equity and 
Wellness (CHEW) programs. To support healthier nutrition, HFHS provides 
smartphone apps to educate children and hospital visitors about the basics of nutrition 
and food services. Furthermore, it performs Community Care Services through conduct-
ing home health care visits or nursing homecare, and offers school-based community 
health programs (Henry Ford Health System, 2016). 
To promote urban development, HFHS established the “Live Midtown” which supports 
urbanization by paying a bonus to its employees for moving into downtown Detroit. 
Each employee gets a $20,000 incentive for buying a house in midtown for the first time 
or a $2,500 one-off payment for the first rented residence (Henry Ford Health System, 
2016). Furthermore, HFHS invests in various ways in the cityscape of Detroit. One ex-
ample of that capital-intensive project is seen on West Grand Boulevard. The HFHS 
spent more than $500 million for restructuring of the environment surrounding the 
Henry Ford Hospital. Along with creating facilities for the medical services of the 
HFHS, including a new Cardinal Health Distribution Center, the HFHS created a school, 
green spaces, and foot and bike paths to encourage people to be healthier (Henry Ford 
Health System, 2016, and Kash, 2015, p. 383).  
6 Economic Importance of HFHS 
Considering the economic influence of the Henry Ford Health System for the city of 
Detroit, its position as an employer is of particular importance. With a total of more than 
29,000 employees, HFHS is the fifth-largest employer in the Detroit metropolitan area, 
and has a great significance for the Detroit labor-market. The organization provides 
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9,200 jobs and 11,500 jobs related to the HFHS in Detroit alone (Henry Ford Health 
System, n.d.b). In the ranking of the Detroit Economic Growth Corporation, HFHS is 
considered the third-largest employer in Detroit and the second largest in the healthcare 
sector (Figure 16.5). Considering the high impact of the automotive industry in Detroit, 
these figures are remarkable in describing the economic importance of the HFHS and 
the healthcare sector for Detroit. Due to the poor labor market situation and the high 
poverty rate, the HFHS is one of the economic pillars of the city. 
 
Figure 5: Largest Employer in Detroit 
 
Source: Author’s own representation based on Detroit Economic Growth Corporation, n.d. 
With its revenue of $5 billion and a net income of $72 million in 2015, the HFHS pro-
vided a total economic impact of $6.018 billion on the Detroit metropolitan area (Henry 
Ford Health System, 2016). Regional suppliers, subcontractors, partners and other affil-
iated companies are gaining economic benefits from the operations of the HFHS.  
The regional connection of the HFHS also results in a strong belief in the future of De-
troit. Thus, the HFHS is constantly investing in the region and its own system. With the 
establishment of the Henry Ford West Bloomfield Hospital during the global financial 
crisis in 2009, the HFSH set a strong signal for its future in Detroit. By investing about 
$350 million in the Henry Ford Hospital Campus in Detroit, the opening of new ambu-
latory centers and the expansion of existing ambulatory clinics, the HFHS supported 
Detroit not only as stabilizing factor in the labor market, but it also helped improved the 
forecast of surviving the financial crisis (Kash, 2015, p. 382).  
The HFHS also has prospective plans to further expand its system and facilities. The 
“Henry Ford - Detroit Pistons Performance Center”, a combined complex planned in 
cooperation with the NBA’s Detroit Pistons and Wayne State University, is one of the 
new facilities to be established. It will provide space for training facilities for the sports 
# Organization Detroit Employees 
1 Detroit Medical Center         12,398
2 City of Detroit   10,92
3 Henry Ford Health System 9,014
4 Detroit Public Schools 7,839
5 U.S. Government 6,454
6 Quicken Loans/Rock Financial Inc.      5,984
7 Wayne State University 5,924
8 Blue Cross Blue Shield of Michigan 5,172
9 State of Michigan 4,555
10 Chrysler Group LLC 4,042
11 General Motors Corp. 3,947
12 St. John Providence Health Systems 3,863
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team and corporate headquarters for the NBA franchise. It will include a comprehensive 
sports medicine and treatment and rehabilitation facility managed by the Henry Ford 
Health System as well (Henry Ford Health System, 2017). Besides the structural invest-
ments, those joint ventures between Detroit´s institutions and HFHS will support a stable 
future for the city. As part of the agreement, the Henry Ford Health system will be the 
official healthcare provider for the NBA sports team.  
For a long-term stabilization of its position as a significant employer in Detroit, the 
HFHS relies on its education and training program. The Henry Ford Health System is 
categorized as academic medical center because of its teaching, research, and advanced 
patient care supply. The HFHS trains about 1,800 medical students, residents, and fel-
lows on an annual basis. Medical education is provided for 80,000 physicians, nurses, 
and allied health professionals (Henry Ford Health System, 2016). The Henry Ford 
Health System University (HFHSU), established in 2004, provides education programs 
across the system. The range of education includes classroom events, as well as online-
courses. Special focus at the HFHSU is also given to leadership trainings (Hawkins et 
al., 2013, pp. 14-15). 
7 Discussion 
The significance of HFHS, with its wide range of medical services, is undisputed. 
HFHS’ position as a non-profit organization ensures that economic interests and corpo-
rate-centered goals of healthcare remain in the background. Employee, as well as com-
munity, health and well-being are instead pushed to the forefront. The Henry Ford Ac-
countable Care organization and the Health Alliance Plan established as part of the 
Henry Ford Health System are setting additional strong incentives to supporting long-
term health and optimal medical outcomes for the patients. The integration of financing 
and delivery are not only achieving benefits for the patient care. Employment contracts 
for physicians ensuring fixed salaries consolidate the patient focus and eliminate possi-
ble interests in optimizing personal revenues during medical care. Furthermore, the 
ACO-model creates even lower costs for the HFHS (Kash, 2015, p. 382).  
Along with its economic influence on the Detroit metropolitan area, HFHS tries to revi-
talize the city in various other ways. Incentives created by an attractive education and 
continuing-training program help to strengthen HFHC’s position as an important em-
ployer. Furthermore, HFHC is eager to help make to downtown Detroit more attractive 
for its employees, and thus renew Detroit as a city. In addition, HFHS established many 
partnerships with various institutions in Detroit to improve health outcomes. Moreover, 
these newly-created networks are good chances to stabilize Detroit´s economy in the 
long run. Continuous expansions of the HFHS in the metropolitan Detroit area will gen-
erate other new jobs for the region and help counteract the high unemployment-rate in 
Detroit. With the creation of new job opportunities, increasing the city’s population by 
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bringing in new employees or by encouraging current employees to move into midtown, 
HFHS is making a major contribution in tackling Detroit´s problems. 
Expanding its system and investing high amounts into Detroit´s social development, 
does however, increase HFHS’s dependence on the city. A failure of the urban develop-
ment in Detroit would directly relate to significant difficulties for the HFHS. Con-
versely, the dependence of Detroit on the HFHS increases with a growing engagement 
and support from HFHS to Detroit´s structure. With a continuing decrease of the manu-
facturing sector, Detroit´s dependence on the service sector, and thus the HFHC, could 
increase further.  
Serving the city of Detroit, the HFHC is not just focused on providing medical services. 
The HFHS has made strong efforts to create long-term community health and well-being 
as well as to achieve a restructuring of Detroit.  
8 Conclusion 
Considering the economic, medical, and social importance of the HFHS, it is obvious 
that HFHS has an enormous impact on the development of the Detroit metropolitan area. 
As a major employer and a highly respected health system, HFHS has a significant im-
pact on the stabilization of the economically battered city of Detroit. Besides contrib-
uting to getting through the financial crisis, the HFHS supports the belief in a positive 
development of the city with its investments in Detroit´s cityscape and a long-term com-
mitment to its roots. Since its foundation, the HFHS has been directly linked to Detroit 
and its good intention to stabilize and shape the region is clearly recognizable. The 
HFHS significantly consolidates the city and the metropolitan area with its social en-
gagement and economic impact, as well as its position as provider of medical services, 
and is partly responsible for the ability of a positive development in Detroit. On the other 
hand, high investments on the part of the HFHS into the shrinking city of Detroit involve 
economical risks. The city of Detroit and HFHS have entered into a mutual dependency, 
and both are relying on a positive economic and population development in the city in 
order to ensure a successful future.   
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